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Summary 
 
Acute myeloid leukaemia (AML) is a disorder characterised by the accumulation of 
blast cells or progenitors of one of several non-lymphoid haematopoietic cell lineages and is 
classified into two types: primary and secondary. HOX genes are over-expressed in both AML 
and other cancers. This over-expression is associated with an intermediate/unfavourable 
cytogenetic subset of AML. Although HOX over-expression is a common feature of AML, 
conventional knockout methods have failed to fully evaluate their functions due to their 
functional redundancy. We have applied an alternative approach by using a synthetic peptide 
called HXR9 to antagonise the interaction between HOX proteins and their cofactor PBX, 
which interacts with HOX proteins in groups 1-10. 
AML cell lines derived from different AML types express different subsets of HOX 
genes at different levels due to the heterogeneity of AML. It is showed for the first time that 
targeting the HOX-PBX interaction using HXR9 led to cell death of the tested AML cell lines. 
This cell death did not appear to be through apoptosis, as there were no signs of the caspase 
activation and nuclear fragmentation. Likewise, there was also no activation of key necrotic 
markers such as cypD and PARP1. Instead, cell death involved, at least in part, the expression 
of c-FOS and p21 in p53-independentmanner. In addition, HXR9 caused cell death in 
MEK/ERK and p38 independent pathways, but the JNK pathway exerted a resistant effect in 
K562 cells. It was found that inhibiting the Ca2+ downstream mediators CaM, PKC and HO-1 
significantly sensitised tested AML cell lines to HXR9. Taken together, these findings indicate 
a novel cell death pathway in AML cells. In vivo modelling also showed that HXR9 could delay 
tumour growth in a mouse model of AML.  
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Chapter 1 Introduction
2 
 
1.1 Overview 
Haematopoiesis is defined as the formation of new blood cells. Initially, 
haematopoietic stem cells (HSCs) differentiate into multipotent haematopoietic 
progenitors that undergo a gradual differentiation to give rise to array of more lineage-
restricted progenitors that ultimately produce highly specialised and differentiated 
mature blood cells (Figure 1.1). Mature cells can be classified into myeloid cells 
including neutrophils, eosinophils, basophils, monocytes, platelets and red cells, and 
lymphoid cells including B- lymphocytes, T-lymphocytes and natural killer (NK) cells 
(Orkin and Zon 2008; Doulatov, Notta et al. 2012). 
Haemtological malignancies are a group of heterogeneous diseases that are 
initiated by leukaemic stem cells that are able to both self-renew and differentiate like 
normal HSCs, although in an abnormal fashion, thereby increasing their number and 
giving rise to differentiated cells that represent the majority of cells found in the tumour. 
The classification of haemtological malignancies depended on the stage of the disease 
(acute or chronic leukaemia) and the immunophenotype of the cells (myeloid or 
lymphoid) (Table 1.1) (Warr, Pietras et al. 2011).  
3 
 
 
Figure 1.1 A schematic diagram of haematopoiesis. HSC differentiate to MPP that give rise to lineage-
committed progenitors which in turn are differentiated to more mature blood cells. HSC: haematopoietic 
stem cell, MPP: multipotent progenitor, CLP: committed lymphoid progenitor, CMP: committed 
myeloid progenitor, Pro-NK: pro-natural killer cell, MEP: megakaryocyte-erythrocyte progenitor, GMP: 
granulocyte-monocyte progenitor, MP: megakaryocyte progenitor, EP: erythrocyte progenitor, GP: 
granulocyte progenitor, MP: monocyte progenitor. 
 
 
Table 1.1 Classification of leukaemia. 
 Acute Chronic 
Myeloid origin Acute myeloid leukaemia Chronic myeloid leukaemia 
Lymphoid origin  Acute lymphoid leukaemia Chronic lymphoid leukaemia 
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Acute myeloid leukaemia (AML) is a heterogeneous group of genetically and 
phenotypically aggressive disorders where the differentiation of haematopoietic 
progenitors (HPs) is blocked, increasing their self-renewal ability and disturbing the 
normal regulation of  proliferation (Frohling, Scholl et al. 2005). In the UK, AML is 
the most frequent acute leukaemia in adults, accounting for 77% of cases. The median 
age at presentation is 69 years and the male: female ratio is about 5: 4 (Smith, Howell 
et al. 2011). The disease is commonly classified by either the French-American-British 
system, or that described by the world health organization. The former is based on 
morphology and maturation stage and classifies AML into eight groups (M0-M7). The 
latter is also based on morphology, but also includes immunophenotyping, genetics and 
clinical manifestations, and classifies AML into four main groups: AML with recurrent 
genetic abnormalities, AML with myelodysplasia (MDS)-related changes, therapy-
related AML and MDS or AML that does not fit into any of these groups (Table 1.2).  
Non-random chromosomal alterations, such as balanced translocations, monosomies, 
trisomies, inversion and deletions have been found in the leukaemic cells of almost 55% 
of AML patients, and until recently they were considered to be the most crucial 
prognostic factors for complete remission (CR), likelihood of relapse, and overall 
survival (OS) (Estey and Döhner 2006; Mrózek, Marcucci et al. 2007). 
About 55% of AML cases have chromosomal aberrations and about 15% have 
complex karyotype, three or more cytogenetic aberrations (Betz and Hess 2010). 
Cytogenetic studies is used as prognostic indicator and classify AML into three 
prognostic groups: favorable, intermediate and adverse. AML cases with t(15;17), 
t(8;21) and t(16;16) are associated with favorable-risk group. The intermediate-risk 
group includes cases with t(9;11), along with cases exhibiting loss of the Y 
chromosome or gains of whole chromosome. This prognostic group also includes AML 
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cases with normal karyotype that account almost 45% of AML cases. The adverse-risk 
group includes complex karyotype, t(6;9), inv(3)/ t(3;3) (Roche, Zeng et al. 2004; 
(Marcucci, Mrozek et al. 2005; Betz and Hess 2010; Buccisano, Maurillo et al. 2012). 
 
Table 1.2 AML classification according WHO classification (WHO 2008). 
Categories  
AML with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
APL with t(15;17)(q22;q12); PML-RARA 
AML with t(9;11)(p22;q23); MLLT3-MLL 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
AML with myelodysplasia-related changes 
Therapy-related AML 
AML, not otherwise specified  
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukemia 
Acute monoblastic/monocytic leukemia 
Acute erythroid leukemia 
Pure erythroid leukemia 
Erythroleukemia, erythroid/myeloid 
Acute megakaryoblastic leukemia 
Acute basophilic leukemia 
Acute panmyelosis with myelofibrosis  
Down syndrome related AML 
Transient abnormal myelopoiesis  
Myeloid leukemia associated with Down syndrome 
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Recent advances in molecular diagnosis have resulted in both gene alterations 
and the dysregulation of specific genes becoming increasingly important as prognostic 
elements in AML. This has helped to clarify the numerous heterogeneities of AML 
subsets, particularly AML subsets showing normal karyotype AML (NK-AML) 
(Dohner and Dohner 2008) and furthered understanding of the molecular mechanisms 
of leukaemogenesis.  
 
1.1.1 Genetic changes in AML  
The origin of AML is associated with two distinct genetic changes, referred to 
as Class I and Class II. Class I consists of mutations that enhance proliferation signal 
transduction pathways and induce the proliferation of HSCs or HPs and usually affect 
kinase signaling pathways, such as FLT3, KIT, NRAS/KRAS and JAK/STAT 
mutations. Class I mutations take place late and cause disease progression. Class II 
mutations target haematopoietic transcription factor genes leading to a block in myeloid 
differentiation and conferring the self-renewal ability of HPs. These mutations take 
place early and initiate the AML disease (Dohner and Dohner 2008; Renneville, 
Roumier et al. 2008; Betz and Hess 2010). One of the most affected and mutated 
transcription factors are homeobox (HOX) genes.  
1.2 HOX Genes 
The HOX genes are a family of homeodomain-containing transcription factors 
(Garcia-Fernandez 2004), initially characterized in Drosophila as master regulators of 
trunk and tail development during embryogenesis (Shah and Sukumar 2010). 
Duplication of the original HOX gene cluster has given rise to 39 genes in mammals, 
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separated into four clusters known as A, B, C, and D (Amores, Force et al. 1998; 
Abramovich, Pineault et al. 2005; Shah and Sukumar 2010). These clusters are located 
on four different chromosomes, HOXA (7p15), HOXB (17q21), HOXC (12q13), and 
HOXD (2q31) (Rice and Licht 2007). Ancestors of the original gene in each of the 
clusters are known as paralogs, and generally they show a high degree of sequence 
similarity as well as functional redundancy (Figure 1.1) (He, Hua et al. 2011).  
   The arrangement of HOX genes into clusters allows for enhancer sharing which 
enables a precise spatial and temporal coordination of expression during development. 
The relative regulatory dominance also varies between HOX genes, giving rise to what 
is often referred to as a 'HOX code' (Knittel, Kessel et al. 1995), and resulting in the 
following distinctive criteria: (1) Temporal distribution. The expression of HOX genes 
starts from the 3' end of the cluster and proceeds stepwise towards the 5' end. (2) Spatial 
distribution. The 3’ most member of the cluster is expressed with a more anterior limit 
than the next member and each subsequent member has a more posterior limit of 
expression resulting in an overlapping series of expression domains. (3) Posterior 
prevalence.  In each individual cluster, the function of the posterior gene products is 
dominant over the more anterior genes (He, Hua et al. 2011). 
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Figure 1.2 A schematic structure of clustered HOX genes. The 39 HOX genes are located on four 
different chromosomes. Homology of human HOX genes HOX-C to Drosophilia HOM-C genes is 
showed by colours. Blank squares show missing genes (Previously published in Alharbi, Pettengell et al. 
2012).   
1.3 HOX Cofactors 
DNA binding site studies suggest that HOX proteins have relatively limited 
selectivity and specificity, and they need cofactor interactions in order to increase both 
(Phelan, Rambaldi et al. 1995; Moens and Selleri 2006; Mann, Lelli et al. 2009). The 
most important HOX-cofactors are the three amino acid loop extension proteins, which 
comprise the pre B cell leukaemia (PBX) and myeloid ectropic insertion site (MEIS) 
families (Moens and Selleri 2006; Mann, Lelli et al. 2009). These cofactors  have 
crucial roles in development and haematopoiesis (Thorsteinsdottir, Kroon et al. 2001). 
For example, Pbx1 null mice die during the embryonic stage as a result of severe 
haematopoietic defects (DiMartino, Selleri et al. 2001) and Meis1-deficient mice fail to 
generate megakaryocytes, exhibit severe hemorrhaging and likewise die during the 
embryonic stage (Hisa, Spence et al. 2004). In zebrafish, Meis1 and Pbx contribute to 
Drosophilia
(HOM-C)
Pb
Chromosome number
Iab Dfd Scr Antp Ubx Abd A Abd B
Antennapedia Complex (Ant-C) Bithorax Complex (BX-C)
1 32 5 6 7 10 11 12 1394HOX A
1 2 3 4 5 76 9 138
Mammalian 
(HOX-C)
HOX B
54 136 8 9 10 11 12
93 4 8 1110 12 13
7p15
17q21
12q13
2q31
HOX C
HOX D
3` 5`
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the production of erythropoietic cells and the inhibition of myelopoiesis (Pillay, 
Forrester et al. 2010). Generally, Hox proteins 1-10 bind with Pbx1 (Shen, Chang et al. 
1996), whereas Hox proteins 9-13 bind with Meis1 (Shen, Montgomery et al. 1997). 
Recently, it has been reported that HOXA6 binds to MEIS1 which indicates that MEIS1 
interaction is not limited to the 5' end HOXs.(Dickson, Liberante et al. 2013).   
1.4 HOX genes in haematopoiesis 
HOX genes are expressed in HSCs and HPs in a manner reminiscent of their 
expression in early development, with lineage and differentiation stage-restricted 
manners. Thus, for example, HOXB3, HOXB4, and HOXA9 are highly expressed in 
uncommitted haematopoietic cells, whereas HOXB8 and HOXA10 are expressed in 
myeloid committed cells. Different mammalian CD34+ cell subpopulations express at 
least 22 of the 39 HOX genes (Grier, Thompson et al. 2005). Anterior '3' end' HOX 
genes (HOX1-6) are highly expressed in the most primitive HSCs. Subsequently, the 
anterior HOX genes are downregulated, and posterior '5' end' HOX genes are expressed 
during commitment (Sauvageau, Lansdorp et al. 1994). HOX genes are highly 
expressed in the most primitive HSCs and HPs, while their expression is almost absent 
in CD34- cells, which are considered differentiated bone marrow (BM) cells 
(Sauvageau, Lansdorp et al. 1994; Pineault, Helgason et al. 2002; Helen Wheadon 
2011). The analysis of HOX gene expression in human multipotent stem cells and T-
cell progenitors showed that HOXA genes are prominently expressed during T-cell 
development, in particular AbdominalB-HOXA (AbdB-HOXA) including HOXA7-
HOXA11, with only HOXB3 and HOXC3 expressed from other HOX clusters (Taghon, 
Thys et al. 2003). 
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1.4.1 Gain of function studies 
The function of HOX genes in normal haematopoiesis has been widely studied 
using gene expression analysis and knockin or knockout studies in HSCs and early HPs 
(Table 1.1). Generally the over-expression of a HOX gene leads to an expansion of stem 
and progenitor cell populations together with a block on differentiation. Notable 
example of this include the over-expression of murine Hoxb6, which resulted in the 
expansion of HSCs and myeloid progenitors, together with the inhibition of 
erythropoiesis and lymphopoiesis (Fischbach, Rozenfeld et al. 2005), and over-
expression of murine Hoxb3 that resulted in several haematological abnormalities, such 
as a block of  B- and T-cell differentiation as well as a delay in MP proliferation 
(Sauvageau, Thorsteinsdottir et al. 1997). Over-expression of human HOXC4 resulted 
in expansion of early and committed myeloid and erythroid progenitors (Daga, Podesta 
et al. 2000), and knockin of human HOXA5 caused an increase in the number of myeloid 
progenitors and blocked erythroid differentiation (Crooks, Fuller et al. 1999; Fuller, 
McAdara et al. 1999). Likewise, over-expression of HOXA10 in human cord blood or 
fetal liver CD34+ HPs resulted in a significant production of blast cells and 
myelopoiesis concomitant with a complete block of erythroid differentiation and a 
severe reduction in B-cell development (Buske, Feuring-Buske et al. 2001). Other HOX 
genes are required for the maintenance of progenitor or stem cell status and promote 
their proliferation, especially HOXA9 and HOXB4. The former is the most 
preferentially expressed HOX gene in human CD34+ HSCs and early HPs and is 
subsequently down-regulated during differentiation. Murine Hoxa9 over-expression 
enhances HSC expansion and myeloid progenitor proliferation and, with a long latency, 
leads to leukaemia (Kroon, Krosl et al. 1998; Thorsteinsdottir, Mamo et al. 2002). In 
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contrast to myeloid progenitors, Hoxa9 over-expression resulted in a partial inhibition 
of pre-B cell differentiation, but did not affect T-cell development (Thorsteinsdottir, 
Mamo et al. 2002). Hoxb4 is also highly expressed in HSCs and down-regulated during 
differentiation (Sauvageau, Lansdorp et al. 1994; Pineault, Helgason et al. 2002). Its 
over-expression in murine and human cell lines results in a remarkable expansion of 
HSCs in vivo and in vitro without resulting in leukaemia or lineage disturbances 
(Sauvageau, Thorsteinsdottir et al. 1995; Amsellem, Pflumio et al. 2003). Indeed, the 
self-renewal ability of Hoxb4-transduced HSCs is 20-50 fold greater than untreated 
cells, and can be increased still further by knocking down Pbx1 (Krosl, Beslu et al. 
2003; Cellot, Krosl et al. 2007).  
 
1.4.2 Loss of function studies 
In addition to the knockin and over-expression approaches described above, 
knockdown and deletion studies in murine models and cell lines have also been used to 
evaluate the role of HOX genes in haematopoiesis. However, owing to the functional 
redundancy of HOX genes, the results of knockdown assays are sometimes difficult to 
interpret and do not always reflect the findings of studies where the gene has been over-
expressed. For example, it has been found that Hoxb4 null mice exhibit a significant 
reduction in size and cellularity of haematopoietic organs, such as spleen and liver, and 
a slight decrease in HSCs and HPs number without a significant disturbance of lineage 
commitment (Brun, Björnsson et al. 2004; Bijl, Thompson et al. 2006). Likewise, 
Hoxb3 null mice display a notable reduction in B-cell progenitors, and a reduction in 
BM cellularity, but no significant reduction in B-cell numbers in the spleen (Ko, Kwan 
Lam et al. 2007). HOXb3/b4 -/-  mice have a greater reduction in HSCs and HPs, yet no 
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difference in haematopoietic cell commitment (Bjornsson, Larsson et al. 2003). Using 
polymerase chain reaction (PCR), it has been demonstrated that fetal liver cells (c-Kit+) 
of Hoxb4 null mice expressed other Hoxb genes to a significantly higher level than 
control cells (Bijl, Thompson et al. 2006). Thus, Hoxb3 and Hoxb4 can regulate the 
normal function of HSCs but are not individually essential for the production of major 
blood lineages because of redundancy with other members of the Hox gene family.  
Bijl and colleagues (2006) found that an individual loss of Hoxb4 or even the 
complete loss of the Hoxb cluster (b1-b9) did not affect the ability of murine fetal liver 
HSCs to self-renew. The repopulation and differentiation potential were retained, 
compared with wild-type control cells. Thus, the Hoxb cluster may not be necessary for 
haematopoiesis, with members of the other Hox clusters presumably having largely 
duplicate roles. Analysis of Hox gene expression in fetal liver cells (c-Kit+ Hoxb1-
Hoxb9-/-), revealed genetic interactions between members of the Hoxa, Hoxb and Hoxc 
clusters, whereby these cells exhibited down-regulation of all Hoxa genes, except 
Hoxa13, and up-regulation of Hoxc4, Hoxc9 and Hoxc11, also suggesting  functional 
redundancy and complex genetic interactions between Hox genes.   
An exception to the general prevalence of functional redundancy amongst the 
HOX gene family is HOXA9, the most highly expressed HOX family member in HSCs. 
Hoxa9-/- mice showed significant deficiencies in myeloid and lymphoid cells 
concomitant with a significant defect in repopulating ability (So, Karsunky et al. 2004; 
Lawrence, Christensen et al. 2005). These deficiencies include commom myeloid 
progenitors, granulocyte/monocyte progenitors, common lymphoid progenitors and 
lymphoid progenitors (pro- and pre-B cells, pro-T cells) (So, Karsunky et al. 2004). 
There is also a corresponding reduction in spleen cellularity and size (Magnusson, Brun 
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et al. 2007). Notably, compared to the entire cluster Hoxb deficient fetal liver HSCs, 
Hoxa9-/- fetal liver HSCs exhibited a more dramatic defect in repopulating ability (Bijl, 
Thompson et al. 2006; Magnusson, Brun et al. 2007), and HSCs from Hoxa9/b3/b4 null 
mice had the same repopulating ability as those from  Hoxa9 null mice (Magnusson, 
Brun et al. 2007). Gene knockdown studies have revealed that some additional HOX 
genes are also essential in normal haematopoiesis. Knockdown of HOXA5 led to an 
increase in erythroid progeneitors and a reduction in the number of myelomonocytic 
cells (Crooks, Fuller et al. 1999; Fuller, McAdara et al. 1999), and Hoxa7 null mice 
showed a reduction in megakaryocytic/erythroid progenitors as well as reticulocytosis 
and thrombocytopenia (So, Karsunky et al. 2004). Knockout of Hoxb6 resulted in an 
increase in early erythroid progenitors in murine BM and fetal liver cells (Kappen 
2000). Likewise, Hoxc3-/- mice showed a reduction in late erythroid progenitors without 
affecting the haemoglobinization size (Takeshita, Bollekens et al. 1993), and Hoxc8 
deficient mice showed a significant reduction in erythroid, granulocyte and macrophage 
colony formation potential (Shimamoto, Tang et al. 1999). 
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Table 1.3 HOX gene studies (Previously published in Alharbi, Pettengell et al. 2012). 
HOX gene Gain of function Loss of function Species 
HOXA5 ↑Myeloid progenitors and 
block erythroid 
differentiation (Crooks, 
Fuller et al. 1999; Fuller, 
McAdara et al. 1999) 
↑Erythroid progenitors and 
↓myelomonocytic cells (Crooks, 
Fuller et al. 1999; Fuller, McAdara 
et al. 1999) 
Human 
Hoxa7  ↓ MEP, reticulocytosis and 
thrombocytopenia (So, Karsunky 
et al. 2004) 
Mouse  
Hoxa9 ↑HSCs expansion and 
myeloid progenitor 
proliferation. 
Block erythroid 
differentiation (Kroon, 
Krosl et al. 1998; 
Thorsteinsdottir, Mamo et 
al. 2002). 
↓↓CMP, GMP, CLP, lymphoid 
progenitors, repopulating ability 
and spleen cellularity and size (So, 
Karsunky et al. 2004; Lawrence, 
Christensen et al. 2005). 
Mouse 
HOXA10 ↑↑ Blast cells and 
myelopoiesis, ↓ B cell 
differentiation and block 
erythroid differentiation 
(Buske, Feuring-Buske et 
al. 2001). 
 Human 
Hoxb3 Block B- and T-cell 
differentiation and a delay 
in myeloid progenitor 
proliferation (Sauvageau, 
Thorsteinsdottir et al. 1997). 
↓↓ B-cell progenitors and bone 
marrow cellularity (Ko, Kwan 
Lam et al. 2007). 
Mouse 
HOXB4/ 
Hoxb4 
↑↑ HSCs expansion 
(Sauvageau, 
Thorsteinsdottir et al. 1995; 
Amsellem, Pflumio et al. 
2003). 
↓↓ Haematopoietic organs 
cellularity and size, ↓ HSCs and 
HPCs and ↑ Hoxb genes (Brun, 
Björnsson et al. 2004; Bijl, 
Thompson et al. 2006). 
Human / 
mouse 
Hoxb3/b4  ↓↓ HSCs and HPCs (Bjornsson, 
Larsson et al. 2003).  
Mouse 
Hoxb6 ↑HSCs expansion and 
myeloid progenitors. 
 ↓ erythropoiesis and 
lymphopoiesis (Fischbach, 
Rozenfeld et al. 2005). 
 ↑ Early erythroid progenitors 
(Kappen 2000). 
Mouse 
Hoxc3  ↓ Erythroid progenitors (Takeshita, 
Bollekens et al. 1993). 
Mouse 
HOXC4 ↑ Early and committed 
myeloid and erythroid 
progenitors (Daga, Podesta 
et al. 2000). 
 Human 
Hoxc8  ↓Erythroid, granulocyte and 
macrophage colony formation 
potential (Shimamoto, Tang et al. 
1999).  
Mouse 
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1.5 Upstream regulators of HOX genes 
Knockout models of HOX gene upstream regulators have helped to define their role in 
normal haematopoiesis. Regulators include transcriptional activators such as mixed 
lineage, myeloid lymphoid, leukaemia (MLL), and a family of caudal-type homebox 
transcription factors (CDX1, CDX2, and CDX4). The existence of HOX genes in 
clusters makes them particularly sensitive to changes in chromosomal organization, and 
repressors of HOX transcription include genes that mediate this process, most notably 
members of the polycomb group (Beuchle, Struhl et al. 2001). These regulators have 
crucial roles in normal development and haematopoiesis through the regulation of HOX 
genes. A number of studies demonstrated that Mll-deficient embryonic bodies and Mll-
conditional knockout mice showed a dramatic reduction in HSCs and HPs. In addition, 
these embryonic bodies and the mice exhibited greatly reduced expression of a number 
of Hox genes including Hoxa7, Hoxa9, Hoxa10 and other Hoxb and Hoxc genes (Ernst, 
Mabon et al. 2004; Jude, Climer et al. 2007). Likewise, Cdx compound-deficient 
zebrafish and murine embryonic stem cells showed dysregulation of the embryonic HPs 
as well as impaired expression of Hox genes (Davidson and Zon 2006; Wang, Yabuuchi 
et al. 2008).  However, it has been shown that Cdxs are not essential for normal 
haematopoiesis in adult mice. For example, Cdx4-deficient mice showed minimal 
haematopoietic defects, though it was highly expressed in wild-type myeloid progenitor 
cells (Koo, Huntly et al. 2010). In addition, human CDX2 is not expressed in normal 
HSCs, or in myeloid, B-cell, or T-cell progenitors (Scholl, Bansal et al. 2007; Rawat, 
Thoene et al. 2008). In addition, it has been found that HOX gene expression is also 
regulated by small single-stranded RNAs (miRNAs) and the non-coding RNA 
HOTAIR (Bhatlekar, Fields et al. 2014).  
16 
 
miRNAs regulate HOX expression by repressing the expression of anterior genes, 
thereby supporting posterior prevalence while HOTAIR was reported as a negative 
regulator of HOX expression (Yekta, Tabin et al. 2008; Nakayama, Shibazaki et al. 
2013).  
1.6 HOX downstream target genes in haematopoietic cells 
The mechanism by which HOX proteins regulate haematopoiesis is not yet fully 
understood. However, genome-wide analyses after experimentally induced changes in 
HOX genes expression have identified some potential downstream targets. Amongst 
these are the HOX genes themselves, some of which have been shown to cross-regulate 
their neighbours, or their cofactors. HOXA9, HOXA10 and HOXB4 are the most 
comprehensively studied genes in this respect because of their key roles in normal 
haematopoiesis and leukaemia. It is particularly noteworthy that HOXA9 positively 
regulates the transcription of other HOX genes including HOXA7 and HOXA10 and its 
cofactor PBX3 and MEIS1 (Faber, Krivtsov et al. 2009). A summary of HOX 
downstream target genes is presented in Table 1.2.   
As described above, HOXA9 is a key regulator of haematopoiesis and behaves 
as an oncogene in leukaemia. It is therefore unsurprising that it activates the 
transcription of genes known to regulate cell proliferation and survival. For example, 
Hoxa9 directly activates the Pim1 gene, the product of which enhances proliferation by 
activating c-Myb, and also exerts an anti-apoptotic effect by phosphorylating and 
inactivating the BAD protein (Leverson, Koskinen et al. 1998; Hu, Passegué et al. 
2007). c-Myb has also been identified as an indirect transcriptional target of Hoxa9-
Mies1 that mediates transformation in Mll-Enl leukaemia (Hess, Bittner et al. 2006). 
Other HOXA9 targets include the oncogene ID2, which is up-regulated, and BIM, 
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which encodes an apoptotic factor and is down-regulated (Nagel, Venturini et al. 2010). 
HOXA9 also activates the CYBB gene, which encodes the Gp91phox (a phagocyte 
respiratory burst oxidase protein), and is expressed in differentiated myeloid cells (Bei, 
Lu et al. 2005). In mice, Hoxa9 has been shown to directly activate the transcription of 
the flt3 gene, which is associated with an unfavourable prognosis of AML (Gwin, Frank 
et al. 2010) and it also regulates its own cofactor, Meis1, through binding to Meis1 
upstream regulator genes cerb1 and pknox1 (Hu, Fong et al. 2009). More proliferative 
genes have been identified as downstream targets for Hoxa9 including Camk2d, Cdk6, 
Erg, Etv6, Flt3, Foxp1, Gfi1, Kit, Lck, Lmo2, Myb and Sox4 (Huang, Sitwala et al. 
2012). In the same study, it was shown that Hoxa9 down-regulates differentiation and 
inflammation genes including Ifit1, Tlr4, Ccl3, Ccl4, Csf2rb, Ifngr1, Runx1, Cd28 and 
Cd33. HOXA9 also regulates the anti-apoptotic gene Bcl-2 which may explain the cell 
survival role of HOXA9 (Brumatti, Salmanidis et al. 2013). The fusion protein 
nucloporin 98 (NUP98-HOXA9) has been found to stimulate the proliferation of HSCs 
by activating the expression of other HOX genes; including HOXA9, HOXA7, MEIS1 
and PBX3. It also up-regulates a number of  leukaemogenic transcription factors 
including EVI1 and MEF2C, and receptor tyrosine kinases including FLT3 and KIT 
(Takeda, Goolsby et al. 2006). 
It is also of note that there are both overlapping and opposing functions between 
the closely related HOXA9 and HOXA10 transcription factors. For example, in a similar 
manner to Hoxa9, Hoxa10 activates the expression of proliferative genes that result in 
myeloid progenitor expansion  such as Itgb3, Hif, Tgfβ2 and Fgf2 by direct binding to 
their promoters (Bei, Lu et al. 2007; Magnusson, Brun et al. 2007; Shah, Wang et al. 
2011; Shah, Bei et al. 2012). HOXA10 also activates the transcription of anti-apoptotic 
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genes such as DUSP4 which encodes mitogen-activated protein phosphatase 2. 
mitogen-activated protein phosphatase 2 in turn prevents cell death by down-regulating 
JNK (Wang, Lu et al. 2007). Hoxa10 decreases erythroid differentiation and 
megakaryopoiesis by activating Hoxa5 and inactivating Gata-1, respectively 
(Magnusson, Brun et al. 2007), and it also induces Cdx4 expression in myeloid cells 
(Bei, Huang et al. 2011). 
Unlike HOXA9, HOXA10 can also exert anti-proliferative effects. For 
example, in cooperation with its trimeric cofactors, HOXA10 induces p21 transcription 
leading to cell cycle arrest and differentiation (Bromleigh and Freedman 2000). It also 
represses CYBB transcription (Eklund, Jalava et al. 2000), thereby acting in an opposing 
manner to HOXA9. In a fusion form with Nup98, Hoxa10 activates more than 400 
genes including the self-renewal genes Flt3, Prnp, Hlf and Jag2 (Palmqvist, Pineault et 
al. 2007).   
Many HOXB4 target genes have also been identified in three studies (Lee, 
Zhang et al. 2010; Oshima, Endoh et al. 2011; Fan, Bonde et al. 2012). Over-expression 
of  Hoxb4 resulted in transcriptional up-regulation of Meis1, Dntt, Hlf, Sox4 and Runx2, 
while it down-regulated the transcription of lymphoid specific genes, such as B220, and 
myeloid-specific genes, such as Hmbs (Lee, Zhang et al. 2010). Some HOXB4 targets 
seem to vary in a context-dependent manner, for example, it has been found to down-
regulate the transcription of c-MYC in the HL-60 cell line leading to cell differentiation 
(Pan and Simpson 2001), while it activates c-Myc transcription in murine BM cells 
(Satoh, Matsumura et al. 2004). As with HOXA9, Hoxb4 activates the transcription of 
its neighbouring genes, Hoxb2, Hoxb3 and Hoxb5 (Satoh, Matsumura et al. 2004). 
Hoxb4 also activates activator protein-1 (AP-1) complex members Fra-1 and Jun-B, 
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which leads in turn to an increase in the level of cyclin-D1 and a decrease the level of 
c-Fos transcription, thereby increasing the proliferation capacity of HSCs (Krosl and 
Sauvageau 2000).  
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Table 1.4 A summary of mammalian HOX target genes (Alharbi, Pettengell et al. 2012).   
HOX protein  Targets of transcriptional activation Targets of transcriptional repression Species 
HOXA9/ Hoxa9 Pim1 (Hu, Passegué et al. 2007), ID2 (Nagel, 
Venturini et al. 2010), CYBB (Bei, Lu et al. 
2005), HOXA7, HOXA10, PBX3, MEIS1 
(Faber, Krivtsov et al. 2009). Bcl-2 
(Brumatti, Salmanidis et al. 2013), Flt3 
(Gwin, Frank et al. 2010), Cerb1 and Pknox1 
(Bei, Lu et al. 2005), Camk2d, Cdk6, Erg, 
Etv6, Foxp1, Gfi1, Kit, Lck, Lmo2, Myb and 
Sox4 (Huang, Sitwala et al. 2012). 
BIM (Nagel, Venturini et al. 2010)/ 
Itfi1, Tlr4, Ccl3, Ccl4, Csf2rb, Ifngr1, 
Runx1, Cd28, Cd33 (Huang, Sitwala et 
al. 2012). 
Human/ 
mouse 
Hoxa9-Meis1 c-Myb (Hess, Bittner et al. 2006).  Mouse 
NUP98-HOXA9 HOXA7, HOXA9, MEIS1, PBX3, EVI1, 
MEF2C, FLT3 and KIT (Takeda, Goolsby et 
al. 2006). 
 Human 
HOXA10/ 
Hoxa10 
P21 (Bromleigh and Freedman 2000), 
DUSP4 (Wang, Lu et al. 2007), Itgb3 (Bei, 
Lu et al. 2007), Hlf (Magnusson, Brun et al. 
2007), Tgfβ2 (Shah, Wang et al. 2011), Fgf2 
(Shah, Bei et al. 2012), Dusp4 (Wang, Lu et 
al. 2007), Hoxa5 (Magnusson, Brun et al. 
2007), Cdx4 (Bei, Huang et al. 2011). 
CYBB (Eklund, Jalava et al. 2000)/ 
Gata1 (Magnusson, Brun et al. 2007) 
Human/ 
mouse 
Nup-Hoxa10 Flt3, Prnp, Hlf and Jag2 (Palmqvist, Pineault 
et al. 2007).  
 Mouse 
HOXB4/ Hoxb4 MEIS1, DNTT, HLF, SOX4, RUNX2 (Lee, 
Zhang et al. 2010), c-MYC (Pan and Simpson 
2001), Hoxb2, Hoxb3 (Satoh, Matsumura et 
al. 2004), Fra-1, JunB (Krosl and Sauvageau 
2000).    
B220 and HMBS (Lee, Zhang et al. 
2010), c-Myc (Satoh, Matsumura et al. 
2004). 
Human/ 
mouse 
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1.7 The role of HOX genes in acute leukaemia 
Numerous studies have now shown that HOX genes can promote the 
development of AML by forming chimeric fusions with other genes, but more recent 
work has also shown that their miss-expression, in particular their over-expression, is 
also important in the formation of malignancy. 
1.7.1  HOX fusion proteins 
One of the most frequent fusion partners for HOX genes is nucloporin (NUP98), 
a member of the nuclear pore family (Figure 1.2). It is localized in the nuclear 
membrane and functions as a selective transporter for ribonucleic acid (RNA) and 
proteins between the nucleus and cytoplasm. NUP98-HOX fusion proteins have been 
reported in AML and other leukaemias. In AML, NUP98-HOXA9 is associated with a 
t(7;11)(p15;p15) translocation (Borrow, Shearman et al. 1996; Nakamura, Largaespada 
et al. 1996). There are eight other HOX genes that can be fused with NUP98, including 
HOXA11 and HOXA13 (Fujino, Suzuki et al. 2002; Suzuki, Ito et al. 2002), HOXD11 
and HOXD13 (Raza-Egilmez, Jani-Sait et al. 1998; Taketani, Taki et al. 2002), and 
HOXC13 (Taketani, Taki et al. 2002). Thus only the 5’ most members of each HOX 
complex have been documented to be fused with NUP98 in AML. However, Hoxb3 
has been shown to be a potential leukaemogenic partner with Nup98 (Pineault, 
Abramovich et al. 2004), suggesting that the ability to be a fusion NUP98 partner is not 
limited to the 5’ most HOX genes. Generally, NUP98-HOX fusions induce cell 
proliferation and function as transcriptional activators and NUP98 fusions with HOX 
proteins are more oncogenic than fusions with other partners (Saw, Curtis et al. 2013).  
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Nup98-Hox fusion proteins result in AML with a long latency, around 11-12 
months (Kroon, Thorsteinsdottir et al. 2001). However, this latency can be reduced to 
two months by co-over-expression of the Hox cofactor Meis1  (Pineault, Buske et al. 
2003) and the receptor tyrosine kinase Flt3 (Palmqvist, Argiropoulos et al. 2006). For 
example, concurrent translocation of Nup98-Hoxd13 and Flt3-ITD developed AML in 
3 months (Greenblatt, Li et al. 2012). FLT3 has an essential role in the regulation of 
early HPs growth, and causes increased and uncontrolled self-renewal of these cells 
through a FLT3 ligand-independent pathway (Tosic, Stojiljkovic et al. 2009).  
  
 
Figure 1.3 structures of AbdB-HOX, NUP98 and the predictive fusion protein NUP98-HOXA. A) A 
general structure of AbdB-HOX (9-13) proteins that have been reported to fuse with NUP98. B) Structure 
of normal NUP98 protein. C) Structure of predictive NUP98-HOX fusion protein. This fusion eliminates 
MD and RBD from AbdB and NUP98, respectively. The arrows represent the breakpoints. MD: MEIS 
domain, PM: Pbx motif, H: hexapeptide, HD: homedomain, FG: phenylalanine-glycine, GLEBS: gle2p-
binding-like motif, RBD: RNA binding domain (Previously published in Alharbi, Pettengell et al. 2012). 
 
 
 
 
 
 
PMMD COOHNH2
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1.7.2 HOX over-expression in AML 
HOX genes may also be indirectly involved in AML through chromosomal 
rearrangements that involve their upstream regulators, such as MLL. MLL fusion 
proteins constitute about 10% of therapy related AML and 3% of de novo AML (Slany 
2009). There are more than 64 translocation partner genes that fuse with the MLL N-
terminus (Meyer, Kowarz et al. 2009). Normally, Mll positively regulates the 
transcription of Hox genes by maintaining their expression through direct binding to a 
proximal promoter region (Milne, Briggs et al. 2002). MLL fusion proteins activate 
HOX gene transcription more efficiently than MLL alone (Liu, Cheng et al. 2009; Slany 
2009), especially the 5’ end members of the HOXA cluster, together with their co-
activator MEIS1. As a consequence, myeloid differentiation is blocked and proliferation 
is enhanced (Marschalek 2011). Consistent with this proposed mechanism, it has been 
reported that MLL-AF9, like NUP98-HOXA9, leads to a block in erythroid/myeloid 
maturation and to erythroid hyperplasia (Abdul-Nabi, Yassin et al. 2010), and the Mll-
Enl fusion protein requires Hoxa7 and Hoxa9 for efficient immortalization of HPs 
(Ayton and Cleary 2003). Conversely, a number of studies demonstrated that the 
expression of HOXA genes is not crucial for MLL leukaemogenesis, yet their 
expression affects disease phenotype. For instance, Hoxa7 and Hoxa9 influence AML 
latency and phenotype; yet they are not essential to initiate Mll-Gas7-mediated 
leukaemogenesis (So, Karsunky et al. 2004). Furthermore, suppression of HOXA9 
expression in cells with a chimeric MLL-AF9 gene reduces the survival of leukaemic 
cells and changes the disease phenotype, but it does not affect AML initiation (Faber, 
Krivtsov et al. 2009). 
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The dysregulation of another regulator of HOX genes, the CDX gene family, has 
also been shown to drive the development of AML. CDX2 is expressed in the majority 
of AML cases (90%), but not in normal adult haematopoiesis, and Cdx2-elevated 
expression leads to AML with only a short latency period (Scholl, Bansal et al. 2007). 
In contrast, the closely related CDX4 gene is expressed in 25% of AML cases, and is 
expressed in normal adult haematopoiesis, and Cdx4 over-expression in murine BM 
results in AML but only with a long latency period (Bansal, Scholl et al. 2006). This 
latency can be accelerated in mice through cooperation of Meis1 which results in the 
over-expression of a number of Hox genes including Hoxa6, Hoxa7, Hoxa9, Hoxb4, 
Hoxb8 and Hoxc6 (Bansal, Scholl et al. 2006). Cdx2 expression alone is sufficient to 
drive the up-regulation of a related set of HOX genes (Rawat, Thoene et al. 2008), 
demonstrating the importance of the Cdx family in the dysregulation of Hox genes 
during AML.  
The dysregulation of HOX gene expression is also associated with the 
nucleophosmin 1 (NPM1) mutation. NPM1 is a chaperone protein that shuttles between 
the nucleus and cytoplasm, although its  predominant localization is in the nucleus (Rau 
and Brown 2009). NPM1 has a crucial role in several biological processes, such as 
ribosome biogenesis, genomic stability and cell cycle progression. In adult AML, 
NPM1 mutation is the most common genetic aberration, reported in about 35% of all 
adult AML and approximately in 45-55% of NK-AML (Falini, Mecucci et al. 2005). In 
pediatric AML, NPM1 mutations are significantly less common, occurring in 8-10% of 
cases, and in about a quarter of normal karyotype cases (Brown, McIntyre et al. 2007; 
Hollink, Zwaan et al. 2009). The relocation of NPM1 into the cytoplasm (NPMc+) 
occurs only in AML (Falini, Bolli et al. 2009). This relocation causes up-regulation of 
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a number of HOX genes, some of which are similar to those seen in AML initiated by 
a MLL chimeric gene fusion, while some are distinct. Thus for example, HOXA4, 
HOXA6, HOXA7, HOXA9, HOXB9 and MEIS1 are over-expressed in both contexts, 
while HOXB2, HOXB3, HOXB5, HOXB6 and HOXD4 are up-regulated in NPMc+ 
AML only (Mullighan, Kennedy et al. 2007). It has been reported that activation of a 
humanized Npm1 allele led to over-expression of Hoxa5, Hoxa7, Hoxa9 and Hoxa10, 
induction of HSC self-renewal and the expansion of myelopoiesis (Vassiliou, Cooper 
et al. 2011). The exact mechanism of the association between the NPM1 mutation and 
the up-regulation of HOX genes is still unclear. A possible explanation is that NPM1 
directly disturbs the expression of HOX genes, or alternatively, that NPM1 mutations 
arrest the differentiation of early HPs in which HOX expression is up-regulated (Rau 
and Brown 2009).  
1.7.3 HOX gene dysregulation in acute lymphoid leukaemia (ALL) 
The dysregulation of HOX genes has also been reported in ALL including both 
B- and T-progenitor ALL (B-ALL and T-ALL), especially when MLL translocations 
are involved. For example, human HOXA9, HOXA10 and  HOXC6, and their cofactor 
MEIS1 were up-regulated in both MLL-ENL T-ALL and MLL B-ALL (Ferrando, 
Armstrong et al. 2003). Human HOXA9 and MEIS1, and murine Hoxa5, Hoxa9 and 
Meis1 were likewise up-regulated in MLL-AF4 B-ALL (Rozovskaia, Feinstein et al. 
2001; Krivtsov, Feng et al. 2008). A common signature of MLL rearrangements in 
AML and ALL is the over-expression of HOXA genes including HOXA3, HOXA5, 
HOXA7, HOXA9 and HOXA10 (Zangrando, Dell'Orto et al. 2009). In addition, HOX 
genes can be involved in other translocations such as CALM-AF10 T-ALL, where 
human HOXA5, HOXA9, HOXA10 and MEIS1 are over-expressed (Dik, Brahim et al. 
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2005). HOXA proteins can also form chimeric fusion proteins with T-cell receptor in 
T-ALL, which results in the global over-expression of HOXA genes (Soulier, Clappier 
et al. 2005; Speleman, Cauwelier et al. 2005). Surprisingly, the aberrant expression of 
CDX2 in ALL, an upstream regulator of HOX genes, is not correlated with HOX gene 
dysregulation (Thoene, Rawat et al. 2009).  
1.7.4 HOX genes as prognostic markers  
HOX gene expression has become an important prognostic factor in AML. 
Over-expression of HOX genes is associated with an intermediate/unfavorable 
cytogenetic subset of AML. For example, among 6817 genes that have been 
investigated in AML patients, the single gene correlated with the worst outcome and 
relapse of disease as well as short survival was HOXA9 (Golub, Slonim et al. 1999). 
Likewise, high expression of HOXA9 associates with low CR rate (Li, Li et al. 2013). 
Correspondingly, low HOXA9 expression was found to correlate with the best outcome 
and response to therapy (Andreeff, Ruvolo et al. 2008). It is also noteworthy that low 
expression of HOXA4 and MEIS1 are also favorable predictors for AML patient 
outcome (Zangenberg, Grubach et al. 2009). In addition,  a signature of up-regulation 
of HOXA6, HOXA9 and PBX3 with a low expression of MEIS1 is an independent poor 
prognostic marker in NK-AML, and simultaneous knockdown of HOXA6 and HOXA9 
caused cell death and AML cell lines became more sensitive to cytarabine (Dickson, 
Liberante et al. 2013). Furthermore, high expression of HOXA7, HOXA9 and HOXA11 
along with the cofactor PBX3 is an independent prognosis marker of adverse OS in 
abnormal karyotype AML (Li, Huang et al. 2012). The global levels of HOX expression 
also seem to reflect the outcome of disease, possibly reflecting the functional 
redundancy exhibited by many of the HOX genes. Thus the highest levels of HOX genes 
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are seen in FLT3 mutation cases, which have unfavorable outcomes, and generally the 
HOX genes are expressed only at a very low level in favorable subsets of AML. 
Although recent work has established the importance of HOX genes in the 
development of AML, it is still not clear exactly what the functions of these genes are 
beyond a general inhibition of differentiation and an increase in cell proliferation. This 
lack of precise mechanistic knowledge for individual HOX genes may be owing to the 
functional redundancy showed by many members of this family, making the 
knockdown of single HOX genes generally difficult to interpret, and it may also help to 
explain the contrast in gene knockin and knockout results. In myeloma and some solid 
malignancies this has been addressed by targeting the HOX proteins as a group by 
antagonizing their interactions with the PBX cofactor using the peptide inhibitor HXR9 
(Morgan, Pirard et al. 2007; Shears, Plowright et al. 2008; Plowright, Harrington et al. 
2009; Daniels, Neacato et al. 2010; Morgan, Plowright et al. 2010). 
PBX binds to PBX motif in HOX paralogus group 1-10. HOX-PBX dimers have 
more binding affinity and specificity for target DNA sequences than the HOX monomer 
alone. Of note, HOX-PBX dimers are strictly involved the interaction of PBX to the 
conserved hexapeptide sequence WYPWMK that is found N terminal to the 
homeodomain of HOX proteins from paralogous groups 1-10 for cooperative DNA 
binding by PBX and HOX partners (Chang, Shen et al. 1995; Shen, Rozenfeld et al. 
1997; Medina-Martinez and Ramirez-Solis 2003). The peptide inhibitor HXR9 contains 
a hexapeptide sequence mimics the HOX protein hexapeptide sequences that binds to 
PBX and thereby interfering the DNA binding of HOX-PBX. HXR9 is cytotoxic to 
cells, predominantly through the induction of apoptosis, which in turn depends upon a 
rapid increase in expression of c-FOS (Morgan, Pirard et al. 2007; Shears, Plowright et 
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al. 2008; Espinosa, Shinohara et al. 2009; Plowright, Harrington et al. 2009; Daniels, 
Neacato et al. 2010). A similar approach may be useful in AML for addressing 
redundant functions of HOX genes.  
  
1.8 Hypothesis and aims 
The hypothesis of this study was that AML would also be sensitive to killing by 
HXR9, and indeed it may be that the HOX genes could represent a useful therapeutic 
target, especially in AMLs that show high levels of HOX expression and a 
correspondingly poor prognosis. In order to assess this hypothesis, three main 
objectives were set up. 
The first objective of this study was to investigate the cytotoxicity of HXR9 on 
AML cell lines derived from different AML subtypes and if so to investigate the 
combination therapy of HXR9 with AML first line chemotherapy. The strategies for 
conducting this were: 
 To measure the expression of the whole panel of 39 HOX genes in five 
AML cell lines. 
 To investigate the cytotoxicity of HXR9 on the five cell lines either 
alone or in combination with AML first line chemotherapy. 
The second objective was to investigate the mechanism of HXR9 cytotoxicity 
on the AML-derived cell lines. The strategies for conducting this were: 
 To determine whether HXR9 induced cell death through apoptosis or 
necrosis. 
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 To assess the involvement of some signaling pathways such as MAPK 
and pro-apoptotic proteins such as p53. 
The third objective was to investigate the efficacy of HXR9 against AML 
disease in vivo. The strategies for conducting this were: 
 To establish an AML model. 
 To assess the efficacy of HXR9 either alone or with co-treatment with 
some non-toxic inhibitors. 
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Chapter 2 Materials and Methods
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2.1 Materials 
2.1.1 Reagents 
 
Table 2.1 Reagents were used in this study and their suppliers. 
 
Reagent Supplier 
SYBR® green jumpstatTM Taq ready mixTM Sigma (Dorset, UK) 
 Penicillin-streptomycin  
μI-1640 
DMEM 
Trypan blue 
HBSS 
Histopaque®-1077 Hybri-Max 
β-mercaptoethanol 
Daunorubicin 
Mitoxantrone 
DAPI stain 
z-VAD-FMK 
Cyclosporin A 
Necrostatin-1 
Fructose 
EDTA 
U0126 monoethanolate 
SP600125 
SB 203580 
DPI 
Calpain inhibitor I 
W-7 
Ro31-8220 methanesulfonate and  pifithrin-α 
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Reagent Supplier 
Protoporphyrin IX Sigma (Dorset, UK) 
 Carestream® Kodak BioMax® light film 
Fixer and replenisher  
Developer and replenisher 
Cloned AMV first-strand synthesis kit  invitrogen, Thermo scientific (Paisley, UK) 
Glutamine 
FBS 
IMDM medium 
Enz Chek® Caspase-3 Assay Kit#2 
NuPAGE® LDS sample buffer 
BenchmarkTM prestained protein ladder 
NuPAGE novex 12% Bis Tris 
DMSO 
Pierce® RIPA buffer 
Protease inhibitor cocktail 
NuPAGE® sample reducing agent 
NuPAGE® MES SDS running buffer 
InvitrolonTM PVDF filter paper sandwich  
Novex cryoTubeTM vials 
SuperSignal® West Pico Chemiluminescent substrate 
Annexin V-PE apoptosis detection kit  BD pharmingen (Cambridge, UK) 
Cytotoxicity detection kit  Roche (Mannheim, Germany) 
RNeasy mini kit and RBC lysis solution  Qiagen (West Sussex, UK) 
Gene Primers  Eurgentec (Seraing, Belgium) 
Mycoplasma detection kit  lonza (Slough, UK) 
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2.1.2 Instruments 
Instruments used in this study were: Beckman coulter a plate reader, Miltenyibiotec a 
fluorescence-activated cell sorting (FACS) machine, Lebtech a Nanodrop spectrophotometer 
ND-1000, and Stratagene Mx 3005P, SHADON cytospin 4, a fluorescent microscope, 
eppendorf centrifuge 5415R. 
2.1.3 Cell lines  
Human and mouse derived AML cell lines were used in this study. Human derived cell 
lines used were primary or secondary. Primary AML cell lines derived from patients with de 
novo mutations including KG-1, a cell line derived from an erythroleukaemia (Koeffler and 
Golde 1978), HEL 92.1.7, an erythroleukaemia cell line (Martin and Papayannopoulou 1982) 
and HL-60, a cell line obtained from  acute promyelocytic leukaemia (APML) (Collins, Ruscetti 
et al. 1978). Secondary AML cell lines are derived from patients that developed AML from 
MDS, chronic myeloid leukaemia (CML) or following previous treatment with chemotherapy. 
These include  K562, a CML cell in blast crisis (Lozzio and Lozzio 1975) and KU812F, also a 
CML cell in blast crisis (Kishi 1985). The mouse derived cell line G1498-GFP was a kind gift 
from Dr. Justin Kline (Department of Medicine Section of Haematology/Oncology, Chicago, 
USA).  
2.1.4 HXR9 and CXR9 peptide synthesis 
 The synthesis of these peptides has been described previously (Morgan, Pirard et al. 
2007). Briefly, HXR9 is a short peptide of 18 amino acids, comprising a hexapeptide sequence 
and nine C-terminal arginine residues (R9) that enables cell penetration. The hexapeptide 
mimics the hexapeptide sequence of HOX proteins of paralogs 1-10, this sequence functions as 
a competitive inhibitor of HOX/PBX. CXR9 is a control peptide that does not have a functional 
hexapeptide portion but has the R9. The stability of the peptides was increased using D-isomers 
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NH2- and COOH- terminals. The half-life of both peptides is about 12 hours at the serum 
(Morgan, Pirard et al. 2007). A conventional column-based technique was used to synthesise 
HXR9 and CXR9 and were purified to at least 80% (Biosynthesis Inc., Lewisville, TX, USA). 
The peptide sequences are as follows: 
HXR9: WYPWMKKHHRRRRRRRRR (2700.06 Da) 
CXR9: WYPAMKKHHRRRRRRRRR (2604.14 Da) 
2.1.5 Mice 
Female C57BL/6, nude and severe combined immune-deficient (SCID) mice, 
approximately 6 to 8 weeks age, were purchased from Jackson laboratory, Kent, UK. These 
mice were maintained in pathogen-free cages and fed with irradiated food and acidified water. 
All experiments were performed under the compliance of Home Office and institutional 
instructions. 
2.2 Methods  
2.2.1 General cell culture methods 
2.2.1.1 Routine cell culture 
All cell culture techniques were performed in a class II microbiological safety cabinet 
and all equipment and reagent bottles were sterilised using 70% ethanol solution before use. 
K562, KU812F and HEL92.1.7 cells were grown in a culture medium consisting of Roswell 
Park Memorial Institute (RPMI-1640) medium complemented with 10% fetal bovine serum 
(FBS), 5% L-glutamine and 5% antibiotics (1000 units of penicillin/ml and 10 mg/ml 
streptomycin, P/S). KG-1 and HL-60 cells were cultured in Iscove’s Modified Dulbecco’s 
medium (IMDM) supplemented with 20% FBS and 5% antibiotics. C1498-GFP cells were 
maintained as a suspension culture in Dulbecco’s Modified Eagle’s Medium (DMEM) 
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supplemented with 10% FBS, 5% L-glutamine and 5% antibiotics. All cell lines were cultured 
in T-75 sterile cell culture flasks at 37°C in a humidified environment containing 5% CO2 and 
95% air. Cells were sub-cultured routinely three times a week (Table 2.2). Mycoplasma 
contamination test was carried out at monthly intervals using MycoAlert™ Mycoplasma 
Detection Kit.  
 
Table 2.2 Cell lines used in this study. This table shows sources and diseases that cell lines were derived from. 
All cell lines were cultured at 37°C, 5% CO2 and split 3 times a week.   
Cell line Source Disease Culure media References 
KG-1 Human Erythroleukaemia IMDM, 20%FBS, P/S  (Koeffler and 
Golde 1978) 
HEL92.1.7 Human Erythroleukaemia RPMI, 10%FBS, P/S 
and L-glutmaine 
(Martin and 
Papayannopoulou 
1982) 
HL-60 Human APML IMDM, 20%FBS, P/S  (Collins, Ruscetti 
et al. 1978) 
KU812F Human CML in blast 
crisis 
RPMI, 10%FBS, P/S 
and L-glutmaine 
(Kishi 1985) 
K562 Human CML in blast 
crisis 
RPMI, 10%FBS, P/S 
and L-glutmaine 
(Lozzio and 
Lozzio 1975) 
C1498-GFP Murine AML DMEM, 10%FBS,  
P/S and L-glutmaine 
(Zhang, Gajewski 
et al. 2009) 
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2.2.1.2 Cell counting and cell density calculation using a haemocytometer  
A 10μl aliquot of cell suspension was mixed with 90μl of trypan blue stain and 10μl of 
the mixture was loaded onto the grid of a Neubauer haemocytometer. Only healthy and round 
cells that were located in the four corner squares of the Neubauer haemocytometer were counted 
and averaged in order to determine the cell density (Figure 2.1).  
 
 
                                                                                                                                                                                                                                                                                                                               
Figure 2.1 A haemocytometer diagram. It indicates the four corner squares that were used for counting cell 
number; only cells that were healthy and round cells that only were counted. The number of cells in one set of 16 
squares is equal to the number of cells x104/ml. 
 
2.2.1.3 Cryopreservation of cell stocks 
After calculating the cell density, a volume containing 5x106 cells was transferred into a 
25ml universal tube and centrifuged at 1500rpm for 3 minutes. Then, supernatant was removed 
and cell pellets were re-suspended in 1ml storage medium, which was full growth medium 
supplemented with 5% (v/v) dimethyl sulphoxide (DMSO). The cell suspension was then 
transferred into 1.8ml cryovials. Cells were stored at -80ºC for overnight before being 
transferred to liquid nitrogen for long term storage. 
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2.2.1.4 Revitalisation of cryopreserved cells 
Cryopreserved cells were thawed rapidly by incubating in a 37ºC water bath for 2 
minutes. Then, cells were transferred to 10ml of pre-warmed full growth medium and 
centrifuged at 1500rpm for 3 minutes. The supernatant was discarded in order to remove DMSO 
traces and cell pellets were re-suspended in 10ml full growth medium in a T-25 sterile cell 
culture flask and cultured at 37°C in a humidified environment containing 5% CO2. After cell 
growth had resumed, cells were transferred to a T-75 flask and used for experiments. 
2.2.2 Gene expression analysis by real-time PCR (RT-PCR) 
Gene expression analysis using SYBR greenTM was carried out in order to measure the 
changes in expression of genes of interest. The RT-PCR method is characterised by its 
sensitivity and specificity for the detection of the level of messenger RNA (mRNA) expression 
(Marone, Mozzetti et al. 2001). This technique was performed in three stages. Firstly, mRNA 
was extracted from cells of interest. Secondly, mRNA was reverse transcribed to 
complementary deoxyribonucleic acid (cDNA). Thirdly, the resultant cDNA was employed as 
a PCR amplification template using specific primers for the genes of the interest. During PCR 
amplification, the products of the genes of the interest were measured in real-time by assessing 
the fluorescence produced by SYBR green, when it binds to double-stranded DNA. The 
intensity of fluorescence reflects the amount of the target gene in the sample. The relative 
expression of the target genes was assessed by comparing their expression to the expression of 
the housekeeping gene β-actin.   
2.2.2.1 mRNA extraction 
This procedure was applied in order to extract and purify mRNA that will be used in 
synthesis of cDNA. mRNA was extracted using the RNeasy® Plus Mini Kit according to the 
manufacturer's instructions. Cells were suspended in 5% FBS media at a concentration of 5×105 
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cell/ml, seeded in 6-well plates, and treated in triplicate with the half maximal inhibitory 
concentrations (IC50) of HXR9, unless otherwise specified, with the equivalent concentrations 
of CXR9, or with media only. After treatment for two hours, cells were transferred into 
eppendorfs. Then eppendorfs were spun at 1000rpm for five minutes and supernatants were 
removed. After that, cells were lysed using RLT plus lysis buffer and β-mercaptoethanol, which 
inhibits RNase. Next, cell lysates were vortexed in order to lyse more cells and yield the 
maximum amount of RNA. Then, cell lysates were passed through a genomic DNA eliminator 
spin column to remove the genomic DNA. Ethanol was added to cell lysates to allow RNA 
binding to the RNeasy® silica gel membrane spin column. Then, cell lysates were washed using 
the provided buffer RW1 to remove biomolecules that were non-specifically bound to the 
membrane, such as carbohydrates, proteins, fatty acids, the small RNAs, ribosomal RNA and 
transferase RNA. After that, the silica membrane was washed twice by RPE buffer to remove 
ethanol. Finally, mRNA was eluted by using 35μl RNase-free water. mRNA samples were 
stored at -80ºC until needed.  
2.2.2.2 Measuring mRNA concentration 
mRNA concentration was quantified using the Nanodrop® spectrophotometer ND-
1000, which is based on the Beer Lambert law to  measure RNA concentration of 1μl of a 
sample in ng/μl by measuring the ultra violet light absorbance at 260nm. RNA sample purity 
was assessed using the 260/280 ratio, which should be more than two.  
2.2.2.3 Reverse transcription of mRNA into cDNA 
mRNA was reverse transcribed to cDNA using the Cloned AMV First-Strand cDNA 
Synthesis Kit, which initiates the reverse transcription to cDNA of all mRNA molecules present 
in a sample using the random primers method. mRNA samples were thawed on ice and 15μl 
containing 100ng RNA was prepared in 1.5ml eppendorfs using DEPC-treated water. An 
adequate volume of cDNA synthesis mix was prepared according to the manufacturer's 
39 
 
instructions and 5μl was added to each RNA sample (Table 2.3). The mixture was incubated at 
50°C for 30 minutes to synthesise cDNA followed by heating at 85°C for 5 minutes to terminate 
the reaction. Assuming cDNA synthesis efficiency was 100%, this produced almost 100ng of 
cDNA in 20μl at a concentration of 5ng/μl, which was further diluted to 2ng/μl by adding 30μl 
of DEPC-treated H2O and stored at -20°C.  
 
 
 
Table 2.3 cDNA synthesis mix. This table shows the components of the cDNA synthesis mix and volumes used 
to prepare a 5μl of the solution. 
  
cDNA synthesis mix components Volume per reaction (μl) 
5× Buffer 2 
10mM dNTP Mix 1 
0.1M DTT 0.5 
Oligo (dT)20 (50μM)  0.5 
RNaseOUTTM (40U/μl)  0.5 
Cloned AMV RT (15U/μl) 0.5 
Total volume 5 
 
2.2.2.4 Complementary PCR primers design 
Sequences of complementary primers for PCR amplification were designed using 
(http://simgene.com/Primer3). Tables 2.4 and 2.5 show the complementary primer sequences 
for the whole set of HOX genes and pro- and anti-apoptotic genes, respectively, that were 
assessed in this study. All used primers were stored at -20ºC and thawed on ice before use.  
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Table 2.4 HOX gene primers used for PCR amplification. 
Gene Forward Sequence 5’-3’  Reverse Sequence 5’-3’  
Amplicon Length 
(bp) 
HOXA1 CTGGCCCTGGCTACGTATAA TCCAACTTTCCCTGTTTTGG 153 
HOXA2 TTCAGCAAAATGCCCTCTCT TAGGCCAGCTCCACAGTTCT 176 
HOXA3 ACCTGTGATAGTGGGCTTGG ATACAGCCATTCCAGCAACC 227 
HOXA4 CCCTGGATGAAGAAGATCCA AATTGGAGGATCGCATCTTG 271 
HOXA5 CCGGAGAATGAAGTGGAAAA ACGAGAACAGGGCTTCTTCA 193 
HOXA6 AAAGCACTCCATGACGAAGG TCCTTCTCCAGCTCCAGTGT 158 
HOXA7 TGGTGTAAATCTGGGGGTGT TCTGATAAAGGGGGCTGTTG 285 
HOXA9 AATAACCCAGCAGCCAACTG ATTTTCATCCTGCGGTTCTG 203 
HOXA10 ACACTGGAGCTGGAGAAGGA GATCCGGTTTTCTCGATTCA 159 
HOXA11 CGCTGCCCCTATACCAAGTA GTCAAGGGCAAAATCTGCAT 279 
HOXA13 GGATATCAGCCACGACGAAT ATTATCTGGGCAAAGCAACG  176 
HOXB1 TTCAGCAGAACTCCGGCTAT CCTCCGTCTCCTTCTGATTG 157 
HOXB2 CTCCCAAAATCGCTCCATTA GAAAGGAGGAGGAGGAGGAA 259 
HOXB3 TATGGCCTCAACCACCTTTC AAGCCTGGGTACCACCTTCT 299 
HOXB4 TCTTGGAGCTGGAGAAGGAA GTTGGGCAACTTGTGGTCTT 155 
HOXB5 AAGGCCTGGTCTGGGAGTAT GCATCCACTCGCTCACTACA 189 
HOXB6 ATTTCCTTCTGGCCCTCACT GGAAGGTGGAGTTCACGAAA 184 
HOXB7 CAGCCTCAAGTTCGGTTTTC CGGAGAGGTTCTGCTCAAAG 249 
HOXB8 GTAGGCTTCAGCTGGGACTG GGGAGCCTTTGCTTAAATCC 265 
HOXB9 TAATCAAAGACCCGGCTACG CTACGGTCCCTGGTGAGGTA 198 
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Gene 
 
 
Forward Sequence 5’-3’  
 
 
Reverse Sequence 5’-3’  
 
 
Amplicon Length 
(bp) 
HOXB13 CTTGGATGGAGCCAAGGATA CCGCCTCCAAAGTAACCATA 234 
HOXC4 CGCTCGAGGACAGCCTATAC GCTCTGGGAGTGGTCTTCAG 276 
HOXC5 CAGTTACACGCGCTACCAGA AGAGAGGAAAGGCGAAAAGG 268 
HOXC6 AAGAGGAAAAGCGGGAAGAG GGTCCACGTTTGACTCCCTA 190 
HOXC8 CTCAGGCTACCAGCAGAACC TTGGCGGAGGATTTACAGTC 150 
HOXC9 AGACGCTGGAACTGGAGAAG AGGCTGGGTAGGGTTTAGGA 190 
HOXC10 CGCCTGGAGATTAGCAAGAC GGTCCCTTGGAAGGAGAGTC 289 
HOXC11 CGGAACAGCTACTCCTCCTG CAGGACGCTGTTCTTGTTGA 186 
HOXC12 CAAGCCCTATTCGAAGTTGC GCTTGCTCCCTCAACAGAAG 180 
HOXC13 GTGGAAATCCAAGGAGGACA TTGTTGAGGGACCCACTCTC 170 
HOXD1 TTCAGCACCAAGCAACTGAC TAGTGGGGGTTGTTCCAGAG 232 
HOXD3 CAGCCTCCTGGTCTGAACTC ATCCAGGGGAAGATCTGCTT 176 
HOXD4 TCAAATGTGCCATAGCAAGC TCCATAGGGCCCTCCTACTT 173 
HOXD8 TCAAATGTTTCCGTGGATGA GCTCTTGGGCTTCCTTTTTC 290 
HOXD9 TCCCCCATGTTTCTGAAAAG GGGCTCCTCTAAGCCTCACT 236 
HOXD10 GCTCCTTCACCACCAACATT AAATATCCAGGGACGGGAAC 154 
HOXD11 GGGGCTACGCTCCCTACTAC GCTGCCTCGTAGAACTGGTC 253 
HOXD12 CGCTTCCCCCTATCTCCTAC CTTCGGGCGCATAGAACTTA 201 
HOXD13 GGGGATGTGGCTCTAAATCA AACCTGGACCACATCAGGAG 265 
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Table 2.5 Pro- and anti-apoptotic and β-actin gene primers used for PCR amplification. 
Gene Forward Sequence 5’-3’  
 
Reverse Sequence 5’-3’  
 
Amplicon Length 
(bp) 
Bad CGGAGGATGAGTGACGAGTT GATGTGGAGCGAAGGTCACT 180 
Bak1 TTTTCCGCAGCTACGTTTTT GGTGGCAATCTTGGTGAAGT 248 
Bax TTTGCTTCAGGGTTTCATCC CAGTTGAAGTTGCCGTCAGE 246 
Bcl2 GAGGATTGTGGCCTTCTTTG ACAGTTCCACAAAGGCATCC 170 
Bid CTGCAGGCCTACCCTAGAGA ACTGTCCGTTCAGTCCATCC 195 
XIAP GGGGTTCAGTTTCAAGGACA CGCCTTAGCTGCTCTTCAGT 182 
Apaf1 TTCTGATGCTTCGCAAACAC CTGGCAAATCTGCCTTCTTC 237 
Caspase-3 TTTTTCAGAGGGGATCGTTG CGGCCTCCACTGGTATTTTA 151 
Caspase-6 ATCCTCACCGGGAAACTGTG AATTGCACTTGGGTCTTTGC 161 
Caspase-7 AGTGACAGGTATGGGCGTTC CGGCATTTGTATGGTCCTCT 164 
Caspase-9 CTAGTTTGCCCACACCCAGT GCATTAGCGACCCTAAGCAG 172 
PARP1 GCTCCTGAACAATGCAGACA CATTGTGTGTGGTTGCATGA 233 
c-FOS CCAACCTGCTGAAGGAGAAG GCTGCTGATGCTCTTGACAG 232 
p21 GACACCACTGGAGGGTGACT 
 
CAGGTCCACATGGTCTTCCT 171 
p53 GTGGAAGGAAATTTGCGTG CCAGTGTGATGATGGTGAGG 
 
183 
β-actin  ATGTACCCTGGCATTGCCGAC GACTCGTCATACTCCTGCTTG 227 
 
2.2.2.5 RT-PCR  
Each gene of interest was tested in triplicate. The housekeeping gene β-actin was used 
as an endogenous control. An adequate volume of PCR mastermix was prepared in an 
eppendorf as detailed in table 2.6. This mastermix contains cDNA, SYBR® Green JumpStartTM 
Taq ReadyMixTM, ROX reference dye and DEPC-treated H2O. 20μl of the PCR mastermix was 
added into three wells of a Mx 3000P® 96-well plate for each gene. 5μl of 1μM of each primer 
pair was added into the designated wells. Plates were then sealed with optical caps and 
centrifuged at 1500rpm for 1 minute to bring all reagents to the well bottoms and remove air 
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bubbles. The Plates were then run on a Stratagene Mx3005P thermal cycler. The thermal 
profiles employed were: heating once for 10 minutes at 95°C, followed by 30 seconds at 95°C, 
1 minute at 60°C, 30 seconds at 72°C for 40 cycles. After completing the thermal profiles, the 
detected fluorescence of each reaction was converted to cycle threshold using MxPro software. 
The mean of the cycle threshold values of the triplicate repeats for each gene was calculated 
and used for measuring gene expression, as detailed below.  
 
 
Table 2.6 RT-PCR reaction components. This table shows the components of single RT-PCR reaction. All 
components were stored at -20°C and thawed on ice before use. 
PCR reaction components Volume per reaction (μl) 
cDNA (2ng/μl) 1 
DEPC-treated H2O 6.25 
SYBR® Green JumpStartTM Taq ReadyMixTM 12.5 
ROX reference dye 0.25 
Primers-forward and reverse mixture 5 
Total volume 25 
 
 
2.2.2.6 RT-PCR data analysis 
A previously described relative quantification method was used to analyse RT-PCR data 
(Livak and Schmittgen 2001). Two steps were performed in this analysis. Firstly, the expression 
of genes of interest was normalised to the expression of the housekeeping gene β-actin. 
Secondly, the normalised data of genes of interest of HXR9 or CXR9 treated samples were 
compared to that of untreated control samples. Microsoft Excel was used to perform all 
calculations. Experiments were repeated three times. Results were expressed as the mean of the 
relative gene expression of the three experiments with error bars to show the standard error of 
mean (SEM).    
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2.2.3 Lactate dehydrogenase (LDH) assay 
LDH is present in the cytoplasm of all cells. It is released into culture medium if the cell 
membrane is permeablized. Therefore, the amount of this enzyme in the culture medium 
indicates to the integrity of cell membrane and hence provides an estimation of cytotoxicity 
(Haslam, Wyatt et al. 2000). LDH activity is assessed in two steps. Firstly, LDH oxidises lactate 
to pyruvate by reducing NAD+ to NADH/H+. Secondly, diaphorase, a catalyst, transfers 2H 
from NADH/H+ to a tetrazolium salt (INT) which results in the formation of the red salt 
formazan. Hence, the amount of formazan formed directly correlates to the amount of LDH in 
the culture medium and thereby to the number of damaged cells (Figure 2.2).  
 
 
Figure 2.2 LDH cytotoxicity assay. LDH catalyses the reduction of NAD⁺ to NADH⁺/H⁺ through the conversion 
of lactate to pyruvate. Then, diaphorase reduces the yellow tetrazolium salt INT to the red formazan salt in the 
presence of NADH⁺/H⁺.  
 
The LDH assay was used to measure the cytotoxicity of HXR9, daunorubicin (DNR) 
and mitoxantrone (MTX). In HXR9 cytotoxicity determination, cells were treated with HXR9 
or its negative control CXR9 for 2 hours. In DNR or MTX cytotoxicity determination, cells 
were treated with either drug for 24 hours as per the following:  
Cells were suspended in 5% FBS of the appropriate culture medium at a concentration of 5×105 
cell/ml and seeded in 96-well flat-bottom plates at a concentration of 5×104 cell/well. Then cells 
were treated with 100μl of a serial dilution of the tested drug, which have been already diluted 
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in 5% FBS of the appropriate culture medium. Each plate included untreated cells (negative 
control), 2% triton-treated cells (positive control), and 5% FBS medium only (background 
control). Each condition was repeated six times. The plates were incubated in a humidified 
incubator at 37ºC, 5% CO2 for either 2 or 24 hours according to the tested drug. After treatment, 
the plates were spun at 1000rpm for 5 minutes and 100μl of supernatant was decanted from 
each well into a fresh, 96-well flat-bottom plate. An equal amount of LDH reagent was prepared 
according the manufacturer's instructions and added to the supernatants for two minutes, and 
then LDH enzymatic activity was estimated by reading the absorbance at 492nm, using a plate 
reader.  
2.2.3.1 LDH assay data analysis 
In order to assess the percentage of surviving cells, the cytotoxicity percentage was 
calculated first. The average absorbance values of the six repeats of each condition were 
calculated. Then, the average absorbance value of the background control was subtracted from 
each of the other conditions average absorbance values. After that, the cytotoxicity percentage 
was calculated according to the manufacturer's instructions as per the following: 
 Cytotoxicity% =
 treated value−negative control 
positive control−negative control
 × 100 
Then, the proportion of surviving cells was determined as the following: 
%surviving cells = 100 - cytotoxicity  
The %surviving cells was plotted on X-Y scatter diagrams using GraphPad Prism 
software (California, USA) in order to create cytotoxicity curves for each cell line and drug. 
Therefore, the surviving fractions of treated cells can be compared to those of untreated cells. 
Additionally, the cytotoxicity results of the different cell lines can be compared.   
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Each experiment was repeated at least three times (biological repeats) and each valid 
experimental curve should have a linear correlation coefficient (R2) ≥ 0.95. The cytotoxicity 
curves were generated using the mean %surviving cells at different drug concentrations. 
Additionally, the SEM of each single dose was determined and included as an error bar on the 
cytotoxicity curves. 
IC50 was then calculated by CalcuSyn software (Biosoft, Cambridge, UK) as described 
in statistical analysis.  
2.2.4 Assessment of drug combination interaction by LDH 
This assay was performed in vitro to evaluate the interaction levels (synergism, additive, 
or antagonism) between HXR9 and the chemotherapeutic drugs DNR or MTX. 
Cells were suspended in 5% FBS medium and seeded in 96-well flat-bottom plates at a 
concentration of 5×104 cell/well. Then, cells were treated with 100μl of five increasing 
concentrations (IC12.5, IC25, IC50, IC75, IC100) of each drug alone or in combination with HXR9. 
For single treatments, cells were treated with HXR9 or with a chemotherapeutic drug, DNR or 
MTX, for 2 or 24 hours, respectively. For combination treatment, cells were treated with either 
DNR or MTX for 24 hours and HXR9 was added for the last 2 hours of treatment. Each 
treatment was repeated in triplicate. Each plate included negative, positive and background 
controls. After treatment, plates were spun for 5 minutes at 1000rpm, 100μl of supernatant was 
decanted into new 96-well flat-bottom plates and 100μl LDH reagent was added. The 
cytotoxicity was then determined as described for the LDH assay data analysis section and the 
evaluation of the drug interaction between HXR9 and the chemotherapeutic drugs was 
performed as described for the analysis of drug combination assay data section. The 
combination assay data were plotted on column graphs using GraphPad Prism software.  
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2.2.5 Annexin V- PE assay 
The annexin V-PE assay was used to quantify the percentage of the apoptotic cells and 
evaluate the mechanism of cell death. This assay is based on the cell membrane permeability 
of the apoptotic cells. During early stages of apoptosis, the membrane bound phospholipid 
phosphatidlyserine (PS) translocates from the inner surface of the cellular plasma membrane to 
the external surface, where it can be detected by annexin V protein that has a high phospholipid-
binding affinity. Annexin V is conjugated to PE (a fluorochrome) and this compound is used as 
a probe for cell analysis by flow cytometry (Vermes, Haanen et al. 1995). Therefore, 
quantification of exposed PS using PE labelled annexin V by flow cytometry is considered a 
sensitive measurement of apoptosis (Koopman, Reutelingsperger et al. 1994). In addition, 7-
amino actinomycin D (7-AAD), which is a membrane impermeable fluorescent DNA binding 
stain that selectively interacts with guanine and cytosine bases in double-stranded DNA, was 
used to distinguish between viable and non-viable cells (Philpott, Turner et al. 1996). Viable 
cells stain negative with both reagents. Early apoptotic cells stain positive for annexin V-PE 
only. Late apoptotic, necrotic, or dead cells stain positive for both stains, as shown in table 2.7. 
The late apoptotic/ necrotic cells will be reflected to in this study as dead cells, because this 
assay cannot definitely differentiate between these two conditions (Figure 2.3).  
Cells were suspended in 5% FBS of the appropriate culture medium at a concentration 
of 1×106 cell/ml and seeded in 96-well flat-bottom plates at a concentration of 1×105 cell/well. 
Then cells were treated either with 100μl of a serial HXR9 dilution or with a high CXR9 
concentration in triplicate. Each plate included untreated cells (negative control). The plates 
were incubated in a humidified incubator at 37ºC, 5% CO2 for two hours. After two-hour 
treatment, the plates were spun at 1000rpm for five minutes and supernatants were removed. 
Cell pellets were washed twice with cold phosphate buffered saline (PBS) and then cells re-
suspended in 20μL of 1X binding buffer (0.1M Heps/NaOH (pH 7.4), 1.4M NaCl, 25mM 
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CaCl2). Cell suspensions were transferred to culture tubes. 5μL of both annexin V-PE and 7-
AAD were added and then cell suspensions were incubated at the room temperature (RT) for 
15 minutes in the dark. Then, 200μL of 1X binding buffer were added to tubes and analyzed by 
a flow cytometry.  
The percentage of the different cell populations, viable, early apoptotic and dead cells, 
were plotted by GraphPad Prism software (California, USA) on column graphs to allow the 
comparison of treated and untreated negative control cells. Each experiment was repeated at 
least three times independently.  
Table 2.7 Different cell populations in the annexin V-PE assay. 
Annexin V 7-AAD  Cell Stage 
Negative Negative Viable  
Positive Negative Early apoptosis 
Positive Positive Late apoptosis or necrosis (dead 
cells) 
 
             
Figure 2.3 A flow cytometry plot shows different cell populations in the annexin V-PE assay. In the left bottom 
corner are the viable cells that are negative for annexin V and 7-AAD. In the right bottom corner are the early 
apoptotic cells that are stained with annexin V only. In the top part are dead cells that are stained with both annexin 
V and 7-AAD.  
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2.2.6 Caspase-3 activity assay 
Activation of caspases is a key event in apoptosis. In particular, caspases-3/7 are 
considered as executioner caspases that recognise and cleave numerous proteins containing the 
DEVD sequence such as poly ADP ribose polymerase (PARP), resulting in cell apoptosis. The 
caspase-3 assay is based on the ability of active caspase-3 to cleave a synthetic DEVD sequence. 
DEVD is covalently linked to R110 in a compound called Z-DEVD-R110, which suppresses 
the fluorescence R110. The caspase cleavage of DEVD results in R110 fluorescence, which is 
measured at excitation wavelength 492nm and emission wavelength 520nm. Ac-DEVD-CHO 
is a caspase-3/7 inhibitor that can be used to verify the resultant fluorescence is due to caspase-
3 activity. A reference standard can be used to quantify the R110 produced in the reaction. 
 
Cells were suspended in the appropriate culture medium plus 5% FBS at a concentration 
of 2×106 cell/ml and seeded in eppendorfs at a concentration of 1×106 cell/reaction. Cells were 
treated, in triplicate, with 500μl of different HXR9 concentrations or with 500μl of an 
equivalent CXR9 concentration to the highest HXR9 concentration. Each experiment included 
untreated cells (negative control). The plates were then incubated in a humidified incubator at 
37ºC, 5% CO2 for two hours. After the treatment for two hours, eppendorfs were spun at 
1000rpm for 5 minutes and supernatants were removed. Cell pellets were then washed with 
PBS and re-suspended in 100μl of 1X cell lysis buffer and incubated on ice for 30 minutes. The 
lysed cells were then spun at 5000rpm for 5 minutes and 50μl of the supernatant was transferred 
to a new 96-well flat bottom black plate. 50μl of the lysis buffer was added into separate wells 
as non-enzyme controls in order to measure the substrate background fluorescence. As an 
additional control, 1μl of 1mM Ac-DEVD-CHO inhibitor was added to selected samples that 
were incubated at RT for 10 minutes in the dark. During this time, the remaining samples 
(without inhibitors) were kept on ice. 50μl of 500μM Z-DEVD-R110 substrate was then added 
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to all samples. The supernatants were incubated with the substrate for 30 minutes in the dark. 
Serial concentrations of the reference standard were added to the plates in order to quantify 
R110 fluorescence produced in the reaction. Finally the caspase-3 activity was measured by 
reading the plates at 492nm by the plate reader. 
2.2.6.1 Caspase-3 activity data analysis 
For each individual experiment, the average fluorescent value for the different 
conditions was calculated, and the lysis buffer reading (background) was subtracted from the 
other average values. Then, the resultant values were plotted on column graphs using GraphPad 
Prism software to compare caspase-3 activity and calculate the statistical significance between 
untreated control cells and cells treated either with HXR9 or CXR9. 
  
In order to validate each experiment, the reference standard data were plotted separately 
on X-Y scatter graphs and each valid reference standard curve should have R2 ≥ 0.95.  
Each experiment was performed at least in triplicate. The caspase-3 activity data were 
generated by the mean of the fluorescent values of the different cell conditions. The SEM of 
each single dose was determined and included on the graphs.     
2.2.7 Cell cytospins and 4',6-diamidino-2-phenylindole (DAPI) staining 
Cytospin is a method used to concentrate cells. After cell cytospinning, cell morphology 
can be evaluated by staining. DAPI is a cell-permeable blue fluorescent stain that binds 
specifically to the minor groove adenine-thymine regions of double-stranded DNA. The 
binding of DAPI with DNA intensifies the fluorescence about 20 fold and this can be imaged 
using a fluorescence microscope or flow cytometry.  DAPI stain is used to assess apoptosis by 
visualising the nuclear morphology changes such as chromosome condensation and 
fragmentation (Kapuscinski 1995). 
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Cells were suspended in 5% FBS culture medium at a concentration of 1×106 cell/ml 
and seeded in 24-well plates at a concentration of 5×105 cell/well. Then cells were treated either 
with 500μl of HXR9 the IC50 or double the IC50, in duplicate. Each plate included untreated 
negative control cells. The plates were incubated in a humidified incubator at 37ºC, 5% CO2 
for two hours, after which cells were transferred into eppendorfs. Harvested cells were washed 
twice with PBS, and fixed in 4% formaldehyde/PBS solution.  
 Cytospinning was then performed. Microscope-slides, filter cards and cytofunnels were 
assembled using cytospin holders and then the entire apparatus was placed in a cyto-centrifuge. 
Then, 300μl of 4% formaldehyde/PBS fixed cells was added to the cytofunnels and spun at 
500rpm for 5 minutes. Next, the apparatus was dis-assembled. Slides were stained with 1 drop 
of 1:1000 DAPI/PBS for 5 minutes in the dark. After staining, excess DAPI/PBS was removed 
and 1 drop of the mounting media 40% glycerol/PBS added. Then, slides were covered with 
slip covers and sealed using nail vanish. Finally, images were captured with 20x lenses by a 
fluorescent microscope. 
2.2.8 Inhibition of caspases activity by z-VAD-FMK 
Z-VAD-FMK is a cell permeable general caspase inhibitor. It can prevent the induction 
of apoptosis through irreversible binding to caspase protease catalytic sites (Marcelli, 
Cunningham et al. 1999). Pre- and co-treatment of cells with z-VAD-FMK assay was used to 
investigate the role of caspases in cell death. Z-VAD-FMK was diluted in DMSO at 43mM and 
stored at -20ºC.   
Some wells were pre-treated with 50μM z-VAD-FMK. Cells were suspended in 5% 
FBS culture media at a concentration of 1×106 cell/ml and seeded in 96-well flat-bottom plates 
at a concentration of 1×105 cell/well. The plates were then pre-incubated in a humidified 
incubator at 37ºC, 5% CO₂ for one hour. Meanwhile, HXR9 and CXR9 were prepared in 5% 
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FBS media either with or without 50μM z-VAD-FMK. After one hour pre-incubation, cells 
were treated in triplicate with 100μl of HXR9 IC50, double the IC50, or with a CXR9 
concentrations equivalent to double the IC50. Additionally, each plate included untreated 
negative control cells and DNR treated cells as positive control cells. The plates were then 
incubated in a humidified incubator at 37ºC, 5% CO2 for two hours. After treatment for two 
hours, the plates were spun at 1000rpm for five minutes and supernatants were discarded. Cell 
pellets were washed twice with cold PBS and then stained with annexinV-PE as described for 
the annexinV-PE assay section. Data were plotted as described for the annexinV-PE assay. 
Statistical significance was assessed by comparing the data of untreated cells to those of pre- 
and co-treated with 50μM z-VAD-FMK. 
2.2.9 Cyclosporin A (CsA) protection assay 
CsA attenuates mitochondrial permeability transition pore (mPTP) formation by 
binding to cyclophilin D (cypD), which is required for mPTP formation in necrotic 
mitochondrial cell death (Li, Johnson et al. 2004; Basso, Fante et al. 2005; Dube, Selwood et 
al. 2012). CsA was diluted in DMSO to a stock concentration of 20mM, aliquoted and stored 
at -20ºC.  
In this assay cells were pre- and co-treated with or without 5μM CsA and hydrogen 
peroxide (H2O2) treatment was used as a positive control. Cells were suspended in 5% FBS 
culture medium at a concentration of 1×106 cell/ml and seeded in 96-well flat-bottom plates at 
a concentration of 1×105 cell/well. The plates were then pre-incubated in a humidified incubator 
at 37ºC, 5% CO2 for one hour. Meanwhile, HXR9 and H2O2 were prepared in 5% FBS medium 
either with or without 5μM CsA. After one hour pre-incubation, cells were treated in triplicate 
with 100μl of HXR9 at the IC50, double or triple the IC50 or with 20mM H2O2. Additionally, 
each plate included untreated negative control cells. The plates were then incubated in a 
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humidified incubator at 37ºC, 5% CO2 for two hours. After treatment for two hours, the plates 
were spun at 1000rpm for 5 minutes and supernatants were discarded. Cell pellets were washed 
twice with cold PBS and then stained with annexinV-PE as described for the annexinV-PE 
assay. Data analysis was performed by flow cytometry.  
The percentage of viable cells was plotted using GraphPad Prism software on column 
graphs. Each experiment was repeated at least three times independently.  
2.2.10  Necrostatin-1 (Nec-1) protection assay 
Nec-1 is a selective inhibitor of receptor interacting protein 1 (RIP1) (Degterev, Hitomi 
et al. 2008). RIP1 inhibition prevents a form of programmed necrosis called necroptosis 
(Degterev, Huang et al. 2005). Nec-1 was diluted in DMSO to a stock concentration 40mM and 
stored at -20ºC. In this experiment, some cells were pre- and co-treated with 50μM Nec-1. The 
experiment and data analysis was performed as described for the CsA protection assay. 
2.2.11  Fructose protection assay 
Fructose is a glycolytic substrate that at high concentrations significantly sequesters 
phosphate and accordingly intracellular adenosine triphosphate (ATP) is depleted (Figure 2.4). 
This selective depletion of ATP protects cells from apoptosis, but leaves enough levels (15%) 
of ATP to rescue cells from spontaneous necrosis (Nieminen, Saylor et al. 1994). 
  
 
Figure 2.4 ATP depletion by fructose. 
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Cells were pre- and co-treated with a high concentration of fructose (40mM). Fructose 
was freshly dissolved in 5% FBS culture medium. Cells were suspended in 5% FBS culture 
medium supplemented with or without 40mM fructose and seeded in 96-well flat-bottom plates 
at a concentration of 5×104 cell/well. The plates were then incubated at 37ºC, 5% CO2 for one 
hour. Serial HXR9 concentrations were prepared in 5% FBS media either with or without 
40mM fructose. After an hour pre-incubation, cells were treated in triplicate with 100μl of the 
different HXR9 concentrations or 2% triton as a positive control. Additionally, each plate 
contained cells incubated with 5% FBS medium as a low control and background wells 
contained 5% FBS medium only. After treatment for two hours, the plates were spun at 
1000rpm for 5 minutes and 100μl of each supernatant was decanted into fresh, 96-well flat-
bottom plates. Finally, LDH reagents were added as described in the LDH assay section. 
Similarly, data analysis was performed as for the LDH assay. The statistical significance of the 
effect of fructose on the cytotoxicity of HXR9 was performed by comparing the survival 
fractions of fructose treated and untreated cells.   
2.2.12 The effect of ethilenediaminetetra-acetic acid (EDTA) on HXR9 cytotoxicity 
EDTA is a calcium ions (Ca2+) chelator that was used to investigate the role of 
extracellular Ca2+ in the cytotoxicity of HXR9. The role of Ca2+ was assessed by two different 
assays, LDH and annexin V, as described for the fructose protection and CsA protection assays, 
respectively. In both assays, cells were pre- and co-treated with or without 20mM EDTA 
dissolved in 5% FBS medium. The statistical significance of the effect of EDTA on the 
cytotoxicity of HXR9 assessed by comparing the survival fraction of EDTA treated cells to 
untreated cells. 
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2.2.13 The effect of HXR9 on mitogen activated protein kinase (MAPK) pathways 
MAPKs are a family of protein kinases regulating many essential cellular pathways 
including cell survival, proliferation and apoptosis. The most extensive studied MAPK 
pathways are extracellular signal-regulated kinase (ERK), Jun N-terminal kinase (JNK) and 
p38 (Dhillon, Hagan et al. 2007). The effect of HXR9 on those pathways was studied by 
blocking each pathway using a specific inhibitor. The inhibitors used were U0126 
monoethanolate, SP600125 and SB203580 for ERK, JNK and p38, respectively. The inhibitor-
stocks were dissolved in DMSO at concentrations 1mM, 25mM and 5mM of U0126 
monoethanolate, SP600125 and SB203580, respectively. U0126 monoethanolate and 
SP600125 were stored at 4ºC while SB203580 stored at -20ºC until needed.  
In all of the assays that investigate the effect of HXR9 on ERK, JNK and p38 pathways, 
cells were pre- and co-treated with or without the inhibitors. The working concentrations used 
were 20μM, 60μM and 25μM for U0126 monoethanolate, SP600125 and SB203580, 
respectively. Experiments were performed as described for the fructose protection assay; 
however, data were plotted in column diagrams. The statistical significance of the effect of 
blocking MAPK pathways on the cytotoxicity of HXR9 was determined by comparing the 
survival fraction of the different-inhibitors-treated and untreated cells.  
2.2.14 The effect of inhibition of NADPH oxidase (NOX) on HXR9 efficacy 
NOX is a generator of intracellular reactive oxygen species (ROS) (Lambeth 2004). The 
effects of NOX on the efficiency of HXR9 were assessed using an inhibitor called 
diphenyleneiodonium chloride (DPI). DPI is widely used to block the effect of NOX in spite of 
its non-specific binding (Park, Song et al. 2007). DPI stock was dissolved in DMSO at 15mM 
and stored at -20ºC until used.  
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Cells were pre- and co-treated with or without 60μM DPI. The assessment of DPI effect 
on the cytotxicity of HXR9 was performed as described for the fructose protection assay and 
data were plotted in column diagrams. The statistical significance was assessed by comparing 
the survival fraction of DPI treated and untreated cells.  
2.2.15 Role of μ-calpain in HXR9 cell killing 
Calpains are Ca2+-dependent cysteine proteases that commonly activated in Ca2+ 
involved cell death mechanisms (Liu, Van Vleet et al. 2004). Among them, μ-calpain is one of 
the most extensively studied in apoptosis/necrosis processes. Calpain inhibitor I (N-Acetyl-
Leu-Leu-Norleu-al) was used to inhibit the Ca2+/μ-calpain pathway. Calpain inhibitor I was 
dissolved in DMSO at a concentration 20mM and stored at -20ºC until used.  
Cells were pre- and co-treated with or without 60μM calpain inhibitor I. The assessment 
of the role of μ-calpain in the cytotxicity of HXR9 was performed as described for the fructose 
protection assay and data were plotted in column diagrams. The statistical significance was 
assessed by comparing the survival fractions of calpain inhibitor I treated cells to untreated 
cells. 
2.2.16 The effect of calmodulin (CaM) inhibition on HXR9 cytotoxicity 
CaM is one of the main intracellular regulators of Ca2+ (Yuan, Jing et al. 2011). W-7 
(N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride) was used to inhibit 
CaM and assess its role in HXR9 cytotoxicity. W-7 was dissolved in DMSO at a concentration 
50mM and stored at -20ºC.  
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Cells were pre- and co-treated with or without 50μM W-7. The assessment of the effect 
of the inhibition of CaM on the cytotoxicity of HXR9 was performed as described for the 
fructose protection assay and data were plotted in column diagrams. The statistical significance 
was determined by comparing the survival fractions of W-7 treated cells to untreated cells. 
2.2.17 The effect of protein kinase C (PKC) inhibition on HXR9 cytotoxicity 
 PKC is one of the kinases that are affected by intracellular Ca2+ concentrations. Ro31-
8220 (methanesulfonate salt) was used to inhibit and assess the role of PKC in HXR9 
cytotoxicity. Ro31-8220 was dissolved in H2O at a stock concentration 20mM and stored at 
4ºC. Cells were pre- and co-treated with or without 30μM Ro31-8220. The assessment of the 
effect of the inhibition of PKC on the cytotxicity of HXR9 was done as performed for the 
fructose protection assay and data were plotted in column diagrams. The statistical significance 
was assessed by comparing the survival fractions of Ro31-8220 treated cells to untreated cells. 
2.2.18 The effect of the heme oxygenase-1 (HO-1) inhibition on HXR9 cytotoxicity 
HO-1 is an anti-apoptotic protein (Rushworth and MacEwan 2008). Protoporphyrin IX 
(PPIX) was used to inhibit HO-1 protein and assess its role in the cytotoxicity of HXR9. PPIX 
was dissolved in DMSO at a stock concentration 18mM and stored at -20ºC. Cells were pre- 
and co-treated with or without 50μM of PPIX. The effect of HO-1 inhibition on HXR9 
cytotoxicity was determined as described for the fructose protection assay and data were plotted 
in column diagrams. The statistical significance was performed by comparing the survival 
fraction of PPIX treated cells and untreated cells. 
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2.2.19 The effect of the p53 inhibition on HXR9 cytotoxicity 
Pifithrin-α (PFT-α) is an inhibitor of p53-dependent apoptosis and was used to block 
and assess the role of p53 in the cytotoxicity of HXR9. PFT-α was dissolved in DMSO at a 
stock concentration 20mM and stored at -20ºC. Cells were pre- and co-treated with or without 
40μM of PFT-α. The role of p53 in HXR9 cytotoxicity was assessed as described for the 
fructose protection assay and data were plotted in column diagrams. The statistical significance 
was calculated by comparing the survival fraction of PFT-α treated cells and untreated cells. 
2.2.20 Western blotting (WB) for protein expression 
WB was conducted to assess the difference in protein expression between untreated 
cells and HXR9 treated cells. This assay requires treatment of cell lines with HXR9, extraction 
of cytosolic proteins, proteins separation based on their sizes and blotting on a membrane. 
Finally, the proteins of interest are detected by labelled antibodies. In order to compare the 
expression of protein in different samples, the same amount of protein was loaded in each well 
and the same dilution of antibodies was used. 
Cells were suspended in 5% FBS medium at a concentration of 1.5×106 cell/ml and 
seeded in 24-well plates. Then cells were treated with 1ml of 15μM or 30μM HXR9. Each plate 
included untreated cells as a negative control. Each condition was repeated three times. The 
plates were incubated in a humidified incubator at 37ºC, 5% CO₂ for two hours. After treatment 
for two hours, the three repeats of each condition were gathered in one 25ml universal tube and 
centrifuged for 5 minutes at 1500rpm at 4ºC. Supernatants were decanted and cell pellets were 
washed twice with 5ml ice cold PBS. Cell pellets were collected in eppendorfs and lysed as 
described for the preparation of cell lysate.  
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2.2.20.1 Preparation of cell lysate  
Cell pellets containing 4.5×106 cells were suspended in 300μl RIPA solution with 10μl 
of inhibitor cocktail (protease and phosphatase inhibitor) and 10μl of 1mM EDTA. Cell 
suspensions were incubated on ice for 15 minutes and agitated at least twice. Cell membranes 
were sheared by passing cells through 21 gauge needles attached to 1ml syringes for at least 4-
5 times. Cell suspensions were centrifuged at 13000rpm for 5 minutes at 4ºC and supernatants 
were transferred to new eppendorfs. The protein concentration in cell lystaes was determined 
using a bicinchonic acid (BCA) assay. 
2.2.20.2 Measuring protein concentrations by pierce Bradford city assay (BCA) 
This assay was used to measure protein concentrations in cell lysates. It is based on 
reduction of copper Cu2+ to cuprous ion Cu+ by proteins. Cu+ then chelates with two molecules 
of BCA to form a purple-coloured product that can be detected by a 96-well plate reader at 
562nm. The intensity of the formed colour increases linearly with increasing protein 
concentrations allowing protein concentrations to be calculated using a standard curve made of 
bovine serum albumin (BSA). This assay was performed as follows:  
25μl of samples were added in duplicate in 96-well flat-bottom plates. Additionally, each plate 
contained a BSA series dilution added in duplicate. To each sample and standard well, 200μl 
of BCA working reagent, a combination of reagents A and B in a ratio 50:1, was added. The 
plates were gently agitated on a plate shaker and incubated for 30 minutes at 37ºC. After the 
incubation, the plates were left at RT for 5 minutes in the dark before reading the absorbance 
on a plate reader. The absorbance means for the duplicate repeats of each sample and standard 
were calculated. The standard curve was then generated by the absorbance means of BSA series 
dilutions and their corresponding concentrations using Microsoft Excel. Finally, the protein 
concentrations of the samples were calculated using the standard curve linear regression 
equation.  
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2.2.20.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) for 
protein separation 
Cellular proteins were separated based on size using SDS-PAGE. First, 20μl samples 
were prepared (13μl cell lysate, 5μl sample buffer and 2μl reducing agent) and heated at 70ºC 
for 10 minutes. Second, a Novex® NuPAGE 4-12% Bis-Tris Gel, which is used to separate 
proteins, was placed in an XCell SureLockTM Mini-Cell electrophoresis system that contained 
800ml NuPAGE® MES SDS running buffer, which prepared by adding 20 parts of water to the 
buffer. Third, 10μl of Novex® sharp pre-stained marker was loaded in the first well of every 
gel. Forth, 20μl of samples were loaded in the remaining wells. Finally, protein separation was 
performed by running gels at 200 volt for one hour.  
2.2.20.4 Transferring proteins to polyvinylidene fluoride (PVDF) membranes 
 After electrophoretic separation, proteins were transferred to PVDF membranes. Firstly, 
PVDF membranes were soaked in methanol for 2 minutes while filter papers were soaked in 
water. Membranes were then placed in Invitrogen Electrophoresis System and covered with the 
gel and then the filter papers and on top of that transfer sponges were placed. Finally, proteins 
were transferred by running at 30V for 7 minutes.  
2.2.20.5 Detection of proteins by antibodies  
 After transferring proteins, PVDF membranes were blocked in 5% blocking buffer (5% 
(w/v) dried non-fat milk powder, 0.1% (v/v) Tween-20) with gentle rocking for 2 hours at RT. 
Then, the membranes were incubated with primary antibodies with gentle rocking overnight at 
4ºC. After overnight incubation, the membranes were washed 4 times with 0.1% Tween PBS 
solution for 10 minutes at RT with gentle rocking to remove unbound antibodies. Then, the 
membranes were incubated with secondary antibodies for 2 hours at RT with gentle rocking; 
the antibodies used in WB are listed in table 2.8. After 2 hours incubation, membranes were 
washed 3 times, as above. Then, membranes were exposed to superSignal® West Pico 
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Chemiluminescent substrate according to the manufacturer's recommendation. Next, 
membranes were exposed to carestream® Kodak BioMax® light film for 3 minutes to visualise 
the chemiluminescence. After that, films were developed and then fixed using developer and 
fixer, respectively. 
 
Table 2.8 Antibodies used in WB and working dilutions. 
Antibody Type Isotype Molecular 
weight (KDa) 
Working 
concentration 
Supplier 
Primary anti-
PARP1 
Monoclonal Mouse IgM 116 1/4000 Abcam 
Primary anti-β-
actin 
Polyclonal Rabbit IgG 42 1/10000 
Secondary for 
anti-PARP 
Polyclonal Goat IgG  1/4000 
Secondary for 
anti-β-actin 
Polyclonal Goat IgG  1/2000 
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2.2.21 In vivo assays 
2.2.21.1 Cell preparations 
Cells used for in vivo experiments were C1498-GFP and K562 cell lines. Cells were 
spun for 3 minutes and re-suspended and washed twice in HANKS medium. C1498-GFP and 
K562 cells were then suspended in serum-free HANKS medium at density 1x107cell/ml and 
5x107 cell/ml, respectively. 
2.2.21.2 Systemic injection of C1498-GFP in C57BL/6 and nude mice 
C57BL/6 and nude mice were warmed by a heat lamp in order to dilate the vain. C1498-
GFP cells were then injected into the tail vain (1x106 cell/mouse) using 23 gauge needles. Mice 
were then culled randomly during the experiment duration using CO2 to harvest peripheral 
blood (PB) and organs including BM, liver, spleen and kidney to assess the engraftment of 
AML.  
2.2.21.2.1  Harvesting and processing PB 
PB was harvested through cardiac puncture using heparinised needles. Blood were then 
suspended in 10ml PBS and washed twice. Red blood cells were lysed by harvesting cells in 
RBC lysis buffer for 10 minutes. Cells were then spun and supernatant was removed. Cells 
were then re-suspended in 20μL of 1X binding buffer. AML engraftment in PB was assessed 
by the presence of green fluorescent protein (GFP+) cells using flow cytometry.  
2.2.21.2.2  Harvesting and processing BM and other organs 
BM was harvested from femurs by flushing with HANKS medium; cells were spun and 
re-suspended in HANKS medium. Cells were obtained from spleen, liver and kidney by 
mincing and filtration through a cell strainer (70μM). AML engraftment was then assessed as 
described for PB.   
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2.2.21.3 Subcutaneous (S.C.) injection of AML cells into C57BL/6 and SCID mice 
C57BL/6 and SCID mice were anesthetised using isoflurane. C1498-GFP (1x106 
cell/mouse) and K562 (5x106 cell/mouse) cells were then S.C. injected in the flank of C57BL/6 
and SCID mice, respectively. Flank tumour sizes were measured three times a week using 
calliper measurement. Tumour sizes were calculated using the formula: (length x width x 
width)/2. When flank tumour became palpable, the mice were divided into two groups with one 
introduced intratumourly (I.T.) with 50μl of the indicated doses of HXR9 or HXR9 + (500μM 
W-7 + 300μM Ro31-8220) in the result section and the other group (control group) were 
introduced with I.T. with 50μl of PBS. Mice were sacrificed when tumour size ≥ 1500mm3 or 
when mice became sick.  
2.3 Statistical analysis  
Calcusyn software was used to determine the IC50 of the different drugs for the different 
cell lines and for assessing whether the interaction between HXR9 with DNR or MTX was 
synergistic, additive or antagonistic, as described below.  
Student's t-test was applied for data analysis of all assays using GraphPad Prism 
software. Results are expressed as the mean of three separate experiments with error bars to 
show the SEM. Statistical significance was determined by comparing the different conditions 
in each assay with each other and considered significant when p < 0.05 (*), highly significant 
when p < 0.01 (*), or very highly significant when p < 0.001 (***) or p < 0.0001 (****). 
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2.3.1 Calculation of IC50  
 IC50 of HXR9, DNR and MTX for different cell lines were calculated by the median-
effect equation of Chou (Chou 1974) using the Clcusyn software. The equation is:  
fa/fu = (D/Dm)
m  
Where D is the dose of the drug; Dm is the dose need to produce a 50% effect (IC50); fa is the 
fraction affected by the dose; fu is the fraction unaffected by the dose, fu = 1-fa; m is the exponent 
signifying the shape (sigmoidicity) of the dose effect curve. 
2.3.2 The analysis of drug combination assay data 
The combination effects of HXR9 with either DNR or MTX were calculated by a 
combination index (CI) equation introduced by Chou-Talalay (Chou 1991), using Calcusyn 
Software. The equation is  
CI = 
(D)1
(Dx)1
+  
(D)2
(Dx)2
 +  
(D)1(D)2 
(Dx)1(Dx)2
  
Where CI > 1, CI = 1, CI < 1 indicate antagonism, an additive effect and synergism, 
respectively. X is the inhibition percentage so for example, 50%, (Dx)1 and (Dx)2 are the 
concentrations of drug 1 and drug 2 alone, respectively, that cause 50% of cell death and can 
be calculated by the median-effect equation; (D)1 and (D)2  are the concentrations of the drugs 
in combination that also cause 50% of cell death. 
2.3.3 Statistical analysis of in vivo assays 
Data were expressed as the average tumour sizes for each group at the represented day 
with SEM as error bars. The statistical significance in tumour sizes was determined using two-
way anova analysis. 
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Table 2.9 Summary of the in vitro assays performed and reagents used. 
Assay Investigation reagent solvent Stock 
concentration 
Storing  Working 
concentration 
End point 
measurement 
LDH HXR9, DNR 
and MTX 
cytotoxicity 
LDH 
detection 
kit 
  -20ºC  LDH activity 
Combination 
cytotoxicity 
HXR9 
interaction 
with DNR or 
MTX 
LDH 
detection 
kit 
  -20ºC  LDH activity 
Annexin V Cell death 
mechanism 
Annexin V 
and 7-
AAD 
  4ºC  PS exposure 
Caspase-3  Caspase-3 
role 
z-DEVD-
R110 and 
Ac-
DEVD-
CHO 
  -20ºC  LDH activity 
DAPI 
staining 
Nuclear 
fragmentation 
DAPI 
stain 
PBS  -20ºC 1:1000 Nuclear 
fragmentation 
General 
caspase 
activity 
General 
caspase 
activity 
z-VAD-
FMK 
DMSO 43mM  -20ºC 50μM PS exposure 
CsA 
protection 
CypD role CsA DMSO 20mM  -20ºC 50μM PS exposure 
Nec-1 
protection 
RIP1 role Nec-1 DMSO 40mM -20ºC 50μM PS exposure 
Fructose 
protection 
ATP role Fructose medium  RT 40mM LDH activity 
EDTA effect Extracellular 
Ca2+ 
EDTA medium  RT 20mM LDH activity 
and PS 
exposure 
ERK 
inhibition 
EERK role U0126 DMSO 1mM  4ºC 20μM LDH activity 
JNK 
inhibition 
JNK role SP600125 DMSO 25mM  4ºC 60μM LDH activity 
p38 
inhibition 
p38 role SB203580 DMSO 5mM  -20ºC 25μM LDH activity 
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Assay Investigation reagent solvent Stock 
concentration 
Storing  Working 
conentration 
End point 
measurement 
NOX 
inhibition 
NOX role DPI DMSO 15mM  -20ºC 60μM LDH activity 
μ-calpain μ-calpain 
role 
Calpain 
inhibitor I 
DMSO 20mM  -20ºC 60μM LDH activity 
CaM 
inhibition 
CaM role W-7 DMSO 50mM  -20ºC 50μM LDH activity 
PKC 
inhibition 
PKC role Ro31-
8220 
H2O 20mM  4ºC 30μM LDH activity 
Simultaneous 
CaM and 
PKC 
inhibition 
Simultaneous 
CaM and 
PKC 
inhibition 
W-7 and 
Ro31-
8220 
   50μM W-7 
and 30μM 
Ro31-8220  
LDH activity 
p53 
inhibition 
p53 role PFT-α DMSO 20mM -20ºC 40μM LDH activity 
HO-1 
inhibition 
HO-1 role PPIX DMSO 18mM  -20ºC 50μM LDH activity 
WB PARP1 
activation 
Anti-
PARP1 
antibody 
Blocking 
buffer 
 -20ºC 1/4000 Protein level 
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Chapter 3 In vitro cytotoxicity of HXR9 
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3.1 Introduction 
The dysregulation of HOX genes is a common to many types of haematological 
malignancies, including AML (Ferrando, Armstrong et al. 2003), and solid 
malignancies including renal (Shears, Plowright et al. 2008), ovarian (Cheng, Liu et al. 
2005; Morgan, Plowright et al. 2010), lung (Abe, Hamada et al. 2006; Plowright, 
Harrington et al. 2009) and other cancers. Furthermore, over-expression of HOXA9 in 
AML is a poor prognostic factor (Golub, Slonim et al. 1999), whilst down-regulation 
of HOX genes is a favourable prognostic factor (Andreeff, Ruvolo et al. 2008; 
Zangenberg, Grubach et al. 2009). HOX genes have an oncogenic function in 
leukaemias (Eklund 2007) and their over-expression in melanoma maintain cell 
survival, in part through preventing  c-FOS transcription (Morgan, Pirard et al. 2007). 
 
The small cell-permeable peptide HXR9 was used to disrupt the interaction 
between HOX proteins and their partner transcription factor, PBX. This resulted in cell 
death after a two-hour treatment in several cancer cell lines including melanoma, renal 
and ovarian cells (Morgan, Pirard et al. 2007; Shears, Plowright et al. 2008; Morgan, 
Plowright et al. 2010). Therefore, it was investigated whether AML cell lines were also 
sensitive to HXR9.  
 
 I also studied the effect of combining HXR9 with commonly used 
chemotherapies in AML treatment, MTX and DNR (Piccaluga, Visani et al. 2002; 
Minotti, Menna et al. 2004; Fernandez 2010; Larson, Campbell et al. 2012).  
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3.1.1 Amis of chapter 3 
To assess the expression of HOX genes in AML and the cytotoxicity of HXR9 
on several AML cell lines, either alone or in combination with commonly used AML 
chemotherapies.  
To achieve these aims, the following experiments were performed: 
1. The expression of the whole panel of 39 HOX genes was measured in five AML 
cell lines (KG-1, HEL92.1.7, HL-60, KU812F and K562) by RT-PCR. 
2. The cytotoxicity of HXR9 on the five AML cell lines was assessed by LDH 
assay. 
3. The cytotoxicity of common AML chemotherapy drugs including DNR and 
MTX on two AML cell lines was assessed by LDH assay. 
4. The interaction between HXR9 and DNR or MTX was conducted by LDH 
assay. 
 
 
 
 
 
 
 
 
 
 
70 
 
3.2 Results 
3.2.1 HOX gene expression in AML cell lines 
Since HXR9 disrupts the interaction of HOX (1-10)-PBX, the expression of 
these HOX genes was assessed by RT-PCR. The expression of HOX genes was studied 
in the five AML derived cell lines HL-60, KG-1, HEL92.1.7, KU812F and K562. This 
revealed a number of differences in HOX gene expression, with HOXA and HOXB 
cluster genes (Figure 3.1A and B) more highly expressed than those of HOXC and 
HOXD clusters (Figure 3.1C and D). It is also noteworthy that many HOXA cluster 
were highly expressed in KG-1 cell line including HOXA5, HOXA6, HOXA9 and 
HOXA10. As in KG-1, HOXA9 and HOXA10 were highly expressed in the KU812F 
cell line, while HOXB9 was the most highly expressed gene in K562 and HEL92.1.7. 
Intriguingly, HL-60 cells show very little HOX expression.  
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A)  
B) 
 
C) 
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D) 
 
Figure 3.1 HOX gene expression in KG-1, HEL92.1.7, KU812F, K562 and HL-60 cell lines. A) The most 
expressed HOXA genes in the KG-1 cell line were HOXA5, HOXA6, HOXA9 and HOXA10, while HOXA9 and 
HOXA10 were most highly expressed in KU812F. B) HOXB9 was the most expressed HOX gene in HEL92.1.7 
and K562. C) HOXC and D) HOXD genes showed very little expression in tested AML derived cell lines. The 
expression of HOX genes were represented as the logarithm of the ratio of the expression of HOX genes to the 
housekeeping gene β-actin (×10 000). Graphs express the mean of three independent experiments and error bars 
show the SEM.  
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3.2.2 HXR9 is cytotoxic on all tested AML derived cell lines 
To determine whether disrupting the interaction between HOX proteins and PBX 
triggers cell death, the AML derived cell lines including KG-1, HEL 92.1.7 and HL-60, which 
are derived from primary AML patients, and KU812F and K562, which are derived from 
secondary AML patients, were exposed to titrations of HXR9 and its negative control CXR9 
for two hours. The cytotoxic effect of HXR9 and CXR9 was then measured by LDH assay. 
HXR9 had a dramatic cytotoxic effect on all tested AML cell lines, while CXR9 that lacks a 
functional domain had no cytotoxicity (Figure 3.2). The IC50 values were measured by Calcusyn 
software and were 4.5μM, 6.1μM, 19.9μM, 9.1μM and 10.4μM for KG-1, HEL 92.1.7, HL-60, 
KU812F and K562, respectively (Table 3.1).  
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A) 
 
 
 
 
B) 
 
 
 
 C) 
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D) 
 
 
 
E) 
 
Figure 3.2 LDH assay for HXR9 and CXR9 cytotoxicity on AML derived cell lines. The cell lines were treated 
with titrations of HXR9, red curve, and CXR9, blue line, for two hours, and then the LDH enzyme activity was 
measured in supernatants, which indirectly reflects cell survival. IC50s of HXR9 were calculated using Calcusyn 
software. Graphs show the mean of three independent repeats that had R2 ≥ 0.95 and error bars show SEM. A) 
KG-1, B) HEL 92.1.7, C) HL-60, D) KU812F and E) K562 cell lines.  
 
Table 3.1 IC50 values of HXR9 on AML derived cell lines with SEM. 
Cell line Source IC50 of HXR9 (μM) SEM 
KG-1 Primary AML 
patients 
4.5 ± 0.353 
HEL 92.1.7 6.1 ±0.720 
HL-60 19.9 ±0.368 
KU812F Secondary AML 
patients 
9.1 ±1.886 
K562 10.4 ±0.281 
 
The IC50 values represent the mean IC50 of three independent experiments that were calculated by Calcusyn 
software. 
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3.2.3 DNR is cytotoxic on K562 and HL-60 
In attempt to investigate the combination effect of HXR9 and chemotherapeutic drugs 
on AML-derived cell lines, two of the conventional chemotherapies were selected including 
DNR and MTX. It was reported that CD34+ AML cells, KG-1 and HEL92.1.7, were resistant 
for both drugs (Bailly, Muller et al. 1995; Bailly, Skladanowski et al. 1997). Therefore, HL-60 
and K562 that are represented primary and secondary AML, respectively, were selected to 
conduct the combination therapy effect.  
To determine the cytotoxicity of DNR on the AML cell lines K562 and HL-60, the cell 
lines were treated with a titration of DNR for 24 hours and the cytotoxicity was assessed by 
LDH assay. Both cell lines were sensitive to DNR at approximately the same concentration 
after 24-hour treatment with an IC50 of 17.7μM and 17.4μM for K562 and HL-60, respectively 
(Figure 3.3).  
 
 
Figure 3.3 LDH assay for DNR cytotoxicity on K562 and HL-60 cell lines. The cell lines were treated with a 
titration of DNR (range 2.5μM - 30μM) for 24 hours. The cytotoxicity of DNR was estimated by measuring LDH 
enzyme activity in cell free supernatants, which indirectly reflects cell survival. The IC50 of DNR calculated using 
Calcusyn software that was 17.7μM for K562 and 17.4μM for HL-60. The Graph shows the mean of three 
independent repeats that had R2 ≥ 0.95 and error bars show the SEM. The red and blue curves represent K562 and 
HL-60, respectively. 
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3.2.4 Combination effect of HXR9 and DNR 
To determine the effect of a combination between HXR9 and DNR, the cell lines K562 
and HL-60 were treated concurrently with HXR9 and DNR. The cell lines were exposed to each 
drug alone or to the combination of the two drugs (Figure 3.4). In the single drug exposure, the 
cell lines were exposed to HXR9 for two hours or to DNR for 24 hours. In the combination 
therapy, the cell lines were exposed to DNR for 24 hours and in the last two hours HXR9 was 
added. The combination effect of HXR9 and DNR was then estimated for significance using 
Calcusyn software by calculating CI values, as described in the analysis of drug combination 
assay data. The combination therapy had an antagonistic effect at the effective dose 50 (ED50) 
on both cell lines, K562 (ED50 1.34 ± 0.75) and HL-60 (ED50 1.32 ± 0.016), while at ED90, the 
combination therapy was synergistic on K562 (ED90 0.72 ± 0.12) and nearly additive on HL-
60 (ED90 0.98 ± 0.07) (Table 3.2).  
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A)      B) 
 
 
 
 
.    
     
 
 
 
Table 3.2 The analysis of the combination effect of HXR9 and DNR by Calcusyn software. HXR9 and DNR 
combination effect on K562 (A) and HL-60 (B) cells. 
A) HXR9 and DNR combination effect on K562.  
 
 
 
                     
 
 
B) HXR9 and DNR combination effect on HL-60.  
 
 
 
 
       
 
 
 
 
 
 
ED CI Combination effect 
ED50 1.34 ± 0.75 - slight antagonism 
ED75 0.98  ± 0.91 ± Nearly additive 
ED90 0.72 ± 0.12 ++ Moderate synergism 
ED CI Combination effect 
ED50 1.32 ± 0.016 -- Moderate  antagonism 
ED75 1.129 ± 0.045 -- Moderate  antagonism 
ED90 0.98 ± 0.07 ± Nearly additive 
Figure 3.4 LDH assay of HXR9 and DNR combination therapy for K562 and HL-60. Drug 
concentrations used were 0.25, 0.5, 1, 2, 3 times the calculated IC50 of each drug in a constant ratio, 
HXR9 IC50 was 21μM and 20μM, DNR IC50 was 17.7μM and 17.4μM for K562 and HL-60, 
respectively. Cells were treated with HXR9, blue bars, or DNR, red bars, for 2 hours or 24 hours, 
respectively. In addition, cells were treated with DNR for 24 hours and in the last two hours HXR9 was 
added, green bars, in the combination therapy. The graphs show the mean of three independent repeats 
and error bars show the SEM. A) is K562 and B) is HL-60 combination therapy graphs.    
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3.2.5 MTX induces K562 and HL-60 cell death 
To assess the cytotoxicity of MTX on K562 and HL-60, cells were exposed to increasing 
concentrations of MTX (range 2.5μM - 40μM) for 24 hours. The induction of cell death was 
then determined by LDH assay. MTX induced cell death in both cell lines with an IC50 20.6μM 
and 12.8μM for K562 and HL-60, respectively (Figure 3.5).  
 
 
Figure 3.5 LDH assay for MTX cytotoxicity on K562 and HL-60 cell lines. The cell lines were treated with 
different concentrations of MTX (range 2.5μM - 40μM) for 24 hours. Cell death was assessed by measuring LDH 
enzyme activity in cell free supernatants that indirectly reflects cell survival. The IC50 of MTX was calculated 
using Calcusyn software and was 20.6μM for K562 and 12.8μM for HL-60. The Graph shows the mean of three 
independent repeats that had R2 ≥ 0.95 and error bars show the SEM. The red and blue curves represent K562 and 
HL-60, respectively.  
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3.2.6 Combination effect of HXR9 and MTX 
To assess the effect of HXR9 and MTX combination therapy, K562 and HL-60 cells 
were incubated with each agent alone or concurrently (Figure 3.6). Cells were treated for two 
hours and 24 hours with HXR9 and MTX, respectively. In the co-administration therapy, cells 
were treated for 24 hours with MTX and in the last two hours HXR9 was administrated. The 
effect of the HXR9/MTX combination was then analysed by the median effect method, as 
described in the analysis of drug combination assay data. Using this method, HXR9/MTX 
appeared an antagonistic interaction at all drug concentrations used on both cell lines with CI 
values more than 1 (Table 3.3). 
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A)                  B)  
 
 
Figure 3.6 LDH assay of HXR9/MTX combination therapy for K562 and HL-60. Drug concentrations used were 
0.25, 0.5, 1, 2, 3 times the calculated IC50 of each drug in a constant ratio, the HXR9 IC50 was 21μM and 20μM, 
and the MTX IC50 was 20.6μM and 12.8μM for K562 and HL-60, respectively. Cells were treated with HXR9, 
blue bars, or MTX, red bars, for 2 hours or 24 hours, respectively. In addition, cells were treated with DNR for 24 
hours and in the last two hours HXR9 was added, green bars, in the combination therapy. The Graphs show the 
mean of three independent repeats and error bars show SEM. A) is K562 and B) is HL-60 combination therapy 
graphs. 
 
 
Table 3.3 The analysis of the combination effect of HXR9 and MTX by Calcusyn software. 
 
A) HXR9 and MTX combination effect on K562. 
 
 
 
 
 
 
B) HXR9 and MTX combination effect on HL-60.                                                                                                                               
 
 
 
 
 
 
 
 
    
 
 
 
ED CI Combination effect 
ED50 1.47 ± 0.019 - - - Antagonism 
ED75 1.62  ± 0.34 - - - Antagonism 
ED90 1.53 ± 0.175 - - - Antagonism 
ED CI Combination effect 
ED50 2.06 ± 0.50 - - - Antagonism 
ED75 1.75 ± 0.28 - - - Antagonism 
ED90 1.63 ± 0.19 - - - Antagonism 
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3.3 Discussion 
The expression of all 39 HOX genes was evaluated in this study in five AML derived 
cell lines including KG-1 and HEL92.1.7 from erythroleukaemic patients (Koeffler and Golde 
1978; Martin and Papayannopoulou 1982), HL-60 from APML (Collins, Ruscetti et al. 1978), 
and KU812F and K562 derived from CML patients in blast crisis (Lozzio and Lozzio 1975; 
Kishi 1985). Our findings of HOX expression concur with previous studies. Whilst the myeloid 
origin cell line KU812F highly expressed HOXA9 and HOXA10 genes, the erythroid cell line 
HEL92.1.7 highly expressed HOXB9 gene consistent with previous findings (Giampaolo, 
Sterpetti et al. 1994; Kawagoe, Humphries et al. 1999; Pineault, Helgason et al. 2002). Although 
K562 originated from a CML patient in blast crisis, this cell highly expressed HOXB9 gene 
which supports previous studies suggesting that K562 is in fact a human erythroleukaemia cell 
line (Andersson, Jokinen et al. 1979; Andersson, Nilsson et al. 1979). Interestingly, KG-1 
highly expressed HOXA genes including HOXA5, HOXA6, HOXA9 and HOXA10 even though 
it is an erythroid line. It was reported that KG-1 highly expressed HOXA9 and HOXA10 genes 
due to the presence of a trisomy 8 mutation (Kok, Brown et al. 2010). However, the associating 
mechanism between up-regulation of HOXA genes and trisomy 8 is unclear. Intriguingly, the 
APML cell line HL-60 hardly expressed HOX genes, but this is in line with previous studies in 
which APML was found to be characterised by global down-regulation of HOX genes 
(Thompson, Quinn et al. 2003). Notably, the most expressed subset of HOX genes were the 
posterior (6-13) HOX genes. One potential explanation for their up-regulation in AML cell lines 
is their ability to interrupt haematopoietic differentiation (Pineault, Abramovich et al. 2004). 
Overall, the expression of HOX genes in the tested AML lines was consistent with the pre-
established notion that HOX genes are expressed in a lineage-restricted manner, whereby HOXA 
and HOXB genes are expressed in myeloid and erythroid cells, respectively (Giampaolo, 
Sterpetti et al. 1994; Kawagoe, Humphries et al. 1999; Pineault, Helgason et al. 2002).  
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Here it is showed that the high expression of HOX genes can be used as a therapeutic 
target in AML as targeting the HOX-PBX interaction with HXR9 caused cell death in the tested 
AML derived cell lines. The IC50 of HXR9 for the treated AML derived cell lines ranges from 
4.5μM to 20μM after a two-hour treatment. The sensitivity of the tested cell lines to HXR9 
directly correlated to the level of HOX genes expression, for example, KG-1 cells that highly 
expressed HOXA5, HOXA6, HOXA9 and HOXA10 were the most sensitive to HXR9 with an 
IC50 4.5μM after a two-hour treatment while HL-60 cells, which show a global down-regulation 
of HOX genes were the least sensitive to HXR9, with an IC50 19.9μM after a two-hour treatment. 
Furthermore, there was no difference in terms of HXR9 sensitivity between the HEL92.1.7 cells 
derived from a primary AML patient and KU812F and K562, derived from CML patients in 
blast crisis (secondary AML) which might be because these cells express the most highly 
expressed HOX gene at the same level. In general, the tested AML cell lines were more sensitive 
to HXR9 than other cell lines derived from solid malignancies including melanoma, renal, 
ovarian and lung cancers (Table 3.4) (Shears, Plowright et al. 2008; Plowright, Harrington et 
al. 2009; Morgan, Plowright et al. 2010). The difference in the sensitivity between AML cells 
and solid cancers might be because survival of AML cells is totally depending upon the HOX-
PBX interaction, or due to the abundant expression of HOX genes in AML cells compared to 
the solid cancers.  
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Table 3.4 The IC50 values of HXR9 with cell lines derived from different cancers. 
Cell line Cell line source IC50 Treatment period Reference 
KG-1, HEL92.1.7 
and HL60 
Primary AML  4.5μM , 6.1μM and 
19.9μM 
 
 
 
2 hours 
This study 
KU812F and K562 Secondary AML 9.1μM and 10.4μM 
769-p and CaKi-2  Renal  40μM and 44μM (Shears, Plowright et al. 
2008) 
B16F10 Melanoma 20μM (Morgan, Pirard et al. 
2007) 
SK-OV3 Ovarian 70μM (Morgan, Plowright et 
al. 2010) 
A549 and H23 Lung 32.5μM and 69μM 24 hours (Plowright, Harrington 
et al. 2009) 
This table shows the difference in the IC50 values between AML cell lines investigated in this study and cell lines 
derived from solid cancers including renal, melanoma, ovarian and lung cancers established in previous studies. 
All cells were treated with HXR9 for two hours except lung cancer cells, which were treated for 24 hours. 
Generally, AML cell lines were the most sensitive to HXR9.   
 
 
The drug-interaction effect of HXR9 and DNR was performed using the Chou and 
Talaly method of calculating the median effect dose (Chou 1991). Results showed that the 
combination effect was antagonistic at ED50 in both of the tested AML cell lines K562 and HL-
60, but it was either synergistic or additive at ED90 in K562 or HL-60, respectively. DNR causes 
apoptosis by blocking topoisomerase II, intercalating with DNA, and producing ROS, and leads 
to nuclear factor-kappa B (NF-ҠB)-DNA binding as a cellular response to stress (Lanzi, 
Gambetta et al. 1991; Boland, Foster et al. 1997; Boland, Fitzgerald et al. 2000; Laurent and 
Jaffrézou 2001; Campbell, O'Shea et al. 2006; Karl, Pritschow et al. 2009). Interestingly, NF- 
ҠB has an anti-apoptotic role in DNR treatment, as reducing the activity of NF-ҠB and reducing 
the degradation of the NF-ҠB inhibitor IҠB using bortezomib increases the sensitivity of K562 
to DNR (Wang, Wang et al. 2012). In addition, DNR causes up-regulation of PKC that reduces 
DNR cytotoxicity by enhancing NF-ҠB-DNA binding and reducing ROS production (Lanzi, 
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Gambetta et al. 1991; Laurent and Jaffrézou 2001; Bezombes, de Thonel et al. 2002). However, 
Inhibition of PKC sensitized the AML cell line U937 to DNR (Mas, Hernandez et al. 2003). In 
addition, it has been found that ROS production as a result of DNR treatment slows the kinetics 
of NF-ҠB activation and DNA binding (Campbell, O'Shea et al. 2006), which might explain the 
difference in effect of combining low or high doses of HXR9 and DNR. In the low dose DNR 
and HXR9 combination therapy, the level of ROS production might be insufficient to delay 
NF-ҠB-DNA binding long enough for HXR9 to cause the up-regulation of c-FOS that mediates 
HXR9 toxicity and is also a negative regulator of NF-ҠB (Morgan, Pirard et al. 2007; Plowright, 
Harrington et al. 2009; Takada, Ray et al. 2010). However, at high concentrations of both drugs, 
DNR might produce more ROS that would delay the activation of NF-ҠB, allowing HXR9 to 
cause an up-regulation of c-FOS that would inhibit NF-ҠB activity and ultimately lead to either 
a synergistic effect in K562 or at least additive effect in HL-60. These data suggest that HXR9 
is synergistic or at least additive with DNR, a drug commonly used for AML treatment (Figure 
3.7).  
  
Figure 3.7 The proposed interaction mechanism between DNR and HXR9. DNR blocks topoisomerase II that 
leads to activation of the surviving pathway PKC/NF-κB, which in turn reduces necrosis by HR9 through reduction 
of c-FOS activity, and the apoptotic pathway through ROS signalling that delays the activity of NF-κB.  
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Unlike DNR, MTX has an antagonistic effect on HXR9. This antagonism is owing to 
the conflict in the mechanism of both drugs. MTX causes apoptosis by inhibiting topoisomerase 
II, which involves the production of a transient DNA double-strand break, thereby damaging 
DNA that in turn activates NF-ҡB-DNA binding as a consequence of cellular stress response 
(Boland, Foster et al. 1997; Boland, Fitzgerald et al. 2000; Neuhaus, Kieseier et al. 2004; 
Campbell, O'Shea et al. 2006; Karl, Pritschow et al. 2009). Unlike DNR, ROS production is not 
involved in MTX mediated apoptosis (Campbell, O'Shea et al. 2006). In addition, MTX leads 
to activation of PKC, which is a positive upstream regulator of NF-ҡB and it is has been 
reported that pre-treating cells with a PKC activator enhanced the cytotoxicity of MTX (Bhalla, 
Ibrado et al. 1993; Estévez, Vieytes et al. 1996; Lin, O'Mahony et al. 2000; Mut, Amos et al. 
2010; Lutzny, Kocher et al. 2013). However, PKC appeared to cause resistance to HXR9 as it 
was found in this study. While c-FOS, c-JUN and EGR-1 over-expression caused relapse in 
AML patients treated with MTX, c-FOS over-expression is considered as a key event in 
apoptosis induced by HXR9; EGR-1 and c-JUN are also up-regulated by HXR9 (Bailly, 
Skladanowski et al. 1997; Potapova, Basu et al. 2001; Staber, Linkesch et al. 2004; Morgan, 
Pirard et al. 2007; Plowright, Harrington et al. 2009). Whilst disruption of NF-ҡB by short 
interfering RNA caused a dramatic reduction in apoptosis upon MTX treatment, c-FOS was 
reported as a negative regulator of NF-ҡB mediated stress response and c-fos-/- mice showed an 
elevation in NF-ҡB activity (Ray, Kuwahara et al. 2006; Karl, Pritschow et al. 2009; Takada, 
Ray et al. 2010). Likewise, MTX treatment leads to a significant reduction of c-Myc, while c-
Myc was found to be a downstream effector of c-FOS-induced apoptosis (Bhalla, Ibrado et al. 
1993; Kalra and Kumar 2004). In addition, the expression of c-FOS was high in MTX-resistant 
AML cell lines (Bailly, Skladanowski et al. 1997) and c-FOS positively regulates ABCG2, also 
known as breast cancer resistance protein (BCRP), which mediates MTX-resistance in the 
87 
 
breast cancer cell line MCF-7 (Bailey-Dell, Hassel et al. 2001; Schwabedissen, Grube et al. 
2006). Taken together, these data suggest that HXR9 and MTX exerted a reciprocal inhibition.   
 
3.3.1 Summary of chapter  
In summary, this chapter studies show that: 
 AML cell lines derived from different AML types express different subsets of HOX 
genes at different levels due to the heterogeneity of AML.  
 The HOX-PBX interaction is crucial for the tested AML cell lines survival and targeting 
this interaction using HXR9 leads to cell death. 
 HXR9/DNR combination therapy is synergistic or at least additive. 
 HXR9/MTX combination therapy is antagonistic due to the conflict in their mechanisms 
of action. 
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Chapter 4 The mechanism of HXR9 cytotoxicity 
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4.1 Introduction 
Better understanding of the molecular aberrations in cancers resulted in the development 
of several new potential therapeutic agents such as HXR9 that target HOX-PBX interaction. 
However, molecular agents combined with conventional chemotherapies have given rise to 
more curative therapies. In order to provide a rational basis for the selection of a synergistic 
partner for HXR9, the mechanism by which HXR9 induces cell death needs to be identified. 
 The specificity of HXR9 for the HOX-PBX interaction was previously demonstrated in 
melanoma and lung cancer cells (Morgan, Pirard et al. 2007; Plowright, Harrington et al. 2009), 
as were downstream transcriptional changes. Notably, the increased expression of c-FOS was 
responsible, at least in part, for the HXR9 mediated cell death (Morgan, Pirard et al. 2007; 
Shears, Plowright et al. 2008; Plowright, Harrington et al. 2009; Morgan, Plowright et al. 2010; 
Morgan, Boxall et al. 2012; Morgan, Boxall et al. 2014), subsequently, the expression of c-FOS 
was assessed in this study.  In addition, the up-regulation of other genes including ATF1, ATF3, 
NRUA3, JUN, DUSP1 was also observed (Morgan, Pirard et al. 2007; Shears, Plowright et al. 
2008; Morgan, Boxall et al. 2012). Previous studies showed that the general inhibition of 
caspases did not completely prevent HXR9-triggered cell death, which suggests that there may 
be additional mediators of cell death (Shears, Plowright et al. 2008; Morgan, Boxall et al. 2012; 
Morgan, Boxall et al. 2014). However, the nature of these potential mediators of cell death by 
HXR9 remains unknown. Therefore, the possible involvement of necrotic pathways in HXR9 
induced cell death was investigated. In addition, the molecular mechanism of HXR9 action is 
yet to be identified, subsequently, the potential role of MAPK pathways including MEK/ERK, 
p38 and JNK were assessed. 
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Cell death can be classified into accidental cell death and programmed cell death (PCD). 
Accidental cell death results from extreme environmental disturbances including severe 
hypoxia, and extreme temperature changes. Necrosis was described as an unregulated and 
accidental cell death. However, it has also been suggested that necrosis might result from 
regulated enzyme-catalysed biochemical reactions (Fink and Cookson 2005). Therefore, 
necrosis can be categorised as PCD when it results from proteolytic reactions and called 
necrotic-like PCD or regulated necrosis (Galluzzi, Kepp et al. 2014). Regulated necrosis is 
classified into mitochondrial necrosis, necroptosis and parthanatos (Figure 4.1). This type of 
cell death is characterised by the absence of hallmarks of apoptosis such as caspase activation, 
Bcl-2 family member involvement, cyt C release, chromatin condensation, nuclear 
fragmentation and PARP1 cleavage (Saraste and Pulkki 2000; Ziegler and Groscurth 2004; 
Miao and Degterev 2009).  
 
 
Figure 4.1 A schematic diagram of cell death. It can be classified into programmed and accidental cell death. The 
former is further sub-classified into apoptosis and regulated necrosis. Apoptosis is sub-divided into extrinsic and 
intrinsic pathways, both of which are caspase-dependent. Regulated necrosis, which is caspase-independent, is 
subdivided into mitochondrial necrosis, necroptosis and parthanatos.  
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 Cells undergo apoptosis via two main pathways, extrinsic and intrinsic pathway, both 
of which eventually result in caspase activation (Figure 4.1). The extrinsic pathway is initiated 
by the binding of ligands to cell surface death receptors such as those of the tumour necrosis 
factor (TNF) receptor family that in turn leads to activation of initiator pro-caspases such as 
pro-caspase-8 and/or pro-caspase-10 (Jin and El-Deiry 2005). Active caspase-8 and-10 cleave 
the executioner pro-caspases-3/7 (Huerta, Goulet et al. 2007), which in turn cleave many 
substrates including PARP1 and cytoskeletal proteins, and ultimately cause cell death by 
apoptosis (Vermeulen, Van Bockstaele et al. 2005). The intrinsic pathway, also called the 
mitochondrial pathway, involves the release of pro-apoptotic proteins that are trapped in 
mitochondria such as cyt C and apoptosis inducing factor (AIF) (Martin 2010). Mitochondrial 
membrane integrity is controlled by Bcl-2 family members (Galluzzi, Kepp et al. 2014), which 
include anti-apoptotic proteins such as Bcl-2 and Bcl-xL, and pro-apoptotic proteins such as 
Bad, Bid, Bax and Bak1 (Jin and El-Deiry 2005). Under normal conditions, the anti-apoptotic 
members of Bcl-2 and Bcl-xL heterodimerize with the pro-apoptotic members Bax and Bak1 
and consequently preventing their apoptotic function (Martin 2010). During apoptosis, caspase-
8 cleaves Bid that in turn with dephosphorylated Bad promotes apoptosis by binding to the anti-
apoptotic Bcl-2 and Bcl-xL proteins (Li, Zhu et al. 1998; Ghibelli and Diederich 2010; Martin 
2010). As a result, Bax and Bak1 are released and form Bax/Bak channels in the outer 
mitochondrial membrane causing mitochondrial permeabilization (Martin 2010). Cyt C is then 
released into the cytosol and, in the presence of ATP, binds to Apaf-1 and pro-caspase-9 
forming the pro-apoptotic complex apoptosome that leads to auto-cleavage and activation of 
caspase-9 and caspase-3 and -7 (Shi 2002). Then, active caspases 3, 7 and 9 proteolytically 
cleave XIAP which in healthy viable cells binds and inhibits the three caspases (Vermeulen, 
Van Bockstaele et al. 2005). Therefore, both extrinsic and intrinsic apoptotic pathways was 
investigated to assess the involvement of apoptosis in HXR9 cell death. In addition, due its 
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known role in both apoptotic pathways, p53 and its downstream effector p21 involvement in 
HXR9 caused cell death were investigated.   
 Ca2+ is one of the main mediators of regulated necrosis and studying its role in necrosis 
is common. Subsequently, assessing the involvement of extracellular Ca2+ in HXR9 induced 
cell death was addressed in this study. In addition, the role of Ca2+-downstream effectors 
including NOX, µ-calpain, CaM, PKC was assessed.  
CypD is a member of the cyclophilin family located in the mitochondrial matrix (Elrod 
and Molkentin 2013). It is considered as the most important regulator of mPTP because it is the 
only protein known to be required for mitochondrial permeability transition-dependent necrosis 
(Alam, Baetz et al. 2014). 
Necroptosis is a type of regulated necrosis that is mediated by the interaction between 
RIP1 and RIP3 to form a necrosome (Marshall and Baines 2014). RIP1 can be either a 
component of a pro-survival complex inducing the expression of NF-ĸB, an apoptotic complex 
enhancing caspase-dependent apoptosis, or a necrosome complex initiating necroptosis 
(Vandenabeele, Grootjans et al. 2013). However, RIP1 kinase activity and necrosome formation 
are only required in necroptosis (Cho, Challa et al. 2009; He, Wang et al. 2009; Zhang, Shao et 
al. 2009). The molecular downstream mechanism of the necrosome that eventually results in 
necroptotic cell death is yet to be identified, and it remains unclear whether mitochondria are 
involved (Cho, Challa et al. 2009; Zhang, Shao et al. 2009; Tait, Oberst et al. 2013). In addition, 
mixed lineage kinase domain-like protein and phosphoglycerate mutase family member 5 were 
identified as RIP3 downstream mediators of necroptosis (Sun, Wang et al. 2012; Wang, Jiang 
et al. 2012). 
Parthanatos is a form of regulated necrosis that is PARP1-dependent and caspase-
independent. This form of necrosis is characterised by hyper-activation of PARP1 that leads to 
loss of mPTP and subsequently nuclear translocation of AIF from mitochondria, loss of ATP 
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and ultimately cell necrosis (Andrabi, Dawson et al. 2008). PARP1 is a DNA repair protein that 
is activated in response to DNA damage by alkylating agents and Ca2+ signalling pathways 
(Galluzzi, Kepp et al. 2014). 
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4.1.1   Aims of chapter 4 
 To investigate the mechanism of HXR9 action. 
To achieve this aim, the following studies were performed: 
1. Assess whether HXR9 causes up-regulation of c-FOS in AML cell lines as it did in all 
previously tested cancers. 
2. To determine whether HXR9 induced apoptosis in AML cells the following assays were 
used: 
a. Annexin V/7-AAD and DAPI staining assays to assess the morphological 
changes. 
b. RT-PCR to measure the expression of some members of the Bcl-2 family, 
initiator and executioner caspases, apoptosis protease-activating factor 1 
(Apaf1), X linked inhibitor of apoptosis (XIAP) and PARP1. 
c. Inhibition of either caspase-3 by Z-DEVD-R110 and general inhibition of 
caspases by z-VAD-FMK to analyse the role of caspases in the cytotoxicity of 
HXR9.  
3. To assess whether necrosis is involved in the cytotoxicity of HXR9, the following 
studies were performed: 
a. Determining the effect of chelating extracellular Ca2+ by EDTA on the efficacy 
of HXR9 by LDH and annexin V/7-AAD assays. 
b. Assessing the role of CypD in the HXR9 cytotoxicity by inhibiting its role using 
CsA. 
c. Assessing the role of RIP1 in the HXR9 cytotoxicity by inhibiting its role using 
Nec-1. 
d. Assessing the effect of depleting ATP by fructose on the effectiveness of HXR9. 
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e. Determining whether HXR9 causes activation of PARP1 protein. 
4. To determine the role of MAPK pathways and their downstream targets, the following 
assays were analysed: 
a. Members of MAPK pathway MEK/ERK, p38 and JNK. 
b. NOX proteins. 
c. μ-calpain, CaM, PKC and HO-1 proteins. 
5. To assess whether p53 is involved in HXR9-induced cell death, the following assays 
were done: 
a. Measuring the expression of p53 and its downstream target p21 mRNA.    
b. Inhibiting p53 protein. 
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4.2 Results 
4.2.1 HXR9 causes the up-regulation of c-FOS 
 c-FOS up-regulation was found to be a mediator of apoptosis triggered by HXR9 in 
melanoma, lung, ovarian, breast and prostate derived cell lines (Morgan, Pirard et al. 2007; 
Plowright, Harrington et al. 2009; Morgan, Plowright et al. 2010; Morgan, Boxall et al. 2012; 
Morgan, Boxall et al. 2014). To determine whether HXR9 also causes up-regulation of c-FOS 
in AML derived cell lines, the expression of c-FOS was measured in untreated, CXR9 or HXR9 
treated cells by RT-PCR. Cells were treated for two hours with the IC50s of HXR9 or equivalent 
concentrations of the negative control peptide CXR9, which were 4.5μM, 6μM, 20μM, 9μM 
and 10.5μM for KG-1, HEL92.1.7, HL-60, KU812F and K562, respectively. A two-hour 
treatment with HXR9 resulted in a 7.5, 16.7, 3.3, 50, and 7.5 fold increase in c-FOS expression 
in KG-1, HEL92.1.7, HL-60, KU812F and K562, respectively, compared to untreated cells. 
However, there was no significant change in c-FOS expression between untreated cells and 
CXR9 treated cells (Figure 4.1). 
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Figure 4.2 c-FOS expression in AML cell lines after treatment with HXR9. AML cell lines were treated with the 
following concentrations of HXR9 or CXR9: 4.5μM, 6μM, 20μM, 9μM and 10.5μM for KG-1, HEL92.1.7, HL-
60, KU812F and K562, respectively, or were untreated (control), for two hours. After a two-hour treatment, mRNA 
was extracted from cells and c-FOS expression was measured by RT-PCR. Results are presented as a ratio between 
c-FOS and β-actin (x10 000). A two-hour treatment with HXR9 caused an elevation of c-FOS transcript levels 
comparing to untreated cells. Graphs show the mean of three independent repeats and error bars show the SEM. 
*p < 0.05, **p < 0.01 and ***p < 0.001 with respect to untreated cells.  
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4.2.2 HXR9 causes death of AML tested cell lines 
In order to determine the mode of cell death following HXR9 treatment, an annexin V-
PE assay was used. Cell lines were treated with the IC50, double and triple the IC50 of HXR9 or 
of CXR9 equivalent to the highest concentration of HXR9 for two hours and then stained with 
annexin V and 7-AAD. Cells were classified either as viable, early apoptotic or dead cells 
according to 7-AAD penetration and annexin V binding (Table. 2.7). After a two-hour 
treatment, there was no significant change in untreated cells and CXR9 treated cells, whilst 
cells treated with the IC50 of HXR9 rapidly entered apoptosis, and many were dead (Figure 4.2). 
For example, in untreated KU812F cells, 95% were viable cells, 2% and 3% were in early 
apoptosis or dead, respectively, while 55% were viable, 20% were early apoptotic and 30% 
were dead after 9μM HXR9 treatment (Figure 4.2D). Generally, cell treatment with either 
HXR9 concentration killed the majority of cells. For example, treating HL-60 cells with 20μM 
HXR9 killed 55% of cells, while 27% and 18% were viable or in an early apoptotic state, 
respectively (Figure 4.2C).   
 
 
 
 
 
 
 
 
 
 
 
 
99 
 
 
A) 
 
B)  
 
C) 
 
 
100 
 
D) 
 
E) 
 
Figure 4.3 Detection of cell death in AML cell lines by flow cytometry. Cells were treated with the IC50, 2xIC50, 
or 3xIC50 of HXR9, and with a concentration of CXR9 equivalent to the highest concentration of HXR9 for two 
hours. Cells were then stained with annexin V and 7-AAD for 15 minutes in the dark and analysed by flow 
cytometry. In all the tested cell lines, the number of early apoptotic and dead cells increased with increased HXR9 
concentrations. Results are expressed as the mean of three separate experiments and error bars show the SEM. *p 
< 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 with respect to untreated cells. A) KG-1, B) HEL92.1.7, C) 
HL-60, D) KU812F and E) K562 cells. 
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4.2.3 HXR9 does not affect caspase or Bcl-2 family transcription  
RT-PCR was used to analyse the transcriptional changes of several pro- and anti-
apoptotic genes upon disruption of the HOX/PBX dimer by HXR9. This analysis revealed that 
HXR9 did not cause transcriptional changes in the initiator caspase-9 and its partner Apaf1 that 
together form an apoptosome complex with cytochrome C (cyt C) thereby starting the intrinsic 
apoptosis pathway (Adrain and Martin 2001). In addition, executioner caspases-3, -6 and -7, 
which are key mediators of apoptosis (Huerta, Goulet et al. 2007), were not up-regulated after 
HXR9 treatment. Likewise, none of the pro-apoptotic members of the Bcl-2 family including 
Bad, Bax, Bak1 and Bid, nor the anti-apoptotic member Bcl-2, which mediate mitochondrial 
cell death (Green and Kroemer 2004), showed transcriptional changes after HXR9 treatment. 
In addition, neither the transcription of PARP1 nor XIAP was affected by HXR9 treatment 
(Figure 4.3). 
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Figure 4.4 Analysis of transcriptional changes of several pro- and anti-apoptotic genes upon HXR9 treatment. 
Cells were treated with the IC50 of HXR9, CXR9 or untreated (control) for two hours. Then, mRNA was harvested 
from the AML derived cell lines KG-1, HEL92.1.7, HL-60, KU812F and K562 and gene expression was analysed 
using RT-PCR. There was no significant change in any of the analysed genes. Results are presented as a ratio with 
β-actin (x10 000). Statistical analysis was performed using student's t-test by comparing the relative expression of 
a gene of interest in HXR9 or CXR9 treated cells to its counterpart in untreated cells. Graphs show the mean of 
three independent experiments and error bars show the SEM. Results are shown for A) KG-1, B) HEL92.1.7, C) 
HL-60, D) KU812F and E) K562 cells.   
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4.2.4 HXR9 does not activate caspase-3 in the tested AML cell lines 
In order to study the mechanism of cell death, caspase-3 activity was measured after 
treating cells with increasing concentrations of HXR9 or with a CXR9 concentration that was 
equivalent to the highest concentration of HXR9. A fluorescently labelled caspase-3 substrate 
and Ac-DEVD-CHO inhibitor were also added. As an additional control, R110 standard curves 
were generated to validate individual experiments (Appendix 1). There were no significant 
changes between untreated and HXR9 treated cells with respect to caspase-3 activity in any of 
the AML cell lines (Figure 4.4).  
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Figure 4.5 Detection of caspase-3 activity in AML cell lines using Z-DEVD-R110. Cells were treated with IC50, 
2xIC50, 3xIC50 of HXR9, with an equivalent CXR9 to the highest concentration of HXR9 or untreated (control) for 
two hours. Then, cells were harvested and lysed. Next, Ac-DEVD-CHO, a caspase inhibitor, was added to some 
cells as a control. The Z-DEVD-R110 substrate was then added to cells and the fluorescence was read at 492nm. 
Results were then normalised to lysis buffer fluorescence reading, background levels. There was no statistical 
difference in caspase-3 activity between both HXR9- or CXR9-treated cells and untreated control cells. Graphs 
show the mean of three independent experiments and error bars show the SEM. A) A graph represents caspase-3 
activity of KG-1, B) HEL92.1.7, C) HL-60, D) KU812F and E) K562 cells.  
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4.2.5 HXR9 efficacy is not affected by the general inhibition of caspases 
In order to further study the role of caspases in HXR9-induced cell death, K562 and 
HL-60 cells were pre-treated with or without the general inhibitor of caspase activity z-VAD-
FMK. DNR that has been shown to activate caspases was used as a positive control (Liu, Kelsey 
et al. 2002; Kim, Park et al. 2003). Results revealed that 50μM z-VAD-FMK pre-treatment 
dramatically increased the percentage of viable cells in DNR treated cells, p < 0.0001. However, 
there was no statistical difference in terms of the percentage of viable cells between z-VAD-
FMK non- or pre-treated cells. For example, the percentage of viable cells was 62% and 58% 
for z-VAD-FMK non- or pre-treated K562 cells, respectively (Figure 4.5). Likewise, pre-
treatment with z-VAD-FMK did not cause significant changes in the early apoptotic and dead 
cells comparing with z-VAD-FMK non-treated cells (Appendix 2). This suggests that HXR9 
kills cells in a caspase-independent pathway.  
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A) 
 
B) 
 
Figure 4.6 General inhibition of caspase activity in HXR9 treated AML cell lines by z-VAD-FMK. Cells were 
pre-treated either with or without 50μM z-VAD-FMK for one hour, and then treated with the IC50, or 2xIC50 of 
HXR9 for two hours or with 17.5μM DNR for 24 hours, which was used as a positive control. Next, cells were 
harvested and stained with annexin V and 7-AAD for 15 minutes in the dark and analysed by flow cytometry. Data 
showed that there was no statistical difference in terms of sensitivity to HXR9 between pre-treated cells with or 
without 50μM z-VAD-FMK. Graphs show the mean of three independent experiments and error bars show the 
SEM.  ****p < 0.0001 with respect to z-VAD-FMK untreated cells. A) K562 and B) HL-60 cells.  
 
 
 
 
 
 
 
109 
 
4.2.6 HXR9 does not cause nuclear fragmentation 
In order to assess changes in nuclear morphology upon HXR9 treatment, AML derived 
cell lines were stained with the fluorescent stain DAPI and analysed by a fluorescence 
microscope. Changes in the nuclear morphology such as chromatin condensation and nuclear 
fragmentation are markers of late stage apoptosis (Collins, Schandl et al. 1997; Ziegler and 
Groscurth 2004; Huerta, Goulet et al. 2007). It was found that treatment of cells with the IC50s 
of HXR9 did not result in changes to the nuclear morphology when comparing to untreated 
cells in all investigated cell lines (Figure 4.6). This suggests that HXR9-induces cell death in a 
nuclear fragmentation-independent pathway.  
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Figure 4.7 DAPI staining of AML cells upon HXR9 treatment. Cells were treated with the IC50s of HXR9 for 2 
hours. Cells were then harvested, fixed in 4% formaldehyde, and cytospan. Fixed cells were stained with DAPI 
for 5 minutes at the dark. Finally, stained cells were analysed by a fluorescent microscope at 20x lenses.  
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4.2.7 Ca2+ chelating abrogates cell killing by HXR9 
As HXR9 seems to cause cell death in a caspase-independent manner, a number of 
alterative pathways were investigated. Ca2+ is known to mediate caspase-independent cell death 
(Dong, Li et al. 2005; Festjens, Vanden Berghe et al. 2006). Therefore, to analyse the role of 
Ca2+ in HXR9-induced cell death, the extracellular Ca2+ chelator EDTA was used. Interestingly, 
chelating extracellular Ca2+ rapidly attenuated the cytotoxicity of HXR9 and rescued cells from 
cell death. For example, the percentage of viable cells increased from 50% to 80%, ****p < 
0.0001, upon co-treatment with 20mM EDTA in 20μM HXR9 treated K562 cells (Figure 4.7A). 
Likewise, in 20μM HXR9 treated HL-60 cells, the percentage of viable cells increased threefold 
in 20mM EDTA co-treated cells compared to untreated cells (Figure 4.7B). In addition, co-
treatment with EDTA dramatically decreased the percentage of early apoptotic and dead cells 
in both cell lines (Appendix 3).   
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A) 
 
B) 
 
Figure 4.8 Effect of EDTA on HXR9 cytotoxicity. Cells were pre-treated with or without 20mM EDTA for one 
hour, and then treated with 10μM, 20μM and 40μM HXR9, prepared in media either with or without 20mM EDTA, 
for two hours. Next, cells were harvested and stained with annexin V and 7-AAD for 15 minutes in the dark and 
analysed by flow cytometry. Results showed that Pre- and co-treatment of cells with 20mM EDTA significantly 
increased the % viable cells and thereby inhibited the cytotoxicity of HXR9. Graphs show the mean of three 
independent experiments of viable cells, non-stained cells with either stain, and error bars show the SEM. ***p < 
0.001 and ****p < 0.0001 with respect to cells not exposed to 20mM EDTA. A) K562 and B) HL-60 cells. 
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4.2.8 EDTA rescues cells from killing by HXR9 
In order to confirm the previous results that showed chelating extracellular Ca2+ reduced 
the cytotoxicity of HXR9, an LDH assay was performed to analyse the effect of EDTA pre- 
and co-treatment. The results of the LDH assay were consistent with the results obtained using 
the annexin V assay. Chelating extracellular Ca2+ by EDTA markedly reduced the levels of 
LDH enzyme detected in K562 and HL-60 cells. In addition, HXR9 did not have an IC50 up to 
the highest concentration used, 50μM (Figure 4.8). These results showed that EDTA prevented 
cell killing by HXR9.  
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A) 
 
B) 
 
Figure 4.9 LDH analysis of the effect of EDTA on HXR9 cytotoxicity. Cells were pre-treated with or without 
20mM EDTA for one hour, and then with varying concentrations of HXR9 for two hours prepared in media either 
with or without 20mM EDTA, red and blue curves, respectively. LDH activity was then measured in the 
supernatants, which indirectly reflects the fraction of surviving cells. Pre- and co-treatment of cells with 20mM 
EDTA significantly attenuated the cytotoxicity of HXR9. Graphs show the mean of three independent experiments 
and error bars show the SEM. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 with respect to cells not 
treated with 20mM EDTA. A) K562 and B) HL-60 cells.  
 
 
 
 
 
 
 
 
116 
 
4.2.9 Cell killing by HXR9 does not involve CypD  
To assess whether HXR9 causes mitochondrial necrotic cell death through activation of 
CypD that in turn leads to formation of mPTP, cells were treated with CsA that binds to CypD 
and inhibits mitochondrial cell death (Li, Johnson et al. 2004; Basso, Fante et al. 2005; Dube, 
Selwood et al. 2012). H2O2, which triggers mPTP formation and mitochondrial necrotic cell 
death, was used as a positive control for this assay (Baines, Kaiser et al. 2005; Nakagawa, 
Shimizu et al. 2005; Schinzel, Takeuchi et al. 2005; Jobe, Wilson et al. 2008). Cell death was 
measured using the annexin V assay. Treatment with 5μM CsA significantly increased the 
percentage of viable cells exposed to H2O2 from 44.9% ± 1.7 to 69.2% ± 1.34, ****p < 0.0001,  
and from 0.92% ± 0.3 to 34.2% ± 2.4, ****p < 0.0001, of H2O2-treated K562 and HL-60, 
respectively. However, CsA at 5μM could not rescue K562 cells from death caused by HXR9 
treatment, and interestingly, concurrent CsA treatment with HXR9 significantly decreased the 
survival of HXR9 treated HL-60 cells (Figure 4.9, appendix 4). Taken together, it can be 
concluded that CypD activation is not required for HXR9-induced K562 and HL-60 cell death. 
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A) 
 
 
B) 
 
Figure 4.10 Effect of CsA on HXR9 cytotoxicity. Cells were pre-treated with or without 5μM CsA for one hour, 
and then with the IC50, 2xIC50, 3xIC50 of HXR9, 20mM H2O2 (positive control), or were left untreated (negative 
control) for two hours with or without 5μM CsA. The cells were then harvested and stained with annexin V and 
7-AAD for 15 minutes in the dark and analysed by flow cytometry. Results showed no statistical difference in the 
proportion of viable cells between K562 cells (A) incubated with or without 5μM CsA, while incubation with 5μM 
CsA led to a significant decrease in proportion of viable HL-60 cells (B). Graphs show the mean of three 
independent experiments and error bars show the SEM. *p < 0.05, ***p < 0.001 and ****p < 0.0001 with respect 
to 5μM CsA untreated cells.  
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4.2.10 Inhibition of RIP1 modifies the cytotoxicity of HXR9 
Activation of RIP1 is a key event in necroptosis (Holler, Zaru et al. 2000). To assess 
whether HXR9 causes necroptosis through activation of RIP1, the effect of RIP1 inhibition by 
its specific inhibitor Nec-1 on HXR9 cytotoxicity was evaluated using the annexin V assay.  
Nec-1 has been reported to inhibit H2O2-induced cell death; therefore H2O2 was used as a 
positive control for this assay (Hanus, Zhang et al. 2013). Treatment with 50mM Nec-1 rescued 
cells from 20mM H2O2 mediated cell killing. Nec-1 pre- and co-incubation with 20mM H2O2-
treated K562 cells significantly increased the percentage of viable cells from 34.5% ± 3.4 to 
67.1% ± 2.3 and decreased the percentage of early apoptotic and dead cells from 41.3% ± 2.5 
to 27.2% ± 1.4 and from 24.6% ± 3.6 to 7.3% ± 0.25, respectively, compared to Nec-1untreated 
cells (Figure 4.10A). In HXR9-treated K562 cells, there was no significant impact of inhibition 
of RIP1 on the cytotoxicity of increasing concentrations of HXR9 (Figure 4.10A). However, 
Nec-1 at 50μM significantly changed the cytotoxicity of all concentrations of HXR9 on HL-60. 
For example, at 40µM HXR9 treatment, Nec-1 significantly increased the percentage of viable 
cells from 3.7% ± 1.21 to 9.2% ± 1.73 and dramatically delayed cell death by increasing the 
percentage of early apoptotic cells from 16.3% ± 1.2 to 46.4% ± 2.4 and decreasing the 
percentage of dead cells from 80% ± 1.1 to 44.3% ± 2.4, compared to Nec-1 untreated cells 
(Figure 4.10B). Therefore, it can be concluded that the inhibition RIP1 has an impact on the 
cytotoxicity of HXR9 and this effect depends on the cell type.   
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 A) 
  
B) 
 
 
Figure 4.11 Effect of RIP1 inhibition on HXR9 cytotoxicity. Cells were pre-treated with or without 50μM Nec-1 
for one hour, and then with increasing concentrations of HXR9, with an equivalent CXR9 concentration to the 
highest concentration of HXR9, 20mM H2O2 (positive control), or were untreated (negative control), in media 
supplemented either with or without 50μM Nec-1 for two hours. Cells were then harvested and stained with 
annexin V and 7-AAD for 15 minutes in the dark and analysed by flow cytometry. Treatment with 50μM Nec-1 
did not affect the sensitivity of K562 cells (A) to HXR9, while for HL60 (B) it significantly increased the 
percentage of viable and early apoptotic cells and decreased the percentage of dead cells. Graphs show the mean 
of three independent experiments and error bars show the SEM. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 
0.0001 with respect to 50μM Nec-1 untreated cells. 
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4.2.11 HXR9 induces cell death through an ATP-independent pathway 
High levels of fructose have been found to cause ATP depletion (Nieminen, Saylor et 
al. 1994; Latta, Künstle et al. 2000). ATP is necessary for PARP1-dependent necrosis and 
caspase-dependent apoptosis (Los, Mozoluk et al. 2002; Latta, Künstle et al. 2007). To analyse 
whether ATP has a role in HXR9-induced AML cell death, the impact of ATP depletion by a 
high concentration of fructose on the cytotoxicity of HXR9 was measured by the LDH assay 
using an enzyme-linked immunosorbent assay (ELISA). ATP depletion did not reduce the 
cytotoxicity of HXR9 on K562 and HL-60 (Figure 4.11). These results were consistent with a 
caspase-independent and PARP1-independent pathway.     
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A) 
 
B) 
 
Figure 4.12 The effect of ATP depletion on HXR9 cytotoxicity. Cells were pre-incubated with or without       
40mM fructose for one hour, and then with a range of HXR9 concentrations (2.5μM – 50μM) for two hours 
prepared in media either with or without 40mM fructose, red and blue curves, respectively. HXR9 cytotoxicity 
was then measured by assessing LDH enzyme activity in cell-free supernatants. ATP depletion did not inhibit 
HXR9-induced death in either (A) K562 or (B) HL-60 cells. Graphs show the mean of three independent 
experiments and error bars show the SEM.  
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4.2.12 HXR9 induces cell death through a PARP1-independent pathway 
The activation of PARP-1 results in ATP depletion, which is a key event in necrotic cell 
death (Bouchard, Rouleau et al. 2003; Kim, Zhang et al. 2005). To assess the involvement of 
PARP1 in HXR9 induction of AML cell death, the expression of PARP1 protein was estimated 
by WB assay. By comparing the band density of treated cells to their untreated counterparts, it 
can be concluded that HXR9 did not cause PARP1 activation (Figure 4.12). These findings 
concur with those of the ATP depletion assay which suggests that HXR9 treatment results in 
cell death independently of ATP depletion.  
 
 
 
 
Figure 4.13 WB analysis of PARP1 activation after HXR9 treatment. HL-60 and K562 cells were treated with 
increasing concentrations of HXR9 for two hours and then PARP1 protein expression was examined by WB. β-
actin protein was used as a loading control. There was no difference in band densities between treated and treated 
cells after a two hour-treatment with HXR9.  
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4.2.13 The effect of inhibition of MAPK pathways on HXR9 cytotoxicity 
The results presented earlier in this chapter showed that chelating extracellular Ca2+ by 
EDTA prevented HXR9 cytotoxicity. Potential downstream effectors of Ca2+-mediating 
necrosis are MAPK pathway members and therefore the effect of HXR9 treatment on three key 
components of this pathway, MEK/ERK, p38 and JNK was evaluated (Dhillon, Hagan et al. 
2007).   
4.2.13.1 HXR9 induces cell death in a MEK/ERK independent pathway 
Ca2+ enhances the activation of the MEK/ERK pathway (Egea, Espinet et al. 1999; 
Huang, Maher et al. 1999; Lallemend, Lefebvre et al. 2003). To test whether the MEK/ERK 
pathway has a role in HXR9 cytotoxicity, this pathway was blocked by a specific inhibitor, 
U0126, and the cytotoxicity of HXR9 was examined using the LDH assay. H2O2 that causes 
cell death through activation of the MEK/ERK pathway was used as a positive control (Chung, 
Jeong et al. 2002; Ray, Huang et al. 2012). Treatment with 20μM U0126 significantly inhibited 
the cytotoxicity of H2O2 (Appendix 5). However, U0126 could not attenuate the cytotoxicity of 
HXR9 on K562 or HL-60 cells (Figure 4.13). These findings suggest that MEK/ERK pathway 
is not required for HXR9-mediated cell death of these cells.   
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A) 
  
 
B) 
 
 
Figure 4.14 The effect of inhibiting the MEK/ERK pathway on the cytotoxicity of HXR9. Cells were pre-treated 
with or without 20μM of the MEK/ERK inhibitor U0126 for one hour, and then with increasing concentrations of 
HXR9 prepared in media with or without 20μM U0126, red and blue curves, respectively. The proportion of 
surviving cells was then measured using the LDH assay. Pre- and co-treatment of cells with 20μM U0126 did not 
prevent the cytotoxicity of HXR9 in (A) K562 or (B) HL60 cells. Graphs show the mean of three independent 
experiments and error bars show the SEM. 
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4.2.13.2 HXR9-mediated cell death does not require p38 pathway signalling 
Ca2+ positively regulates the p38 pathway (Huang, Maher et al. 1999; Hsu, Huang et al. 
2007). To evaluate the role of the p38 pathway in the HXR9-mediated cell killing, its specific 
inhibitor SB302580 was used and the cytotoxicity of HXR9 measured by LDH assay. The p38 
pathway is involved in H2O2 cytotoxicity (Pinkus, Weiner et al. 1996; Tobiume, Matsuzawa et 
al. 2001; Yoon, Kim et al. 2001; Carvalho, Evelson et al. 2004), and therefore H2O2 was used 
as a positive control for this assay. Blocking p38 remarkably inhibited the cytotoxicity of H2O2 
(Appendix 6), but not HXR9 on the AML cell lines (Figure 4.14).    
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A) 
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Figure 4.15 The effect of inhibiting the p38 pathway on the cytotoxicity of HXR9. Cells were pre-treated with or 
without 25μM of the p38 inhibitor SB302580 for one hour, and then with a titration of HXR9 prepared in media 
with or without 25μM SB302580, red and blue curves, respectively. The cytotoxicity of HXR9 was analysed by 
measuring LDH enzyme activity in cell-free supernatants. Pre- and co-treatment of cells with 25μM SB302580 
did not affect the cytotoxicity of HXR9 in either (A) K562 or (B) HL-60 cells. Statistical significance was tested 
using the student's t-test. Graphs show the mean of three independent experiments and error bars show the SEM. 
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4.2.13.3 Inhibition of the JNK pathway sensitises K562, but not HL-60 cells to HXR9 
Like the MEK/ERK and p38 pathways, the JNK pathway is activated by Ca2+ signalling 
(Huang, Maher et al. 1999; Son, Lee et al. 2010; Jan, Su et al. 2013). To test the involvement 
of JNK pathway for HXR9-induced cell death, it was inhibited using the specific inhibitor 
SP600125. Due its ability to induce cell death through activation of the JNK pathway, H2O2 
was used as a positive control for this assay (Pinkus, Weiner et al. 1996; Tobiume, Matsuzawa 
et al. 2001; Yoon, Kim et al. 2001; Carvalho, Evelson et al. 2004; Kadowaki, Nishitoh et al. 
2005). SP600125 at 60μM efficiently abrogated the cytotoxicity of H2O2 (Appendix 7). 
Interestingly, inhibiting the JNK pathway resulted in inconsistent results in terms of HXR9 
cytotoxicity, significantly sensitizing K562 cells, but not HL-60 cells to killing by HXR9. 
Blocking the JNK pathway sharply decreased the percentage of surviving K562 cells from 56% 
± 1.7 to 35.4 ± 2.5, ***p < 0.001, after 20μM HXR9 treatment (Figure 4.15).    
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A) 
 
 
 
B) 
 
 
Figure 4.16 The effect of inhibiting the JNK pathway on HXR9 cytotoxicity. Cells were pre-incubated in media 
supplemented with or without 60μM of the JNK inhibitor SP600125 for one hour, and then treated with increasing 
concentrations of HXR9 prepared in media supplemented with or without 60μM SP600125, red and blue curves, 
respectively. The percentage of surviving cells was measured using the LDH assay. Graphs show the mean of three 
independent experiments and error bars show the SEM. *p < 0.05, **p < 0.01 and ***p < 0.001 with respect to 
60μM SP600125 untreated cells. 
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4.2.14 Blocking NOX enzymes sensitizes cells to HXR9 
Previous studies have reported that members of NOX enzyme family such as NOX1 
and NOX5 are regulated by Ca2+ (Bánfi, Molnár et al. 2001; Bánfi, Tirone et al. 2004; Brueckl, 
Kaestle et al. 2006; Valencia and Kochevar 2007). To test whether NOXs have a role in HXR9 
mediated cell killing, they were inhibited using DPI. Inhibition of NOX activity by DPI 
remarkably sensitised both K562 and HL-60 cells to HXR9. For example, after 20μM HXR9 
treatment, the proportion of surviving K562 and HL-60 cells decreased from 57.9% ± 3.54 to 
32.6% ± 0.21, *p < 0.05, and from 55.2% ± 1.9 to 26.6 % ± 2.7, *p < 0.05,  respectively, 
compared to DPI untreated cells (Figure 4.16). These results show that NOX enzymes exert an 
anti-necrotic effect in HXR9 treatment.   
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A) 
 
B) 
 
Figure 4.17 The effect of NOX inhibition on the cytotoxicity of HXR9. Cells were pre-treated with or without 
60μM of the NOX inhibitor, DPI, for one hour, and then with a range of HXR9 concentrations (2.5μM – 50μM) 
prepared in media with or without 60μM DPI, red and blue curves, respectively. Next, the cytotoxicity of HXR9 
was assessed using the LDH assay. NOX inhibition significantly sensitised both (A) K562 and (B) HL-60 cells to 
HXR9. Graphs show the mean of three independent experiments and error bars show the SEM. *p < 0.05 and **p 
< 0.01 with respect to 60μM DPI untreated cells. 
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4.2.15 μ-Calpain is not required for HXR9-induced cell death 
μ-Calpain or calpain type I is a downstream effector of Ca2+ (Mathiasen, Sergeev et al. 
2002). To analyse whether HXR9 caused AML cell death through the activation of μ-Calpain, 
its activity was blocked by the specific inhibitor calpain inhibitor I and assessed using the LDH 
assay. Due to its ability to activate μ-Calpain, H2O2 was used as a positive control for this assay 
(McClung, Judge et al. 2009; Pallepati and Averill-Bates 2011). Calpain inhibitor I significantly 
inhibited the cytotoxicity of H2O2 (Appendix 8). However, calpain inhibitor I at 60μM could 
not abrogate the cytotoxicity of HXR9 on tested AML cell lines, K562 and HL-60 (Figure 4.17). 
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A) 
 
 
B) 
 
Figure 4.18 The effect of blocking μ-calpain on HXR9 cytotoxicity. Cells were pre-treated with or without 60μM 
calpain inhibitor I for one hour, and then for two hours with increasing concentrations of HXR9 prepared in media 
with or without 60μM calpain inhibitor I, red and blue curves, respectively. Next, the cytotoxicity of HXR9 was 
assessed in cell-free supernatants using the LDH. μ-calpain inhibition did not affect HXR9 cytotoxicity in either 
(A) K562 or (B) HL-60 cells. Graphs show the mean of three independent experiments and error bars show the 
SEM. 
 
  
133 
 
4.2.16 CaM inhibition dramatically increases the sensitivity of cells to HXR9 
CaM is one of the main Ca2+ concentration sensor (Balshaw, Xu et al. 2001; Hoeflich 
and Ikura 2002; Yuan, Jing et al. 2011). To assess the involvement of CaM in the cytotoxicity 
of HXR9, its role was blocked by the specific inhibitor W-7. Interestingly, treating cells with 
50μM W-7 alone did not affect cells, yet co-treatment of cells with HXR9 significantly reduced 
cell survival. Co-treatment of K562 and HL-60 cells with 20μM HXR9 and 50μM W-7 sharply 
decreased the percentage of surviving cells from 57% ± 1.6 to 15% ± 1.8, ****p < 0.0001,  and 
from 61% ± 2.4 to 26% ± 2.1, ***p < 0.001, respectively (Figure 4.18). It also reduced the IC50 
of HXR9 on K562 cells by threefold, from 21μM to 7μM, and on HL-60 cells by twofold, from 
24μM to 13μM (Figure 4.18C).   
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A) 
 
 
B) 
 
 
C)  
 IC50 
Cell line/condition HXR9 HXR9 + 50μM W-7 
K562 21.4μM ± 3.1 7μM ± 2.9  
HL-60 24μM ± 1.7 13μM ± 1.2 
  
Figure 4.19 The effect of CaM inhibition on HXR9 sensitivity. Cells were pre-treated with or without 50μM 
W-7 for one hour, and then for two hours with increasing concentrations of HXR9 prepared in media with 
or without 50μM W-7, red and blue curves, respectively. The LDH assay was used to measure cytotoxicity. 
W-7 dramatically increased the sensitivity to HXR9 of both (A) K562 cells and (B) HL-60 cells. Graphs 
show the mean of three independent experiments and error bars show the SEM. C) A table shows the 
difference in HXR9 IC50 between 50μM W-7-treated and untreated cells. *p < 0.05, **p < 0.01, ***p < 0.001 
and ****p < 0.0001 with respect to 50μM W-7 untreated cells.  
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4.2.17 Inhibition of PKC greatly increases the sensitivity of K562 and HL-60 cells to 
HXR9 
PKC is a family of kinases that are regulated by intracellular Ca2+ (Zhu, Fang et al. 1999; 
Reyland 2007). To analyse the impact of blocking PKC on HXR9-induced AML cell death, the 
specific inhibitor Ro31-8220 was used and the cytotoxicity of HXR9 was assessed with the 
LDH assay. 30μM Ro31-8220 was not cytotoxic for AML cells, yet it significantly increased 
HXR9-mediated cell killing. In K562 cells, Ro31-8220 remarkably sensitized cells to a very 
low concentration of HXR9, 1.25μM, *p < 0.05 (Figure 4.19A). In addition, it caused a huge 
reduction in the IC50 of HXR9, by 4.3 fold, from 21.4μM ± 1.5 in K562-HXR9 only treated 
cells to 5μM ± 2.9 (Figure 4.19C). Similarly, inhibition of PKC in HL-60 increased cell killing 
by HXR9 and decreased the IC50 by 2.7 fold from 29.3μM ± 1.9 to 10.7μM ± 0.8 (Figure 4.19B 
and C). These results showed that PKC activity protects against HXR9 cytotoxicity.  
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B) 
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Figure 4.20 The effect of blocking of PKC on the cytotoxicity of HXR9 on K562 and HL-60 cells. Cells were pre-
treated with or without 30μM Ro31-8220 for one hour, and then for two hours with different concentrations of 
HXR9 in media supplemented with or without 30μM Ro31-8220, red and blue curves, respectively. The LDH 
assay was then used to measure the cytotoxicity of HXR9 in cell-free media. Ro31-8220 co-treatment significantly 
reduced cell survival. Graphs show the mean of three independent experiments for (A) K562 cells and (B) HL-60 
cells and error bars show the SEM. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 with respect to 30μM 
Ro31-8220 untreated cells. C) Differences in the IC50 values between HXR9-only treated cells and HXR9 + 30μM 
Ro31-8220 treated cells. 
 IC50 
Cell line/condition HXR9 HXR9 + 30μM Ro31-8220 
K562 21.4μM ± 1.5 5μM ± 2.9 
HL-60 29.3μM ± 1.9 10.7μM ± 0.8 
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4.2.18 Simultaneous inhibition of CaM and PKC potentiates HXR9 cytotoxicity  
To test whether simultaneous inhibition of CaM and PKC produced a further 
sensitisation to HXR9, K562 and HL-60 were exposed to the inhibitors of both proteins and 
treated with a titration of HXR9 and the cytotoxicity was measured using the LDH assay. The 
concurrent regimen significantly increased the sensitivity to HXR9. For example, at 10μM 
HXR9 treatment, the concurrent inhibition of both proteins dramatically decreased the 
percentage of surviving cells by 55%, ****p < 0.0001, and 57%, ****p < 0.0001, for K562 and 
HL-60, respectively, comparing with HXR9-only treated cells (Figure 4.20A and B). In 
addition, the IC50 of HXR9 was reduced by 4.3 and 3.1 fold for K562 and HL-60, respectively 
(Figure 4.20C).  
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A) 
 
 
B) 
 
 
C) 
 
 IC50 
Cell line/condition HXR9 HXR9 + (50μM W-7 30μM Ro31-8220) 
K562 21.1μM ± 4.5 4.9μM ± 3.5 
HL-60 14.8μM ± 3.9 4.8μM ± 2.7 
 
Figure 4.21 The impact of concurrent inhibition of CaM and PKC on the cytotoxicity of HXR9. Cells were pre-
incubated with or without 50μM W-7 and 30μM Ro31-8220 for one hour, and then for two hours with a range of 
HXR9 concentrations (0.625μM – 50μM) prepared in media with or without the inhibitors, red and blue curves, 
respectively. The cytotoxicity of HXR9 was assessed using the LDH assay. The concurrent inhibition of CaM and 
PKC significantly increased the HXR9-mediated cell death. Graphs show the mean of three independent 
experiments with (A) K562 cells and (B) HL-60 cells, and error bars show the SEM. **p < 0.01, ***p < 0.001 and 
****p < 0.0001 with respect to W-7 and Ro31-8220 untreated cells. C) The difference in the IC50s between HXR9-
only treated cells and HXR9 + (50μM W-7 + 30μM Ro31-8220) treated cells. 
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4.2.19 HO-1 inhibition increases the sensitivity to HXR9 
HO-1 acts as an anti-apoptotic protein in AML (Rushworth and MacEwan 2008). In 
addition, HO-1 is a downstream effector of NOXs and PKC (Tsoyi, Jang et al. 2011; Schroder, 
Zhang et al. 2012; Lee, Yang et al. 2012; Nguyen, Kim et al. 2013).  To assess whether the 
inhibition of HO-1 could increase the sensitivity to HXR9, HO-1 activity was blocked by its 
specific inhibitor PPIX and the sensitivity of AML cells to HXR9 assessed. HO-1 inhibition 
resulted in a significant reduction in the survival of both cell lines (Figure 4.21). PPIX decreased 
the IC50 of HXR9 by 2.2 fold and 1.4 fold for K562 and HL-60, respectively (Figure 4.21C). 
Therefore, HO-1 activity inhibits HXR9-mediated cell killing.     
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A) 
  
B) 
 
 
C) 
 IC50 
Cell line/condition HXR9 HXR9 + 50μM PPIX 
K562 23.7μM ± 3.4 10.9μM ± 4.2 
HL-60 22.5μM ± 5.1 16μM ± 1.4 
 
Figure 4.22 The effect of HO-1 inhibition on the cytotoxicity of HXR9. Cells were pre-treated with or without 
50μM PPIX for one hour and then for two hours with HXR9 in media with or without 50μM PPIX, red and blue 
curves, respectively. Cell death was assessed using the LDH assay. Graphs show the mean of three independent 
experiments for (A) K562 and (B) HL-60 cells, and error bars show the SEM. *p < 0.05, **p < 0.01, ***p < 0.001 
and ****p < 0.0001 with respect to 50μM PPIX untreated cells. C) Differences in the IC50s between HXR9-only 
treated cells and HXR9 + 50μM PPIX treated cells. 
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4.2.20 HXR9 induces p21 expression but not p53 
To analyse whether HXR9 causes up-regulation of p53 and its downstream effector p21, 
the expression of both genes was analysed by RT-PCR. Results showed that HXR9 did not 
affect the expression of p53 in K562 or HL-60 cells, but it did lead to a significant increase in 
the expression of p21. For example, the expression of p21 in K562 cells increased by 2.5, **p 
< 0.01, and 4.5, ****p < 0.0001, fold after treatment with 15μM and 30μM of HXR9, 
respectively (Figure 4.22B).    
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A) 
 
 
B) 
 
 
Figure 4.23 RT-PCR analysis of p53 and p21 expression in response to HXR9 treatment. RNA extracted from 
cells after a two-hour treatment with 15μM and 30μM HXR9, or 30μM CXR9. The expression of p53 and p21 
genes are given as ratio to the expression of the housekeeping gene β-actin (×10 000). Graphs show the mean of 
three independent experiments and error bars show the SEM. **p < 0.01, ***p < 0.001 and ****p < 0.0001 with 
respect to untreated cells.  
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4.2.21 HXR9-induces AML cell death through a p53-independent pathway 
To further investigate the role of p53 in HXR9-mediated cell killing, the activity of p53 
protein was blocked by PFT-α, and the cytotoxicity of HXR9 was measured by LDH assay. 
Blocking p53 protein did not affect the sensitivity of AML cells to HXR9 (Figure 4.23). 
 
A) 
 
B) 
 
Figure 4.24 The effect of blocking p53 protein on HXR9 cytotoxicity. Cells were pre-treated with or without 
40μM PFT-α for one hour, and then for two hours with a titration of HXR9 prepared in media supplemented with 
or without 40μM PFT-α, red and blue curves, respectively. Graphs show the mean of three independent 
experiments for (A) K562 and (B) HL-60 cells, and error bars show the SEM.  
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4.3 Discussion  
HXR9 has previously been shown to induce cell death in a range of solid malignancies, 
and here it is demonstrated that HXR9 also induces AML cell death. The efficacy of HXR9 
could be improved by better understanding its mechanism of action, allowing synergistic 
therapies to be identified.       
Antagonism of the HOX/PBX interaction resulted in a remarkable up-regulation in the 
expression of c-FOS. The induction of c-FOS expression by HXR9 was previously documented 
to be responsible, at least partially, for triggering cell death in human melanoma, renal, lung, 
ovarian, breast and prostate cancer cell lines (Morgan, Pirard et al. 2007; Shears, Plowright et 
al. 2008; Plowright, Harrington et al. 2009; Morgan, Plowright et al. 2010; Morgan, Boxall et 
al. 2012; Morgan, Boxall et al. 2014), and knocking down c-FOS expression partially rescued 
melanoma and prostate cancer cell lines from HXR9-induced apoptosis (Morgan, Pirard et al. 
2007; Morgan, Boxall et al. 2014). c-FOS is a component of the AP-1 transcription activating 
complex, and upon dimerisation with its binding partner JUN, regulates cell proliferation and 
cell cycle progression (Durchdewald, Angel et al. 2009). It has been shown to be a proto-
oncogene in a variety of human tumours including those of the bone, brain and skin (Gamberi, 
Benassi et al. 1998; Silvestre, Gil et al. 2010; Guinea-Viniegra, Zenz et al. 2012). However, a 
reduction in c-FOS expression in epithelial ovarian carcinoma was found to be an independent 
marker of shorter progression-free and OS (Mahner, Baasch et al. 2008). In addition, c-FOS 
over-expression has a pro-apoptotic function in vitro, and caused a delay in tumour growth and 
metastasis of the ovarian cancer OvCa cells in vivo by dysregulating adhesion proteins 
(Oliveira-Ferrer, Rossler et al. 2014). It was also found to be involved in the induction of the 
human ovarian carcinoma cell line A2780 in response to fenrtinide treatment (Appierto, Villani 
et al. 2003). Moreover, c-FOS exerted a pro-apoptotic function by repressing the anti-apoptotic 
gene cellular FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (L) (c-FLIP (L)) 
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which resulted in sensitising prostate cells to tumour necrosis-related apoptosis-inducing ligand 
(TRAIL) (Zhang, Zhang et al. 2007). It also induced human hepatoma Huh7 apoptosis by 
mediating c-MYC expression (Kalra and Kumar 2004). c-Fos over-expression resulted in cell 
cycle arrest by up-regulating the expression of the nuclear protein CHOP and the cell cycle 
inhibitors p16INK4A and p57KIP2; suppressing rat sarcoma (Ras)-mediated malignancy that 
ultimately led to apoptosis of murine epithelial hepatocytes (Mikula, Gotzmann et al. 2003). Its 
prolonged expression also suppressed cell cycle entry of murine BM cells (Okada, Fukuda et 
al. 1999). Furthermore, c-Fos enhanced hepatocyte apoptosis by directly up-regulating the 
major isoform of bim gene BimEL (Kitamura, Ogawa et al. 2003).     
Externalisation of PS was seen in all tested AML cell lines after HXR9 treatment. This 
finding was consistent with previous studies in different cancer cell lines upon HXR9 treatment 
(Morgan, Pirard et al. 2007; Shears, Plowright et al. 2008; Plowright, Harrington et al. 2009; 
Daniels, Neacato et al. 2010; Morgan, Plowright et al. 2010; Morgan, Boxall et al. 2012; 
Morgan, Boxall et al. 2014). In viable cells, PS is localised on the inner leaflet of the cell surface 
and its transfer to the outer leaflet is thought to be an engulfment signal by macrophages (Fink 
and Cookson 2005). It is well-known that the exposure of PS to the outer leaflet of the cell 
surface is a distinctive feature for apoptosis and results from the activation of caspase-3 
(Mandal, Moitra et al. 2002; Bonomini, Dottori et al. 2004). Therefore, the binding-ability of 
annexin V to PS was used specifically to detect and quantify apoptotic cells. However, the outer 
leaflet exposure of PS before the damage of the plasma membrane was reported in thymocytes 
at the prelethal stage of necrosis, oncosis (Waring, Lambert et al. 1999). In addition, oncotic 
L1210 cells, a mouse leukaemia cell line, showed annexin V+ /PI- phenotype after serum amine 
oxidase exposure (Bonneau and Poulin 2000), and exposure of Jurkat cells to different oncotic 
stimuli led to externalisation of PS, annexin V+ /7-ADD-, to the outer leaflet before the loss of 
cell membrane integrity (Lecoeur, Prevost et al. 2001; Lecoeur, de Oliveira-Pinto et al. 2002). 
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Likewise, caspase-8 deficient and Bcl-2 over-expressing Jurkat cells exhibited PS exposure 
during the oncotic stage (Krysko, de Ridder et al. 2004). H2O2 also was reported to cause PS 
externalisation in a cypD-dependent pathway, i.e. mitochondrial necrosis (Jobe, Wilson et al. 
2008). Therefore, externalisation of PS does not actually differentiate between apoptosis and 
necrosis (Fink and Cookson 2005; Verheij 2008; Blankenberg and Strauss 2012).     
The hallmark of apoptosis is caspase activation, and this was not found to be necessary 
in HXR9-induced cell death. These data are consistent with the likely mechanism of HXR9-
induced cell death in the renal cancer cell lines Caki-2 and 769-P, in malignant B cell lines and 
some prostate cell lines (Shears, Plowright et al. 2008; Daniels, Neacato et al. 2010; Morgan, 
Boxall et al. 2014). However, the general inhibition of caspases decreased the cytotoxicity of 
HXR9 on the tested renal, ovarian, breast and prostate cancer cell lines, although this decrease 
did not completely abrogate the effect of HXR9 (Shears, Plowright et al. 2008; Morgan, 
Plowright et al. 2010; Morgan, Boxall et al. 2014). This may be due to the presence of other 
mediators of HXR9-induced cell death. The results of this study support this. For example, 
HXR9 treatment of AML cells did not change the expression of PARP1 at the RNA or protein 
level. Nuclear fragmentation of apoptotic cells results from the cleaving of the cytoskeletal 
protein lamin by caspase-3 or -6 (Kagawa, Go et al. 2001; Ruchaud, Korfali et al. 2002), which 
might explain the absence of nuclear fragmentation in HXR9 treated AML cell lines. In 
addition, the expression of the anti-apoptotic genes Bcl-2 and XIAP that were known as targets 
of active caspases (Jin and El-Deiry 2005; Vermeulen, Van Bockstaele et al. 2005) were not 
affected by HXR9 treatment.   
The findings of this study suggest that mitochondrial apoptosis is not required for 
HXR9-mediated cell death. For example, an unchanged ratio between the anti-apoptotic Bcl-2 
and the pro-apoptotic Bax and Bak1 may reflect the intactness of mitochondrial membranes, 
since the presence of excess pro-apoptotic members of the Bcl-2 family enhances mitochondrial 
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permeabilization (Martin 2010). Furthermore, the mitochondrial release of cyt C would 
ultimately lead to caspase activation. In addition, the cleavage and activation of Bid that 
mediates mitochondrial apoptosis depends on the activation of caspase-8, which was not 
required for HXR9 cytotoxicity. Likewise, HXR9 seemed to induce cell death in a Bax-
independent process, since Bax-dependent apoptosis involves either caspase-9 or p53 activity, 
neither of which was needed for HXR9 mediated-cell killing (Janssen, Pohlmann et al. 2007; 
Gogada, Prabhu et al. 2011; Meng, Zhang et al. 2012). 
The absence of apoptotic-hallmarks activation, including caspase activation, Bcl-2 
family involvement, chromatin condensation and nuclear fragmentation suggest that HXR9 
induces AML cell death through a necrotic pathway.  
EDTA is a general cation-chelating agent, despite being widely used as an extracellular 
Ca2+ chelator (Dong, Li et al. 2005; Allen, Gemel et al. 2011; de Araújo Leite and Marques-
Santos 2012). For example, EDTA can form complexes with cations such as Na+, Mg+, Fe2+, 
Cu2+, Zn2+ that can be easily removed from the extracellular environment (Flora and Pachauri 
2010). Interestingly, the cell penetrating peptide (CPP) of HXR9 is R9 that is a highly cationic 
sequence (Mitchell, Steinman et al. 2000; Sarko, Beijer et al. 2010; Regberg, Srimanee et al. 
2012; Bechara and Sagan 2013). In addition, the binding of annexin V to PS is a Ca2+ dependent 
reaction (Vermes, Haanen et al. 1995). Therefore, the abrogation of HXR9 effect by EDTA 
might be due to the chelating of HXR9 and the absence of Ca2+ in annexin V/7-AAD assay.  
CypD knockout studies have demonstrated its crucial role in mitochondrial necrosis by 
Ca2+ overload and oxidative stress, but is not required for apoptosis (Li, Johnson et al. 2004; 
Baines, Kaiser et al. 2005; Nakagawa, Shimizu et al. 2005; Schinzel, Takeuchi et al. 2005). In 
addition, CypD is involved in Ca2+-independent, RIP3- and p53-dependent mPTP necrosis 
(Lerch, Halangk et al. 2013; Tian, Xu et al. 2013; Pei, Shang et al. 2014). Accordingly, HXR9 
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might mediate necrosis of AML in an mPTP-independent pathway, or at least, in a CypD-
independent mechanism.  
In this study it was shown that HXR9 led to cell death through a necroptotic pathway, 
at least in part, through RIP1 activity in HL-60 cells, whilst K562 cell death was RIP1-
independent. It is possible though that the effect of blocking RIP1 HXR9-induced HL-60 cell 
death could reflect a sub-effective dose of the RIP1 inhibitor, as Nec-1 showed some toxic 
effects at higher doses. The latter explanation is consistent with the fact that Nec-1 partially 
protected HL-60 cells from HXR9. Alternatively, other mediators in addition to RIP1 may be 
required in HXR9-induced cell death. It is noteworthy that a RIP1-independent cell death 
pathway does not rule out a potential role for necroptosis since it was reported that viral 
infection resulted in RIP3-dependent but RIP1-independent necroptosis through TNF mediated 
necroptosis (Zhang, Shao et al. 2009; Upton, Kaiser et al. 2010). Therefore, the role of RIP3 in 
HXR9-induced K562 cell death requires further investigation.   
The presence of ATP is crucial for caspase-dependent apoptosis and PARP1 hyper-
activation. In caspase-dependent apoptosis, ATP is involved in the formation of the apoptosome 
complex that mediates apoptotic signalling by cleaving and activating executioner caspases 
(Jochen, Richter et al. 2002). It was reported that ATP depletion by fructose in primary rat and 
mouse hepatocytes abrogated cyt C release and activation of executioner caspases, and DNA 
fragmentation by TNF-mediated apoptosis, and that these events were restored after ATP 
repletion (Latta, Kunstle et al. 2000; Jochen, Richter et al. 2002). In addition, the presence of 
ATP is essential for chromatin condensation and nuclear fragmentation (Tsujimoto 1997). ATP 
depletion by fructose prevented caspase activation and subsequently shifted cell death toward 
necrosis in the leukaemic Jurkat and K562 cells (Leist, Single et al. 1999; Verrax, Dejeans et 
al. 2011). Likewise, PARP1 involves ATP in the transfer of poly (ADP-ribose) from NAD+ 
(Devalaraja-Narashimha and Padanilam 2009; Ethier, Tardif et al. 2012). Taking together, the 
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depletion of ATP elicits the role of caspases and PARP1 hyper-activation in the mechanism of 
HXR9-induced cell death of AML cells. It is well-known that fructose at high concentrations 
traps intracellular ATP and maintains a sufficient cytoplasmic concentration to prevent cell 
necrosis (Latta, Künstle et al. 2000; Latta, Künstle et al. 2007; Speicher, Köhler et al. 2012). 
The results of this study revealed that ATP depletion by a high concentration of fructose did 
not prevent HXR9-induced necrotic death of the tested AML cells, which also supports a 
caspase- and PARP1- independent mechanism for HXR9-induced cell death.   
Despite its well-known crucial role in TNF-induced necrosis, PARP1 was dispensable 
in TNF-mediating necroptosis (Xu, Huang et al. 2006). Accordingly, it can be concluded that 
TNF activates necroptosis and necrosis in distinct pathways, although PARP1 was also shown 
to be a downstream effector of the necrosome in TRAIL-induced necroptosis (Jouan-Lanhouet, 
Arshad et al. 2012). In this study, it was reported that HXR9-induced necrosis in a PARP1-
independent mechanism. While the JNK pathway is involved in PARP1-induced necrosis, 
HXR9-induces necrosis of AML cells in JNK-independent pathway (Degterev, Huang et al. 
2005; Xu, Huang et al. 2006; Jog, Dinnall et al. 2009; Ethier, Tardif et al. 2012; Sosna, Voigt 
et al. 2014). Since PARP1 is a crucial player in mPTP, the results of PARP1 activation in this 
study support a mitochondria-independent pathway for HXR9-induced necrosis (Abramov and 
Duchen 2008).   
The MAPK family of protein kinases consists of four members; ERK, p38, JNK and the 
big mitogen activated protein kinase. MAPK proteins regulate different cellular pathways 
including cell survival, proliferation and cell death (Chen and Sommer 2009). In this study 
inhibition of MEK/ERK and p38 did not affect HXR9-induced cell necrosis. JNK inhibition 
also did not affect the efficacy of HXR9 in HL-60, although it increased the cytotoxicity of 
HXR9 for K562. This effect of JNK inhibition might be due to the expression of the BCR-ABL 
oncoprotein in K562 cells that is reported to induce leukaemogenesis through activation of JNK 
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signalling pathway (Hess, Pihan et al. 2002; Hantschel, Warsch et al. 2012; Chen, Gallipoli et 
al. 2013). In addition, the JNK pathway is reported to be an inducer of clonal evolution of 
Fanconi anaemia to AML (Li, Sejas et al. 2007) and sustained activation of the JNK pathway 
with AKT/FOXO signalling maintains AML cells in an undifferentiated state (Sykes, Lane et 
al. 2011). In FL15.12 cells, a haemopoietic pro-B cell line, IL-3 promoted cell survival by 
phosphorylating BAD through JNK signalling (Yu, Minemoto et al. 2004). More recently, it 
was reported that co-inhibition of the TNF-JNK pathway increased the sensitivity of primary 
human AML cells in vitro to NF-ĸB inhibitors (Volk, Li et al. 2014), and that the JNK pathway 
promoted proliferation and metastasis in several cancers including those of the liver and skin 
(Chen, Nomura et al. 2001; Han, Moon et al. 2009; Bettermann, Vucur et al. 2010; Ke, Harris 
et al. 2010; Ebelt, Cantrell et al. 2013). 
NOXs are a family of proteins that are considered to be a primary resource of ROS in 
living cells and regulated by intracellular Ca2+ signalling (Yu, Kim et al. 2006; Morgan, Kim et 
al. 2008; El Jamali, Valente et al. 2010; Hole, Darley et al. 2011; Jiang, Zhang et al. 2011; 
Pandey, Gratton et al. 2011) and mediate necrotic cell death (Ouyang, Shi et al. 2012). DPI is 
a widely used NOX inhibitor, though it is also a broad inhibitor of other flavoenzymes including 
nitric oxide synthase and xanthine oxidase (Li, Ragheb et al. 2003; Park, Song et al. 2007). In 
this study DPI increased the efficacy of HXR9 on the tested AML cells, suggesting that NOXs 
has survival roles upon HXR9 treatment. In line with these findings, it was found that DPI 
mediated the apoptosis of the pancreatic cancer cell line PANC-1 by blocking the survival 
pathway NOX4/ROS/AKT (Mochizuki, Furuta et al. 2006). DPI was also shown to mediate 
p53-dependent apoptosis (Kim, Song et al. 2007; Park, Song et al. 2007). In addition, NOXs 
were found to be regulated by PKC and CaM kinases that were identified in this study as 
mediators of cell resistance to HXR9 (Inoguchi, Sonta et al. 2003; Cai, Torreggiani et al. 2010; 
Pandey, Gratton et al. 2011).  
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Calpains are a family of 14 cysteine proteases that are regulated by Ca2+. The most 
extensively studied members of this family are μ-calpain or calpain I that is present in the 
cytosol and is stimulated by micro-molar Ca2+ concentrations, and m-calpain or calpain II that 
is present in the cell membrane and is activated by mille-molar concentration of  Ca2+ (Kar, 
Chakraborti et al. 2009; Szydlowska and Tymianski 2010). In this study, the potential role of 
μ-calpain was studied because it was reported a mediator of Ca2+-dependent necrosis 
(Mathiasen, Sergeev et al. 2002; Zhivotovsky and Orrenius 2011; Ouyang, Shi et al. 2012). 
However, HXR9-induced necrosis of AML cells in a μ-calpain-independent manner. This 
might be explained by the caspase-independent pathway of HXR9-mediated cell death, as μ-
calpain was shown to cleave and activate pro-caspases-3/9 in human lung adenocarcinoma cells 
(Liu, Xing et al. 2009). This finding is also consistent with the suggestion that HXR9-induced 
cell death does not require mitochondria, since μ-calpain was found to cause cleavage and 
activation of the pro-apoptotic members of Bcl-2 family Bax and Bid (Chen, He et al. 2001; 
Mandic, Viktorsson et al. 2002; Toyota, Yanase et al. 2003; Sanchez-Gomez, Alberdi et al. 
2011). It has also been shown that μ-calpain is a downstream mediator of PARP1 in the release 
of AIF that ultimately leads to mitochondria-dependent necrosis (Cao, Xing et al. 2007; Liu, 
Xing et al. 2009; Vosler, Sun et al. 2009; Storr, Carragher et al. 2011).  
CaM is a small 17KDa intracellular protein that is considered to be the main regulator 
and Ca2+-binding protein in all eukaryotic cells (Wang, Li et al. 2010; Berchtold and Villalobo 
2014). In this study, the CaM antagonist W-7 enhanced HXR9-induced necrosis. CaM exerts 
surviving effects by positively regulating pro-survival and proliferative proteins, and inhibition 
of CaM alone or in combination therapy promotes cell death in many cancer models. CaM 
inhibition sensitised human lung cancer H1299 cells to TRAIL-induced apoptosis by enhancing 
death-inducing signalling complex (DISC)-triggered apoptosis and/or preventing the 
phosphorylation of the survival protein AKT, leading to a reduction in expression of the anti-
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apoptotic protein c-FLIP (Hwang, Min et al. 2009). CaM also regulates the PI3K survival 
pathway (Lasbury, Durant et al. 2009), and inhibition of CaM attenuated the ERK1/2-dependent 
survival pathway and up-regulated the Bax- and caspase-3-dependent pathway (Bartolomé, de 
las Cuevas et al. 2007). CaM can also maintain NF-ĸB activity by phosphorylating and 
degrading its binding inhibitor IĸB (Shumway, Berchtold et al. 2002; Tano and Vazquez 2011). 
In vitro and in vivo studies of cholangiocarcinoma showed that the inhibition of CaM prevented 
the phosphorylation of AKT and c-FLIP recruitment to DISC, thereby increasing the 
recruitment and activation of caspase-2, caspase-8 and caspase-9. This in turn leads to cleavage 
and activation of caspase-3, releasing cyt C and triggering apoptosis (Ahn, Pan et al. 2003; 
Pawar, Ma et al. 2009; Jing, Yuan et al. 2011; Jing, Yuan et al. 2012).   
PKCs are a family of protein kinases that regulate several cellular functions including 
cell cycle progression, cellular proliferation, differentiation, survival and apoptosis. The PKC 
family is composed of 12 members and is classified into four classes according to structural 
and regulatory characteristics including the conventional/classical PKCs, the novel PCKs, the 
atypical PKCs and PKC-related kinases. Of these, only the conventional PKCs are Ca2+-
dependent (Bosco, Melloni et al. 2011; Shen, Kim et al. 2012; Parker, Justilien et al. 2014). Of 
the 12 PKCs, 7 are anti-apoptotic proteins including PKCα, PKCβ, PKCι, PKCγ, PKCζ, PKCε 
(Reyland 2007). In this study, the general inhibitor of PKC Ro31-8220 increased the sensitivity 
of the tested AML cell lines to HXR9. This supports the findings that NOX inhibition also 
sensitized cells to HXR9, as PKCα and PKCβ are positive regulators for NOXs (Shiraki, Oyama 
et al. 2012; Paneni, Beckman et al. 2013). Up-regulation of PKCα and PKCι were documented 
in breast cancer stem cells, human glioma (Desai, Pillai et al. 2011; Tam, Lu et al. 2013). In 
addition, PKC was found to increase the stability of the anti-apoptotic protein c-FLIP (Kaunisto, 
Kochin et al. 2009). PKCι was documented to cause cell cycle progression by phosphorylating 
CdK7 and CdK2 (Win and Acevedo-Duncan 2009; Pillai, Desai et al. 2011), and in the cancer 
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prostate cell line LNCaP, PKC promoted cell survival through the 
PI3K/PKD1/PKC/ERK1/2/NF-ҡB signalling pathway (Chen, Giridhary et al. 2011). It was also 
reported that PKC enhanced cell survival and invasion by inducing the expression of the growth 
factor bone morphogenic protein-4, components of the Ras signalling pathway, and matrix 
metalloproteinase 2 and 9 (Hwang, Yun et al. 2011; Shimizu, Kayamori et al. 2012; Lonic, 
Powell et al. 2013). During TRAIL-mediated apoptosis, PKC activation was reported to prevent 
DISC formation and consequently inhibited the apoptosis of HeLa cells (Harper, Hughes et al. 
2003). In ALL, PKC inhibition sensitised cells to Ca2+-mobilizers (Zhu, Fang et al. 1999). 
Furthermore, inhibition of PKC resulted in a dephosphorylation and activation of Bad 
concurrently with a down-regulation of Bcl-2 and ultimately to mitochondrial dysfunction and 
caspase-dependent apoptosis (Win and Acevedo-Duncan 2009; Desai, Pillai et al. 2011; 
Whang, Jo et al. 2013).  
The concurrent inhibition of CaM and PKCs alongside with HXR9 treatment resulted 
in AML cell death at very low IC50 in compared to HXR9-alone. This might result from the 
inhibition of both cell survival pathways such as PI3K/AKT, and anti-apoptotic proteins such 
as c-FLIP and anti-apoptotic members of Bcl-2 family. 
HO-1 protein is an important cytoprotective enzyme that has anti-apoptotic properties 
and promotes cancer cell survival, angiogenesis and drug-resistance (Jozkowicz, Was et al. 
2007; Lee, Chun et al. 2011; Park, Jung et al. 2011; Lee, Yang et al. 2012). It is constitutively 
expressed in primary human AML samples, cell lines and multiple myeloma cell lines (Barrera, 
Rushworth et al. 2012; Herrmann, Kneidinger et al. 2012). Inhibiting HO-1 increased the 
sensitivity of AML cells to HXR9. This is consistent with a number of other findings. For 
example, c-FOS is suppressed by HO-1 (Sun 2008), and PKC promotes cell survival through 
two different pathways that both involve HO-1, for example, through PKC/p38/Nrf2/HO-1 or 
PKC/ROS/PI3K/AKT/Nrf2/HO-1 (Tsoyi, Jang et al. 2011; Lee, Yang et al. 2012; Nguyen, Kim 
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et al. 2013). In addition, NOX4 was reported to induce HO-1 expression through the ROS/Nrf2 
pathway (Schroder, Zhang et al. 2012). HO-1 was also found to reduce the expression of p21 
that was found to play a pro-necrotic role following HXR9 treatment in this study (Was, 
Sokolowska et al. 2011). In addition, HO-1 prevents TNF-induced apoptosis in both c-FLIP 
and NF-ҡB knockdown AML cells (Rushworth and MacEwan 2008; Rushworth, Zaitseva et 
al. 2010). HO-1 also protected AML cells from the front-line chemotherapeutic drugs DNR and 
cytarabine and its inhibition enhanced the efficacy of both drugs (Heasman, Zaitseva et al. 
2011).    
p53 is one of the most extensively studied cell death proteins, and stimulates c-FOS 
transcription in cells undergoing p53-dependent apoptosis (Elkeles, Juven-Gershon et al. 1999). 
The results of this study showed that HXR9 did not change the expression of p53 at the RNA 
or at the protein level. These results were consistent with the mechanism of HXR9 killing of 
breast cancer cells that is p53-independent (Morgan, Boxall et al. 2012). In addition, p53 protein 
directly interacts with the anti-apoptotic members of the Bcl-2 family, Bcl-2 and Bcl-XL, 
resulting in the release of the pro-apoptotic members Bak and Bax, leading to caspase-
dependent apoptosis (Mihara, Erster et al. 2003; Vaseva and Moll 2009; Chakraborty, 
Mazumdar et al. 2014; Chi 2014). p53 also up-regulates the transcription of, and physically 
interacts with Bak, Bax and Bad resulting in mitochondrial apoptosis (Chipuk, Maurer et al. 
2003; Chipuk, Kuwana et al. 2004; Leu, Dumont et al. 2004; Jiang, Du et al. 2006; Pietsch, Leu 
et al. 2007; Wenzel, Wunderlich et al. 2012; Chi 2014; Lee, Lee et al. 2014; Saha, Bhattacharjee 
et al. 2014). However, none of the Bcl-2 family members or Apaf1, a mediator of p53-dependent 
apoptosis, changed in expression during HXR9-mediated AML cell necrosis. Furthermore, 
calpain, an inducer of p53 apoptosis, was not required for HXR9-induced AML cell death (Del 
Bello, Moretti et al. 2007; Bukowska, Lendeckel et al. 2012; Woo, Xue et al. 2012). More 
recently, the role of p53 in cypD- and PARP1-dependent programmed necrosis was identified 
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(Vaseva, Marchenko et al. 2012; Montero, Dutta et al. 2013; Pei, Shang et al. 2014). However, 
neither cypD nor PARP1 were involved in HXR9-induced AML necrosis. Taken together, these 
findings suggest that HXR9-indcues AML necrosis in a p53-independent manner.    
p21 is a member of the family of cyclin kinase inhibitors that include p27 and p57 
(Kwon, Jovanovic et al. 2003; Masgras, Carrera et al. 2012). It was originally recognised as a 
main regulator of the progression of the cell cycle (Harper, Adami et al. 1993). However, p21 
also regulates a number of other cellular functions, including apoptosis, cell proliferation and 
autophagy (Asada, Yamada et al. 1999; Dong, Li et al. 2005; Luo, Zou et al. 2011). Although 
it was thought that the regulation of p21 was totally dependent on p53, p21 can in fact be 
regulated by several transcription factors in a p53-independent manner (Liu and Huang 2006; 
Lafarga, Cuadrado et al. 2009; Shin, Kim et al. 2011; Han, Kim et al. 2012; Masgras, Carrera 
et al. 2012). For example, the early growth response-1 protein can induce the transcription of 
p21 independently of p53 (Choi, Kim et al. 2008). The early growth response-1 gene is induced 
in lung cancer cells after HXR9 treatment (Plowright, Harrington et al. 2009). Interestingly, 
p21 has been shown to be involved in p53-independent necrotic cell death (Ussat, Werner et al. 
2002; Kwon, Jovanovic et al. 2003). The results of this study show that the induction of p21 in 
response to HXR9 was p53-independent.  
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4.3.1 Summary of chapter   
In the summary, HXR9-mediated cell death in AML cells was characterised by the 
absence of the well-known features of apoptosis including caspase activation, the up-regulation 
of Bcl-2 family-members, chromatin condensation and nuclear fragmentation. The mechanism 
was also p53-independent. However, the mechanism of cell death involved, at least in part, c-
FOS and p21 over-expression. In addition, RIP1 was partially involved in the cell death of HL-
60, but not K562 cells, and the JNK pathway exerted pro-survival signalling in the HXR9-   
mediated killing of K562 cells. Likewise, CaM, PKC and HO-1 exerted resistance to HXR9-
mediated cell death (Table 4.1).  
 
Table 4.1 The mechanism of HXR9 cytotoxicity on AML cells. 
Causes up-regulation of Involves Independent of Induced by inhibition of 
c-FOS  
p21 
RIP1 (in HL-60) Caspases 
Bcl-2-family members 
Nuclear fragmentation 
CypD 
ATP 
PARP-1 activation 
MEK/ERK pathway 
p38 pathway 
µ-calpain 
p53 
JNK pathway (in K562) 
NOX 
CaM 
PKC 
HO-1 
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Chapter 5 In vivo cytotoxicity of HXR9
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5.1 Introduction 
 In vitro cytotoxicity of HXR9 on the tested AML cell lines was proven. In addition, this 
study data revealed that the concurrent inhibition of CaM and PKC dramatically increased the 
sensitivity of the tested AML cell lines to HXR9. Likewise, in vivo efficacy of HXR9 to 
eradicate solid tumours of different origins including melanoma, lung, ovarian, breast and 
prostate was demonstrated (Morgan, Pirard et al. 2007; Plowright, Harrington et al. 2009; 
Morgan, Plowright et al. 2010; Morgan, Boxall et al. 2012; Morgan, Boxall et al. 2014). In the 
previous studies, HXR9 was administrated via different routes including intravenously (I.V.), 
I.T. or intraperitoneally. In addition, HXR9 did not show adverse side effects on PB and BM 
after 10 days of daily I.V. administration at 15mg/kg/day (Morgan, Pirard et al. 2007). 
However, the in vivo efficacy of HXR9 on AML cell lines and the side effect of I.V. 
administration of high doses of HXR9 have not been studied, yet.  
 To determine the cytotoxicity of high doses of HXR9 on normal PB, a mouse strain with 
the whole blood cells was used, C57BL/6. Due to the intact immunity of C57BL/6 mice, the 
mouse AML cell line C1498 that is originated from C57BL/6 mouse strain, a syngeneic tumour 
model, labelled with GFP (C1498-GFP) was used to evade the immune system and engraft in 
mice. In addition, SCID mice were used to engraft the human AML cell line K562.  
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5.1.1 Aims of chapter 5 
To assess the efficacy of HXR9 against AML disease in vivo either alone or in 
combination with the simultaneous inhibition of CaM and PKC, and to assess the adverse effect 
of high doses of HXR9 on normal PB. 
The main objectives were: 
1. To determine the cytotoxicity of HXR9 either alone or with the simultaneous 
inhibition of CaM and PKC on the C1498-GFP cell line in vitro.  
2. To establish an AML mouse model by engrafting C1498-GFP or K562 cells in either 
C57BL/6 or SCID mice, respectively.   
3. To treat these models with high doses of HXR9.  
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5.2 Results 
5.2.1 HXR9 is cytotoxic for C1498-GFP cells  
To test whether HXR9 induces the cell death of the murine AML cell line C1498-GFP, 
C1498-GFP cells were treated with a series of HXR9 concentrations for two hours, and 
cytotoxicity was determined by LDH assay using ELISA. HXR9 induced C1498-GFP cell death 
(Figure 5.1) with an IC50 15.8μM ± 2.6 that determined using Calcusyn software.  
 
 
 
 
 
Figure 5.1 LDH assay for the cytotoxicity of HXR9 on C1498-GFP cells. Cells were exposed to a titration of 
HXR9 for two hours and the cytotoxicity of HXR9 was assessed by measuring LDH enzyme activity in cell-free 
supernatants. The graph shows the mean of three independent repeats that had R2 ≥ 0.95 and error bars show the 
SEM.    
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5.2.2 CaM blocking enhances the cytotoxicity of HXR9 
To assess whether the inhibition of CaM produces the same effect on the cytotoxicity 
of HXR9 as its inhibition in human AML cell lines, CaM was blocked in the murine AML cell 
line C1498-GFP cells using the W-7 inhibitor. As with human AML cells, blocking CaM 
increased the sensitivity of C1498-GFP cells to HXR9. For example, co-treatment of C1498-
GFP cells with 10μM HXR9 and 50μM W-7 significantly decreased the percentage of surviving 
cells from 72% ± 6.2 to 37% ± 3.3, **p < 0.01, compared to HXR9-only treated cells (Figure 
5.2).  In addition, co-treatment caused a dramatic decrease in the IC50 of HXR9 by two folds, 
from 14.4μM ± 1.2 to 7.5μM ± 2.3 (Figure 5.2).   
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   IC50 
Cell line/ condition HXR9 HXR9+50μM W-7 
C1498-GFP 14.4μM ± 1.2 7.5μM ± 2.3 
 
Figure 5.2 The effect of CaM inhibition on the cytotoxicity of HXR9 for C1498-GFP. Cells were pre-incubated 
with or without 50μM W-7 for one hour and then with HXR9 for two hours, with or without 50μM W-7, red and 
blue curves, respectively. The cytotoxicity of HXR9 was then measured by LDH assay in cell-free media. Co-
treatment with 50μM W-7 significantly increased the cytotoxicity of HXR9 on C1498-GFP cells. The graph shows 
the mean of three independent experiments and error bars show the SEM. *p < 0.05, **p < 0.01 and ***p < 0.001 
with respect to 50μM W-7 untreated cells. The table shows the difference in the IC50 between HXR9-only treated 
cells and HXR9 + 50μM W-7 treated cells. 
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5.2.3 Inhibition of PKC activity significantly sensitises cells to HXR9 
To assess the effect of inhibition of PKC activity on the sensitivity of C1498-GFP cells 
to HXR9, PKC activity was blocked using Ro31-8220 and the sensitivity to HXR9 was 
measured by LDH. Ro31-8220 at 30μM dramatically enhanced cell killing by HXR9. For 
example, co-treatment of cells with 30μM Ro31-8220 resulted in a huge reduction, p < 0.0001, 
in the percentage of surviving cells from 89% ± 3.5 to 58% ± 3.3, compared to cells treated 
with 5μM HXR9 alone (Figure 5.3). Likewise, co-treatment with Ro31-8220 decreased the IC50 
of HXR9 by twofold from 14.2μM ± 1.9 to 6.6μM ± 2.1 compared to HXR9-only treated cells 
(Figure 5.3).  
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 IC50 
Cell line/ condition HXR9 HXR9+30μM Ro31-8220 
C1498-GFP 14.2μM ± 1.9 6.6μM ± 2.1 
 
Figure 5.3 The impact of PKC inhibition on the sensitivity of C1498-GFP cells to HXR9. Cells were pre-treated 
with or without 30μM Ro31-8220 for one hour and then with HXR9 for two hours, with or without 30μM Ro31-
8220, red and blue curves, respectively. The sensitivity of C1498-GFP cells to HXR9 was then assessed by LDH 
assay using ELISA. Results show that blocking PKC dramatically increases the sensitivity of C1498-GFP cells to 
HXR9. Graphs show the mean of three independent experiments and error bars show the SEM. *p < 0.05 and 
****p < 0.0001 with respect to 30μM Ro31-8220 untreated cells. The table shows the difference in the IC50 
between HXR9-only treated cells and HXR9 + 30μM Ro31-8220 treated cells. 
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5.2.4 Concurrent inhibition of CaM and PKC significantly enhances the efficacy of 
HXR9 
To assess the impact of the concurrent inhibition of CaM and PKC on the sensitivity of 
C1498-GFP cells to HXR9, both kinases were concurrently blocked and cells were treated with 
increasing concentrations of HXR9 and the cytotoxicity of HXR9 was analysed using the LDH 
assay. The simultaneous inhibition of both proteins remarkably sensitised C1498-GFP cells to 
HXR9. For example, at 5μM HXR9 treatment, the inhibition of CaM and PKC hugely reduced 
the percentage of surviving cells from 83% ± 3.9 to 30.4% ± 4.4 (p < 0.0001), compared to 
HXR9-only treated cells (Figure 5.4). Likewise, the concurrent blocking of CaM and PKC 
remarkably decreased the IC50 of HXR9 by approximately tenfold, from 14.2μM ± 1.3 to 1.5μM 
± 1.4 (Figure 5.4). 
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 IC50 
Cell line/ condition HXR9 HXR9+(30μM Ro31-8220+50μM 
W-7) 
C1498-GFP 14.2μM ± 1.3 1.5μM ± 1.4 
 
Figure 5.4 The effect of CaM and PKC simultaneous inhibition on the efficacy of HXR9. Cells were pre-treated 
with or without the combination of the inhibitors, 50μM W-7 and 30μM Ro31-8220, for one hour and then with 
HXR9 for two hours, with or without both inhibitors (red and blue curves, respectively). The sensitivity of C1498-
GFP cells to HXR9 was then estimated by measuring LDH enzyme activity in cell-free media using ELISA. The 
simultaneous blocking of CaM and PKC remarkably enhanced the efficacy of HXR9. The graph shows the mean 
of three independent experiments and error bars show the SEM. *p < 0.05, **p < 0.01 and ****p < 0.0001 with 
respect to W-7 and Ro31-8220 untreated cells. The table shows the difference in the IC50 between HXR9-only 
treated cells and HXR9 + (50μM W-7 + 30μM Ro31-8220) treated cells. 
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5.2.5 Efficient expression of GFP in C1498 cells 
The murine AML cell line C1498 was previously transduced to express GFP in order to 
monitor tumourgenicity (Zhang, Gajewski et al. 2009). The expression of GFP was confirmed 
by fluorescence microscopy, and flow cytometry, which revealed that approximately 95% of 
C1498 cells express GFP (Figure 5.5).   
 
A)       B) 
   
 
Figure 5.5 Expression of GFP in C1498 cells. A) Detection of GFP expression, green fluorescence, by fluorescent 
microscope (x10). B) Analysis of GFP expression in C1498 by flow cytometry. The percentage of C1498 was 
calculated as the percentage of cells that express GFP.   
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5.2.6 Establishment a systemic C1498-GFP model in C57BL/6 mice 
To establish a murine AML model to assess the cytotoxicity of HXR9 in vivo, C57BL/6 
mice (n=10) were inoculated I.V. with 1x106 C1498-GFP cells on day 0 (Table 5.1). The 
leukaemia burden was monitored in PB by harvesting blood from random mice on days 3, 7, 
13, 17 and 20 (Appendix 9), and estimated by calculating the percentage of GFP+ cells within 
the peripheral white blood cells (Figure 5.6). GFP+ cells were found to have engrafted in 2 of 
10. This engraftment rate was too low to study the effect of HXR9 in vivo.  
A)         B) 
                   
Figure 5.6 FACS analysis of PB from C57BL/6 mice 13 days after injection of C1498-GFP cells. C1498-GFP 
cells were injected in C57BL/6 mice on day 0 and PB was collected from two mice. Peripheral blood mononuclear 
cells were analysed by FACS. A) A plot shows no engraftment of C1498-GFP cells. B) A plot shows engraftment 
of C1498-GFP cells. 
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Table 5.1 A summary of injection of C1498-GFP I.V. in C57BL/6 mice. 
Mouse strain C57BL/6 
Number of mice 10 
Cell line C1498-GFP 
Cell inoculation number  1x106 cell/mouse 
Inoculation site I.V. 
Harvested organ PB 
Experiment length (days) 20  
Engraftment rate 2 out of 10 
(1 in day 13 and 1 in day 17) 
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5.2.7 Establishment a systemic C1498-GFP model in C57BL/6 and nude mice 
As the first xenograft model did not work, two further mouse strains, C57BL/6 (n=10) 
and nude mice (n=5), were inoculated with 1x106 C1498-GFP cells I.V. on day 0 (Table 5.2). 
In this experiment, the leukaemia burden was monitored by calculating the percentage of GFP+ 
cells within the whole population of white blood cells in many sites including PB, BM, liver, 
kidney and spleen on days 8, 15, 22, 25, 28 and 35 (Figure 5.7 and appendix 10). Results showed 
that the first engraftment site was the liver in both strains. However, cells were engrafted in 3 
and 2 mice in C57BL/6 and nude strains, respectively, and two C57BL/6 mice died in the day 
22 after injection. The low engraftment rate, the late stage engraftment of cells in PB and the 
death of two mice suggested that this xenograft model was not appropriate for analysing the 
efficacy of HXR9 in vivo.  
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A)     C57BL/6 mice     
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B) Nude mice 
                           
                       
 
Figure 5.7 FACS analysis of C1498-GFP cells shows engraftment in several organs of C57BL/6 and nude mice. 
C1498-GFP cells were inoculated I.V. in both strains on day 0. Several sites including PB, BM, liver, kidney and 
spleen were harvested and white blood cells were purified as described in methods. Then, the engraftment of 
C1498-GFP cells was analysed by FACS. A) A plot shows C1498-GFP cells engraftment in organs from a 
C57BL/6 mouse, B) a nude mouse. 
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Table 5.2 A summary of injections of C1498-GFP I.V. in C57BL/6 and nude mice. 
Mouse strain C57BL/6 Nude 
Number of mice 10 5 
Cell line C1498-GFP 
Cell inoculation number 1x106 cell/mouse 
Inoculation site I.V. 
Harvested organs PB, BM, liver, kidney and spleen 
1st engraftment site Liver 
Experiment length (days) 28 35 
Engraftment rate 3 out of 10 
(2 and 1 in days 22 and 28, 
respectively) 
2 out of 5 
(1 in day 22 and 1 in day 28) 
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5.2.8 Development a C1498-GFP flank model in C57BL/6 mice 
As the I.V. inoculation of C1498-GFP cells was not appropriate to establish it as an 
AML model to study the efficacy of HXR9 in vivo, the flank xenograft attempt was done to 
assess its efficacy to be as a model. C57BL/6 mice (n=5) were injected S.C. with 1x106 C1498-
GFP cells on day 0 (Table 5.3). The leukaemic tumours started to be measured on day 7 and all 
mice had tumours by day 20. Therefore, the flank xenograft was used to conduct in vivo 
experiments. 
 
Table 5.3 A summary of injection of C1498-GFP S.C in C57BL/6 mice. 
Mouse strain C57BL/6 
Number of mice 5 
Cell line C1498-GFP 
Cell inoculation number 1x106 cell/mouse 
Inoculation site S.C. 
Experiment length (days) 20 
Engraftment rate 100% 
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5.2.9 HXR9 significantly extended the survival of C1498-GFP xenograft  
Due to its successful engraftment, the flank xenograft of C1498-GFP cells in C57BL/6 
mice was established in order to assess the effect of HXR9 in vivo. C1498-GFP cells were 
implanted S.C. in the flank, 1x106 cell/mouse. When tumours became palpable, the mice were 
divided into two cohorts of 9 mice each with one cohort treated with 50mg/kg HXR9 three 
times/week I.T. and the other with PBS as a control. Comparison of tumour growth delay 
between the different cohorts at each time point showed that there was no statistical difference 
(p = 0.23) in tumour sizes although the mean tumour volume on day 12 was less than half that 
of the control group (Figure 5.8A). OS data showed that HXR9-treated mice survived 
significant longer than their counterpart (p = 0.036), 22% compared to 0% for HXR9 and PBS 
treated mice, respectively (Figure 5.8B).    
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A) 
 
 
B) 
 
 
Figure 5.8 HXR9 treatment effect on the growth of C1498-GFP xenograft in female C57BL/6 mice. Mice were 
injected with 1x106 C1498-GFP cells S.C. in the flank. When xenografts became palpable, day 0, mice were treated 
I.T. with 50mg/kg HXR9 (n=9) or PBS (n=9) three times/week. Mice were culled when tumour sizes reached ≥ 
1500 mm3. A) Mean changes in xenograft volumes following HXR9 or PBS treatment and error bars show SEM. 
B) The corresponding survival curve for mice treated with HXR9 or PBS shown in A.  
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5.2.10 Simultaneous inhibition of CaM and PKC did not sensitise C1498-GFP flank 
tumour to HXR9  
To assess whether the concurrent inhibition of CaM and PKC in vivo could enhance the 
efficacy of HXR9 as it did in vitro, the same drug combination was used in the C1498-GFP 
flank tumour. Flank tumours were initiated in C57BL/6 mice by S.C. administration of C1498-
GFP cells, 1x106cell/mouse. When tumours became measureable, mice were divided into four 
groups. Two control groups were treated with either PBS or CaM and PKC inhibitors, 500μM 
W-7 and 300μM Ro31-8220, respectively; the other groups were either treated with 50mg/kg 
HXR9 alone or 50mg/kg HXR9 plus the inhibitors simultaneously for three times/week. 
Tumour growth data demonstrated that there were no statistical variances among the different 
groups at any time point. Although the mean tumour volume in HXR9 and the inhibitor treated 
mice on days 21, 23 and 25 showed an entire absence of tumour, this data represented the 
tumour volume of one mouse out of 10 mice (Figure 5.9A).  Consequently, the OS of the treated 
groups with HXR9 alone or HXR9 and the inhibitors were not statistically significant different 
compared to the OS of the control groups (Figure 5.9B).    
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A)  
 
 
 
B) 
 
Figure 5.9 Effect of HXR9 I.T. treatment on the growth of C1498-GFP flank xenograft in C57BL/6 mice. C1498-
GFP cells (1x106) were inoculated S.C. in the mice flanks. When tumours became palpable, mice were split into 
four groups, two control groups were administrated PBS (n=9) and CaM and PKC inhibitors (n=10), 500μM W-7 
and 300μM Ro31-8220, respectively; and the other two groups were administrated either 50mg/kg HXR9 alone 
(n=10) or 50mg/kg HXR9 + (500μM W-7 and 300μM Ro31-8220) (n=10) I.T. for three times/week. When tumours 
reached ≥ 1500 mm3, mice were excised. A) Changes in tumour volumes resulting from treatment with PBS, 
500μM W-7 and 300μM Ro31-8220, 50mg/kg HXR9 or 50mg/kg HXR9 + (500μM W-7 and 300μM Ro31-8220) 
and error bars show SEM. B) Corresponding survival curve for mouse groups shown in A. 
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5.2.11 HXR9 did affect the tumour growth of K562 flank model  
As an additional in vivo model, human AML cell line K562 was used in the SCID mice. 
K562 cells were inoculated S.C. in the flank of SCID mice at 1x106 cell/mouse. When tumours 
became measurable, the mice were split into two groups of 6 mice each. One group was injected 
I.T. with 100mg/kg HXR9 three times/week, except on the 10 and 12 mice were treated with 
300mg/kg and 200mg/kg HXR9, respectively. The control group was injected with PBS. 
Tumour growth delay and median survival data revealed that there was no statistical difference 
between the two groups (Figure 5.10). Of note, 300mg/kg and 200mg/kg HXR9 led to the death 
of two mice each.   
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A) 
 
 
B) 
 
 
Figure 5.10 Impact of HXR9 treatment on the K562 flank-xenograft growth in SCID mice. The xenograft was 
initiated by S.C. injection of 1x106 K562 cells in the flank. When tumours became measureable, day 0, mice were 
treated I.T. with HXR9 (n=6) or PBS (n=6) three times/week. HXR9-treated mice were treated with 100mg/kg 
overall the experiment except on day 7 and 10 where they were treated with 300mg/kg and 200mg/kg respectively. 
Mice were euthanized when tumour volumes reached ≥ 1500 mm3. A)  Mean values of tumour volumes of HXR9-
treated or PBS-treated mice and error bars show SEM. B) OS of HXR9- and PBS-treated mice. 
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5.3 Discussion 
Leukaemic mouse models were established four decades ago after the development of 
SCID mice. This model is characterised by the lack of active T and B lymphocytes (Bosma and 
Carroll 1991). Subsequently, the non-obese diabetic with severe combined immunodeficiency 
(NOD-SCID) model was developed; the mice lack functional T and B lymphocytes and have 
fewer NKs (Shultz, Schweitzer et al. 1995). Another model is nude mice, which are 
characterised by the absence of functional T lymphocytes and a partial absence of B 
lymphocytes. There are also other leukaemic mouse models available including NOD-SCID-
β2 null and NOD-SCID-IL-2Rγ null. The leukaemic xenotransplantations in mice can be 
established by different administrations including I.V., intrafemoral and S.C. inoculations. The 
intrafemoral injection of leukaemic cells into the BM is the most common and effective 
xenotransplantation administration. These preclinical models are used to assess the anti-cancer 
efficacy of drugs.    
One of the aims of this chapter was to measure the cytotoxicity of HXR9 and its 
cytotoxic efficacy on AML cells in vivo. Therefore, C57BL/6 mouse strain that has a full 
functional immune system and the murine AML cell line C1498 labelled with GFP were used 
for this purpose. The in vitro cytotoxicity assay showed the sensitivity of C1498-GFP to HXR9 
and this sensitivity was further induced by either inhibiting CaM or PKC activity alone or 
concurrently, which indicates that C1498-GFP cells respond to HXR9 as human AML cells. 
The systemic injection of C1498-GFP in C57BL/6 mice resulted in only a low engraftment rate. 
This low engraftment in PB might be the result of C1498-GFP cell lysis by NKs and CD8+ 
cytotoxic lymphocytes (Boyer, Orchard et al. 1995). In addition, the level of engraftment 
measured in this study is typically seen in AML xenotransplantation experiments (Sanchez, 
Perry et al. 2009).  
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As a result, the systemic xenotransplantation was redone in two mouse strains including 
C57BL/6 and nude mice, monitoring engraftment in the PB, BM, liver, kidney and spleen. This 
experiment showed engraftment of C1498-GFP cells in all harvested organs with low 
engraftment in PB and BM. Extramedullary infiltration, the presence and proliferation of 
leukaemic cells in sites beyond the medullary spaces of BM including liver, kidney and spleen, 
is a common symptom in AML and associated with poor prognosis and poor OS (Ravindranath, 
Steuber et al. 1991; Creutzig, Harbott et al. 1995; Rubnitz, Raimondi et al. 2002; Chang, 
Brandwein et al. 2004). Extramedullary infiltration was also reported in mouse 
xenotransplantations (Krivtsov, Twomey et al. 2006; Sanchez, Perry et al. 2009). The causes of 
extramedullary infiltration are not fully understood. However, the interaction between the 
chemokine stromal cell-derived factor-1 alpha produced from human and murine liver, kidney 
and spleen, and its receptor C-X-C chemokine receptor type 4 (CXCR4), is highly expressed 
by AML and other leukaemic cells is considered as a crucial step in AML cell proliferation and 
trafficking, AML disease progression and extramedullary infiltration (Mohle, Schittenhelm et 
al. 2000; Kollet, Spiegel et al. 2001; Kollet, Shivtiel et al. 2003; Kato, Niwa et al. 2011). In 
addition, targeting CXCR4 prevented the engraftment of AML cells in the BM and spleen of 
transplanted mice (Tavor, Petit et al. 2004; Zhang, Patel et al. 2012).  Obviously, the overall 
engraftment rate was relatively low in both strains which may due to some immune activity in 
both strains or due to technical issues such as failure to inject cells in the tail vain.  
The I.V. injection of C1498-GFP cells in C57BL/6 and nude mice was clinically 
relevant to AML disease. However, this systemic injection has many limitations. For example, 
the low engraftment rate which could be overcome by pre-treating mice with a combination 
regimen of total body irradiation and a pharmacological immunosuppressive agents. It is well-
documented that total body irradiation of recipient mice sustained engraftment by decreasing 
the homing ability to the marrow microenvironment, decreasing the repopulating ability and 
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causing cell death of the resident stem and progenitor cells and accordingly allowing injected 
cells to engraft (Kahl, Mielcarek et al. 2004). In addition, the combination regimen inhibited 
graft rejection by host T-cells which increased the engraftment rate (Mielcarek, Torok-Storb et 
al. 2011; Shan and Ma 2013). Furthermore, the high engraftment rate of C1498-GFP cells in 
extramedullary organs and the low engraftment rate in PB was a limitation due to the lack of 
non-invasive monitoring system of the progression of AML which could be overcome by using 
bioluminescence imaging. This technique can rapidly and noninvasively detect disease 
progression from early stages by measuring light emission from cells labelled with the 
bioluminescent reporter genes.    
Due to the low systemic engraftment rate; the lack of radiation and bioluminescence 
imaging facilities, the S.C. engraftment model was used in this study. This model is not a 
realistic representation of AML, but it is an acceptable model for the preclinical evaluation of 
drugs (Vinante, Rigo et al. 1999; He, Liu et al. 2003; Siegler, Kalberer et al. 2005; Motiwala, 
Majumder et al. 2009; Zhang, Zhang et al. 2012; Chen, Yang et al. 2013; Park, Mishra et al. 
2013; Sukhai, Prabha et al. 2013; Li, Li et al. 2014; Yang, Yu et al. 2014). The flank model in 
C57BL/6 mice showed 100% engraftment rate that indicated to the usefulness of this model to 
assess the efficacy of HXR9. At the first experiment, the concentration of HXR9 used was 
50mg/kg, which was the half of the maximum concentration that previously used (Morgan, 
Plowright et al. 2010; Morgan, Boxall et al. 2012; Morgan, Boxall et al. 2014). The I.T injection 
of HXR9 showed that HXR9 was effective in delaying the growth of C1498-GFP cell tumour. 
At the second experiment, the concurrent inhibition of CaM and PKC was introduced with the 
same concentration of HXR9, 50mg/kg. Similar to the first experiment, using concurrent 
inhibition of CaM and PKC did not sensitize tumours to 50mg/kg HXR9. This result was 
consistent with in vitro results that showed the concurrent inhibition of CaM and PKC was not 
cytotoxic itself, but increased the sensitivity to HXR9.  
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The human AML cell line K562 and SCID mice were used as a second in vivo model. 
At 100mg/kg, HXR9 was not effective in reducing tumour sizes of treated mice. In addition, at 
300mg/kg and 200mg/kg, HXR9 caused the death of two mice at each concentration. This effect 
might be owing to the systemic leakage of HXR9 through tumour microvessels which might 
result in HXR9 mediated toxicity. The acute toxicity of HXR9 might result from the cationic 
R9 which is well-known for its nonspecific interactions and ability to penetrate most organs 
(Vives, Schmidt et al. 2008; Sarko, Beijer et al. 2010).    
The ethics regulations might underestimate the in vivo cytotoxicity of HXR9 on AML 
cells. According to the ethics mice were culled when tumours reached 1500 mm3, this action 
might underestimate the difference in tumour sizes between different mouse groups, treated and 
untreated mice. This is one of the limitations of using the flank model for AML 
xenotransplantation and could be overcome by using a systemic in vivo model.  
The main challenge of treating cancer is drug resistance. To understand the mechanisms 
of chemoresistance, the structure of solid tumours should be known. Solid tumours are 
heterogenous environment compose of cancer and stromal cells. The stromal cells includes 
fibroblasts, immune, endothelial and mesothelial cells, adipocytes and extracellular matrix 
(Castells, Thibault et al. 2012). The resistance to therapy is complicated and caused by several 
factors. Some of resistance factors are cell intrinsic ''biochemical'' including genetic mutations 
that affect drug uptake, over-expression of antiapoptotic and/or survival genes (Wilson, 
Longley et al. 2006; Bleau, Hambardzumyan et al. 2009). Other factors are cell extrinsic 
''physiological'' that resulted from the stromal microenvironment (Williams, den Besten et al. 
2007; Eckstein, Servan et al. 2009). For example, tumours characterised by their extracellular 
acidity and their alkaline or neutral intracellular environments (Tredan, Galmarini et al. 2007). 
The extracellular pH influences the cellular uptake and thereby the efficacy of chemotherapies. 
For example, increasing the extracellular acidity by I.V. glucose administration, through an 
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unknown mechanism, promoted the uptake and the efficacy of weak acid drugs such as 
chlorambucil, while it decreased the tumour growth delay of the small-cell lung carcinoma cell 
line 54A by the weak base doxorubicin (Gerweck, Vijayappa et al. 2006). In contrast, in vitro 
and systemic in vivo alkalinisation of extracellular environment by sodium biocarbonate 
increased the uptake and the efficiency of weak base drugs including anthracyclines, taxanes 
and alkylating agents on the breast cancer cell line MCF-7, whereas it reduced the cytotoxicity 
of weak acid drugs including cyclophosphamide, 5-fluorouracil and chlorambucil (Mahoney, 
Raghunand et al. 2003; Raghunand, Mahoney et al. 2003). It is noteworthy that HXR9 is 
composed of the functional peptide and R9 which is one of the cell-penetrating peptides that 
characterised by its cationic feature (Jin, Zhang et al. 2013). Therefore, the tumour extracellular 
acidity might affect the uptake and the in vivo efficacy of HXR9 on the tested cell lines 
including C1498-GFP and K562 cells. Tumour microenvironments are also characterised by 
the presence of some hypoxia regions (Tredan, Galmarini et al. 2007; De Bock, Mazzone et al. 
2011). Hypoxia was documented to cause in vivo drug resistance by activating the expression 
angiogenic, anti-apoptotic and survival genes through triggering the over-expression of hypoxia 
inducible factor-1 (Pouyssegur, Dayan et al. 2006). hypoxia inducible factor-1 in turn induces 
the expression of NF-ĸB that activates the survival pathway by enhancing PI3K/Akt (Eltzschig 
and Carmeliet 2011). NF-ĸB also mediates the expression of the inflammatory molecules such 
INF-γ and TNF-α that induces the expression of the angiogenic factor vascular endothelial 
growth factor (VEGF) from endothelial cells and cancer cells (Eltzschig and Carmeliet 2011). 
VEGF is a mediator of the over-expression of the anti-apoptotic proteins including Bcl-2 and 
XIAP (Nör, Christensen et al. 1999; Lee, Shanafelt et al. 2005). However, the inhibition of 
VEGF expression in a S.C. model of K562 led to a decrease in the tumour microvessels and 
caused cell apoptosis (He, Liu et al. 2003). Hypoxia was also reported to cause up-regulation 
of P-glycoprotein, which is responsible of drug efflux (Comerford, Wallace et al. 2002). 
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Tumours cause infiltration and accumulation of immune cells such as macrophages in tumour 
microenvironments (De Palma and Lewis 2011). This subset of macrophages called tumour 
associated macrophages and functions as a tumour growth inducer by increasing tumour 
vascularisation and angiogenesis through over-expressing VEGF (Stockmann, Doedens et al. 
2008). In addition, those macrophages facilitate tumour growth by providing 
immunosuppressive microenvironment through expressing anti-inflammatory molecules such 
as interleukin 10, transforming growth factor β (Hao, Lu et al. 2012). The concurrent treatment 
regimen of tumour associated macrophages and chemotherapy caused a significant reduction 
in tumour sizes (DeNardo, Brennan et al. 2011). Adhesion of stromal cells to cancer cells also 
promoted the survival of cancer cells (Correia and Bissell 2012). Resistance to new therapies 
is multi-factorial and tumour microenvironment has an integral part in it.  
The discrepancy between in vitro and in vivo response of both tested mouse and human 
AML cell lines C1498-GFP and K562, respectively, indicated that tumour microenvironment 
might played a crucial role in the in vivo chemoresistance to HXR9. However, this potential 
explanation does not exclude the acquired chemoresistance that resulted from cell intrinsic 
mutations. To understand and improve the in vivo efficacy of HXR9, more molecular assays 
and the physiology of tumour microenvironment are needed to be investigated. Of note, the 
S.C. injection does not realistically reflect the nature of AML disease. Therefore, there is a need 
to develop a reliable preclinical in vivo model for the assessment of the efficacy of HXR9.  
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5.3.1 Summary of chapter 
In summary, in vitro results showed that HXR9 has a significant anti-tumour activity on 
C1498-GFP cells that was sharply promoted by either inhibition of CaM/PKC or both of which. 
However, S.C. injection of C1498-GFP mouse model results demonstrated that this cell line 
was chemo-resistant to either HXR9-alone treatment or combination treatment of HXR9 and 
concurrent inhibition of CaM and PKC. The chemoresistance to HXR9 was also seen in K562 
S.C. implemented into SCID mice. In addition, HXR9 resulted in death of some mice at high 
concentrations. Finally, the attempt to develop a systemic mouse model for C1498-GFP cells 
in C57BL/6 and nude mice resulted in low engraftment rate. 
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Chapter 6 General Discussion and Future Directions 
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6.1 Discussion 
AML is considered to be the most frequent acute leukaemia to affect adult patients. 
Conventionally, AML is classified cytogenetically according to the cell karyotypes into three 
prognostic groups: favourable prognostic group including t(8;21), inv(16) and t(15;17), an 
adverse prognostic group including complex karyotypes, trisomy 8 and CML-blast crisis, and 
an intermediate prognostic group including most other abnormalities and NK-AML (Roche, 
Zeng et al. 2004). Of note, about 45% of AML cases exhibit normal karyotypes (Marcucci, 
Mrozek et al. 2005). The treatment regimen for all prognostic groups has not been changed 
substantially over the last 4 decades, with the exception of APML. The current standard 
induction therapy is a combination of DNR for 3 days with cytarabine for 7 days in a so-called 
''3+7 regimen''. This regimen usually achieves 70%-75% CR in young (< 60 years), and 50% 
CR in old patients. A post-induction, consolidation regimen consisting of high cytarabine doses 
or alternatively allogeneic transplantation improves the outcome of AML patients. However, 
the outcome of this regimen is heterogonous and the majority of patients will relapse and die 
even after achieving clinical CR (Burnett 2012; Patel and Levine 2012).  
The significant heterogeneity in the outcome of AML patients might be due to several 
reasons. First, the current CR criteria are broad and totally dependent on microscopic counting 
of the number of blast cells in BM to determine if the make-up ≤ 5% of the cell population, and 
has not changed substantially since 1956 (Hourigan and Karp 2013). This limitation could be 
overcome by including the detection of AML-specific molecular stable targets using PCR or 
flow cytometry in CR criteria. The detection of AML cells after chemotherapy at levels under 
the sensitivity level of the microscopic detection is known as minimal residual disease (MRD) 
(Ossenkoppele and Schuurhuis 2013). Second, the low specificity of the current treatment 
regimen also plays a role in the heterogeneity of response. To overcome this limitation, AML 
patients should be treated with more cell-specific drugs. Third, there is heterogeneity of AML 
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cells with respect to treatment sensitivity; for example, favourable prognostic groups respond 
better than poor prognostic groups to the currently used chemotherapy. 
Currently, the evaluation of relapse risk of AML (except for APML) patients in initial 
clinical CR is based on the average clinical results of large historical populations who had the 
same pre-treatment chromosomal and molecular abnormalities at the presentation time 
(Mrozek, Marcucci et al. 2012; O'Donnell, Abboud et al. 2012). This assessment method lacks 
the evaluation of the induction treatment efficiency by patient-individualised-evaluation and 
can be improved by including MRD detection to guide decisions to the most-suitable post-
induction treatment. MRD is currently applicable in CML to detect the BCR-ABL fusion that 
is present in almost all CML cases (Cross, White et al. 2012; O'Hare, Zabriskie et al. 2012). In 
AML, MRD is now only used in APML to detect the PML-RARA fusion (Grimwade, 
Jovanovic et al. 2009; Chendamarai, Balasubramanian et al. 2012). However, MRD is not 
involved in the rest of AML cases; therefore, finding genes that are over-expressed in AML 
cells is still an open area for more studies. For example, the most common mutated genes in 
AML, including NPM1 and FLT3, might be potential detectable by MRD (Kristensen, Møller 
et al. 2011; Buccisano, Maurillo et al. 2012). The detection of molecular targets offers a higher 
sensitive than the current microscopic detection and presents a more-personalised approach to 
diagnosis. It was reported that detection of the NPM1mut MRD preceded haematological relapse 
by a median time of 8 weeks (Schnittger, Kern et al. 2009). Analogously, therapeutic 
intervention after the detection of molecular relapse by MRD improved clinical outcomes 
(Rubnitz, Inaba et al. 2010; Inaba, Coustan-Smith et al. 2012). It is noteworthy that HOX gene 
over-expression is a common event in many AML subtypes and is strongly associated with a 
poor prognosis, as previously mentioned in the introduction, and thus they are potential targets 
in MRD.   
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The heterogeneity of AML is due to the presence of various cytogenetic abnormalities 
in 55% of AML cases including numerical aberrations, structural aberrations and balanced 
translocations (Buccisano, Maurillo et al. 2012). In addition, molecular studies revealed a 
diversity of molecular markers that further sub-classified the majority of NK-AML patients 
(Marcucci, Mrozek et al. 2005). The discovery of molecular markers in NK-AML leads to the 
hypothesis that leukaemogenesis results from the interaction of many mutations. These lead to 
either an increase in cell proliferation (class I mutations) or a block of cell differentiation (class 
II mutations), ultimately leading to AML (Dohner and Dohner 2008; Renneville, Roumier et 
al. 2008; Betz and Hess 2010).    
The burgeoning molecular understanding of AML could be valuable in many ways, 
including the further sub-classification of the disease and the development of more personal 
prognostic predictions that could form the cornerstone for future therapeutic regimens. 
Currently, all-trans retinoic acid (ATRA) is the only widely used molecularly targeted therapy 
in AML, for the treatment of APML characterised by the presence of t(15;17)/PML-RARA. 
Understanding the molecular mechanism, signalling pathways and cooperating mutations will 
pave the way for new potential molecular drugs that hopefully will result in more personalised 
treatment.   
The diversity of cytogenetic and molecular aberrations is one of the main obstacles to 
the development of targeted therapies for AML, and the definition of the common genetic 
abnormalities in patients with different kinds of mutations may lead the way to subtype specific 
therapies. MLL fusion proteins were reported in 10% of therapy-related AML and 3% of de 
novo AML (Slany 2009). Core binding factor translocations including CBFB/MYH11 and 
RUNX1/RUNX1T1 fusions constitute 6% and 10% of all AML cases, respectively (Haferlach 
2008). NUP98-HOX fusion proteins were also reported in AML (Fujino, Suzuki et al. 2002; 
Suzuki, Ito et al. 2002; Taketani, Taki et al. 2002). Advances in molecular techniques also 
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defined genetic aberrant expressions in AML. For example, the dysregulation of CDX2 and 
CDX4 occur in 90% and 25% of AML cases, respectively (Bansal, Scholl et al. 2006; Scholl, 
Bansal et al. 2007). Wilms' tumour gene 1 over-expression was seen in 80%-90% of AML cases 
(Ostergaard, Olesen et al. 2004; Weisser, Kern et al. 2005), and the NPM1 mutation is present 
in 35% of all AML cases and approximately 55% of NK-AML (Falini, Mecucci et al. 2005; 
Thiede, Koch et al. 2006; Schlenk, Döhner et al. 2008). FLT3 mutations are present in 25% of 
all AMLs and in 70% of NK-AMLs (Thiede, Steudel et al. 2002; Yanada, Matsuo et al. 2005). 
The NRAS mutation was reported in 11% of AMLs (Bacher, Haferlach et al. 2006). These 
aberrations can be found alone or in combination. For example, FLT3 is often coincident with 
NPM1 or MLL mutations (Döhner, Schlenk et al. 2005; Olesen, Nyvold et al. 2005).   
The above-mentioned combinations of FLT3 with NPM1 or MLL indicates that genetic 
and cytogenetic aberrations cannot be assessed independently, and may in fact reflect the early 
mechanism of leukaemogenesis and narrow down the potential genetic and signalling pathways 
that are suitable for therapeutic approaches. An in depth analysis of AML subtypes suggest that 
HOX genes can be one of the common denominators of different cytogenetic and molecular 
aberrations. HOX gene over-expression was reported in AML with chromosomal rearrangement 
including MLL fusion proteins and MYST3-CREBBP translocation (Ayton and Cleary 2003; 
Camos, Esteve et al. 2006; Slany 2009). Mll fusion was found to function in AML by 
collaborating with Ras to drive the over-expression of Hoxa9 and activate Raf (Ono, Kumagai 
et al. 2009). Hox proteins can also form fusion proteins with Nup98 that mediate AML 
formation in combination with flt3 (Borrow, Shearman et al. 1996; Nakamura, Largaespada et 
al. 1996; Raza-Egilmez, Jani-Sait et al. 1998; Kroon, Thorsteinsdottir et al. 2001; Fujino, 
Suzuki et al. 2002; Suzuki, Ito et al. 2002; Taketani, Taki et al. 2002; Pineault, Abramovich et 
al. 2004; Palmqvist, Argiropoulos et al. 2006). In addition, NUP98-HOXA9 protein was 
significantly associated with KRAS and Wilms' tumour gene 1 mutations (Chou, Chen et al. 
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2009). Hox genes are regulated by the Cdx family in AML (Bansal, Scholl et al. 2006; Rawat, 
Thoene et al. 2008),and, likewise, gene profiling studies showed a strong association between 
FLT3 mutations and HOXA7, HOXA9 and HOXA10 expression (Roche, Zeng et al. 2004; 
Eklund 2011). Over-expression of several HOX genes was also seen in the presence of NPM1 
mutations (Mullighan, Kennedy et al. 2007; Vassiliou, Cooper et al. 2011). These studies 
suggested that HOX genes are novel targets for molecular targeted therapies in various AML 
subtypes.  
Targeting a group of HOX proteins by disrupting their interactions with their cofactor 
PBX was previously achieved using the small cell-permeable peptide HXR9. This approach 
illustrated the importance of HOX genes in the tumorigenesis and survival of the cancer cells 
derived from several solid cancers (Morgan, Pirard et al. 2007; Shears, Plowright et al. 2008; 
Plowright, Harrington et al. 2009; Morgan, Plowright et al. 2010; Morgan, Boxall et al. 2012; 
Morgan, Boxall et al. 2014). Therefore, this study was carried out based on the hypothesis that 
AML cells would be sensitive to killing by HXR9 and indeed HOX genes might be a useful 
therapeutic target in a subset of AML patients that over-express HOX genes.   
In order to test this hypothesis I measured HOX gene expression in AML cell lines 
derived from different AML subtypes and assessed their susceptibility in vitro to HXR9 
treatment either alone or in combination with first line AML chemotherapies (chapter 3). I also 
performed a comprehensive study of the mechanism of cell killing by HXR9, (chapter 4) and 
assessed the in vivo efficacy of HXR9 to kill AML cells either alone or in combination with 
non-toxic reagents (chapter 5).  
The AML cell lines used in this study represented various AML sybtypes and prognoses. 
These included AML patients with de novo mutations (primary AML), including KG-1, 
HEL92.1.7 and HL-60. In addition, cell lines were derived from CML patients in blast crises 
(secondary AML), including K562 and KU812F. KG-1 is an erythroleukaemia cell line 
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characterised by the expression of CD34 and the presence of a complex karyotype, and is 
consequently associated with a poor prognosis (Koeffler and Golde 1978; Ahmed, Laverick et 
al. 1999; Mrózek, Tanner et al. 2003; Mrozek 2008). HEL92.1.7 is also an erythroleukaemia 
cell line carrying the Janus kinase 2 mutation that is associated with a poor prognosis: 80% of 
patients relapse (Martin and Papayannopoulou 1982; Illmer, Schaich et al. 2007; Fiskus, 
Verstovsek et al. 2011). HL-60 is an APML cell line associated with a favourable prognosis 
and characterised by the presence of t(15;17)/(PML-RARA) (Collins, Ruscetti et al. 1978; 
Dores, Devesa et al. 2012). Both K562 and KU812F are characterised by the presence of the 
Philadelphia (Ph) chromosome t(9;22)/(BCR-ABL) and derived from CML patients in blast 
crisis, which is indicative of a poor prognosis (Lozzio and Lozzio 1975; Kishi 1985; Roche, 
Zeng et al. 2004; Rucker, Sander et al. 2006; Weisberg, Wright et al. 2008).  
The expression of HOX genes in the tested AML lines was consistent with the 
established idea that HOX genes are expressed in a lineage-restricted manner, whereby HOXA 
and HOXB genes are expressed in myeloid (KU812F) and erythroid (HEL92.1.7 and K562) 
cells, respectively. The exception to this was the erythroid cell line KG-1, which expressed 
HOXA genes that were linked to the presence of trisomy 8. In addition, the APML cell line HL-
60 was characterised by a global down-regulation of HOX genes. It is noteworthy that the 
CD34+ cell line KG-1, which is characterised by a poor response to conventional 
chemotherapies, strongly expresses a set of HOX genes compared with the CD34- cell line HL-
60 that represents AML with a favourable prognosis (Ahmed, Laverick et al. 1999; Marone, 
Scambia et al. 2002; Dores, Devesa et al. 2012). This difference in the prognosis is associated, 
at least in part, to the expression of HOX genes since the high and low expression of HOX genes 
corresponds to a poor and favourable prognosis, respectively (Golub, Slonim et al. 1999; 
Andreeff, Ruvolo et al. 2008; Zangenberg, Grubach et al. 2009). In addition, the comparison 
between KG-1 and HL-60 in terms of HOX expression is consistent with the previous 
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observation that HOX genes are highly expressed in CD34+ cells but show virtually no 
expression in CD34- cells (Sauvageau, Lansdorp et al. 1994; Pineault, Helgason et al. 2002). 
The limitation of assessing the expression of HOX genes was the lack of normal CD34+ cells, 
which could be addressed in future studies.   
The functional redundancy of HOX genes obscures our understanding of their 
importance in the survival and proliferation of cancer cells, even though their over-expression 
has been reported in different kinds of cancers. In this study I showed for the first time that the 
high expression of HOX genes could form the basis of individualised medicine in AML as 
antagonising the interaction between a set of HOX proteins and their cofactor PBX by the small 
cell-permeable peptide HXR9 resulted in cell death. I also found that the susceptibility of the 
tested AML cell lines to HXR9 was correlated with the expression level of HOX genes. The 
most susceptible cell line was KG-1 that highly expresses a set of HOX genes, while HL-60 
showed very low HOX gene expression had the lowest susceptibility to HXR9. Interestingly, 
the expression of CD34 is considered to be a marker of a poor prognosis, an adverse clinical 
course and a low CR rate of AML (Repp, Schaekel et al. 2003). In addition, CD34+ AML cells 
were reported to be resistant to the current chemotherapies, yet CD34+ might predict high 
sensitivity to HXR9 since HOX genes are highly expressed in CD34+ cells (Bailly, Muller et al. 
1995; Bailly, Skladanowski et al. 1997). Likewise, gene expression profiling of CD34+ cells in 
CML patients in chronic phase reveals a higher expression of HOXA9, which may suggest that 
HXR9 could be used in combination with imatinib, the first line treatment for CML, which 
targets the BCR-ABL fusion protein (Diaz-Blanco, Bruns et al. 2007; Palandri, Castagnetti et 
al. 2008; Hehlmann 2012). Consistent with this suggestion, the cell lines that express BCR-
ABL fusion, KU812F and K562, were sensitive to HXR9. In addition, it was reported that Bcr-
Abl cooperated with Nup98-Hox proteins to progress to the ultimate phase of CML that is blast 
crisis (Mayotte, Roy et al. 2002; Ito, Kwon et al. 2010; Di Giacomo, Pierini et al. 2014). 
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Analogously, the sensitivity of Ph+ AML cells to HXR9 might suggest that HXR9 could be 
used in a combination with imatinib to kill ALL cells that express both BCR-ABL fusion and 
HOX genes (Redaelli, Piazza et al. 2009). Since HL-60 is sensitive to HXR9, a rational 
approach may be to combine HXR9 with the current first line treatment for APML, ATRA 
(Tallman and Altman 2009).    
Combination therapy is a common approach to treating drug-resistant cancer, and 
depends on a synergistic interaction between drugs that presumably have complementary 
modes of action. Multiple DNA-damaging agents were reported to activate NF-ҡB, such as 
anthracyclines, alkalyting agents and topoisomerase inhibitors (Boland, Fitzgerald et al. 2000; 
Laurent and Jaffrézou 2001; Campbell, O'Shea et al. 2006). However, NF-ҡB is negatively 
regulated by c-FOS, which is the main pro-apoptotic downstream target of HXR9 (Ray, 
Kuwahara et al. 2006; Takada, Ray et al. 2010). In addition, DNA-damage is known to stimulate 
PKC activity that was found to have an antagonistic, anti-apoptotic effect on HXR9 in this study 
(Johnson, Lu et al. 2002; Bluwstein, Kumar et al. 2013). The findings of this study therefore 
suggest that DNA-damaging agents that activate NF-ҡB and PKC might not be suitable 
combination partners to HXR9. The molecular mechanism of HXR9 is yet to be fully 
characterised. The specificity of HXR9 to target the HOX-PBX interaction and modify the 
transcription of some genes were previously assessed, and the mode of cell death of the tested 
solid cancers showed that HXR9 led to cell death by either apoptosis or necrosis (Morgan, 
Pirard et al. 2007; Shears, Plowright et al. 2008; Plowright, Harrington et al. 2009; Morgan, 
Plowright et al. 2010; Morgan, Boxall et al. 2012; Morgan, Boxall et al. 2014). However, the 
findings of this study indicate that there is difference, possibly unique mechanism of cell death 
by HXR9 in AML.  
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The study of cell death was carried out by assessing the changes in various cellular 
compartments after HXR9 treatment. For example, nuclear morphology was assessed by DAPI 
staining. The limitation of this assay was the lack of a positive control for nuclear 
fragmentation. The cytosolic changes were studied by analysing the changes in different 
members including the pro-apoptotic member of the Bcl-2 family, XIAP, Apaf1 and caspase 
activation. In addition, the mitochondrial role was investigated by measuring the expression of 
the pro-apoptotic and anti-apoptotic genes of the Bcl-2 family including Bad, Bax, Bak1 and 
Bcl-2. All the above-mentioned studies revealed that HXR9-induced cell death through an 
apoptosis-independent pathway, involving programmed necrosis.  
Ca2+ and ROS are two main regulators of necrosis (Festjens, Vanden Berghe et al. 
2006). The role of extracellular Ca2+ was assessed using EDTA. However, EDTA is a general-
cation inhibitor that might chelate HXR9 since R9 is a cation sequence. EGTA is another cation 
chelator used in a preliminary experiment, data not shown. EGTA increased the sensitivity to 
HXR9, although this might be the effect of its alkaline solvent NaOH that might increase the 
pH of the extracellular environment and thereby strengthen the interaction between the 
polycation HXR9 and the acidic cell surface (Raghunand, Mahoney et al. 2003). To the best of 
my knowledge, there is no specific cell impermeable Ca2+ chelator. In addition, intracellular 
Ca2+ concentration was not measured in this study, although Ca2+ downstream mediators of 
necrosis were.   
Programmed necrosis is classified into various types such as mitochondrial necrosis, 
parthanatos and necroptosis (Andrabi, Dawson et al. 2008; Elrod and Molkentin 2013; Marshall 
and Baines 2014). The assessment of CypD and PARP1 activation suggested that HXR9-
induced necrosis in mitochondria- and parthanatos-independent pathways, respectively. Of 
note, the limitation of PARP1 activation assay was the lack of a positive control. However, 
RIP1 is involved, at least in part, in HL-60 necroptosis and the absence of any RIP1 inhibition 
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effect on K562 does not exclude a necroptotic pathway since necroptosis can be RIP1-
independent, but RIP3-dependent. Therefore, a RIP1 inhibition assay might suggest the need to 
block the role of RIP1 and RIP3 by short interfering RNA or a pharmacological inhibitor to 
analyse whether HXR9-induced necrosis in the only necroptosis-dependent pathway or whether 
there is another pathway involved.  
ATP depletion was achieved by incubating cells with a high concentration of fructose, 
which is known to deplete intracellular ATP. The limitation of this assay was the lack of a 
positive control. In addition, it might be better to measure intracellular ATP using more specific 
kits in the future.  
Mitochondria do not seem necessary for HXR9-induced death in the tested AML cells. 
Mitochondria participate in apoptosis and some forms of necrosis. In apoptosis, it is involved 
in caspase- and Bax-dependent pathways, yet neither pathway was essential in HXR9-induced 
AML cell death (Martin 2010; Gogada, Prabhu et al. 2011). In necrosis, mitochondria are 
indispensable for CypD- and PARP1-dependent necrosis, but neither CypD nor PARP1 
activation was involved in HXR9-induced AML cell necrosis (Andrabi, Dawson et al. 2008; 
Elrod and Molkentin 2013) .   
 HXR9 caused cell death in c-FOS-dependent pathway, at least in part, in previously 
tested cell lines that derived from different kinds of solid cancers (Morgan, Pirard et al. 2007; 
Shears, Plowright et al. 2008; Plowright, Harrington et al. 2009; Morgan, Plowright et al. 2010; 
Morgan, Boxall et al. 2012; Morgan, Boxall et al. 2014). Likewise, c-FOS up-regulation was 
seen in the tested AML cell lines. In an attempt to understand more about the molecular 
mechanism that is involved in HXR9 cell killing, MAPK pathways were studied using 
pharmacological inhibitors to block their potential role in HXR9 treatment. It was found that 
HXR9 induced necrosis of the tested AML cells in a MAPK-independent pathway. As Ca2+ is 
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a main inducer of necrosis, the role of some of the Ca2+ downstream effectors that might 
regulate HXR9-induced necrosis was also analysed. For example, μ-Calpain was not involved 
in HXR9-induced necrosis. Interestingly, the other analysed Ca2+ downstream mediators 
including NOXs, CaM, PKC and HO-1 had an anti-necrotic effect, as their inhibition 
accelerated the necrosis of the tested AML cells. In addition, it was found that c-FOS induced 
p21 expression in p53-independent pathway. 
The anti-necrotic effect of NOXs, CaM, PKC and HO-1 after HXR9 treatment for AML 
cells might direct the selection of combination drugs that would be used in the future with 
HXR9. For example, cisplatin was reported to result in cell apoptosis through pathways that 
involve the activation of PKC, NOXs and JNK (Persaud, Hoang et al. 2005; Kim, Lee et al. 
2010; Itoh, Terazawa et al. 2011; Pabla, Dong et al. 2011; Pereira, Igea et al. 2013). In addition, 
c-FOS over-expression was highly associated with cisplatin resistance (Muscella, Urso et al. 
2009). Likewise, the alkylating agents treosulfan and etoposide were reported to induce 
apoptosis in a PKC-dependent manner (Schmidmaier, Oellerich et al. 2004; Day, Wu et al. 
2009; Zhao, Duan et al. 2009). Therefore, cisplatin, treosulfan and etoposide might have 
antagonistic effects on HXR9 treatment. However, drugs that inhibit NOXs, CaM, PKC and 
HO-1 might produce synergistic effect upon combination with HXR9.   
ROS seems to exert an anti-necrotic effect in HXR9 treated AML cells. The primary 
sources of ROS are mitochondria, NOXs, and some enzymes and growth factors (Festjens, 
Vanden Berghe et al. 2006; Morgan, Kim et al. 2008; Jiang, Zhang et al. 2011). The results of 
this study suggested that mitochondria are not required for HXR9 cytotoxicity. However, 
inhibition of NOXs enhanced the efficacy of HXR9. In addition, the results of this study showed 
that inhibition of PKC, which is an upstream regulator for HO-1 and JNK pathway and 
downstream effector for ROS also augmented the effect of HXR9 (Liu, Nishitoh et al. 2000; 
Kadowaki, Nishitoh et al. 2005; Tsoyi, Jang et al. 2011). Therefore, HXR9 might increase the 
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expression of anti-oxidant transcription factors and it will be informative to investigate their 
expression and measure ROS levels after HXR9 treatment. 
The in vitro results were promising and were followed up by in vivo models to assess 
the efficacy of HXR9 in inducing the necrosis of AML cells. In addition, one of the aims of this 
study was to assess the cytotoxicity of HXR9 on normal PB; subsequently, the mouse AML 
cell line C1498-GFP and the C57BL/6 mouse strain that has a full immune system were used. 
However, using both this strain and a nude mouse strain for I.V. injection of cell lines and 
HXR9 had several limitations. There was a low engraftment rate of AML cells, which could be 
a result of multiple factors. These include the presence of either a full or partial immune system 
in C57BL/6 and nude mice, respectively. This limitation could be overcome by eradicating the 
immune system by pre-treating mice with immunosuppressive agents and total body irradiation. 
Alternatively, the most common mouse strains for in vivo AML models that are characterised 
by the lack of the immune system are NOD/SCID or NOD/SCID gamma mice that have a high 
rate of engraftment could be used (Shan and Ma 2013). The low engraftment rate could also be 
explained by the low number of injected cells or a failure to inject cells in tail vein. Another 
limitation is the presence of extramedullary infiltration that could be monitored using a 
bioluminescence imaging system.  
The S.C. model of AML cells is an acceptable model for preclinical evaluations of new 
agents, but it does not recapitulate the BM microenvironment. Recent studies demonstrated 
multiple differences among different stromal cells originating from different organs. The 
differences include phenotypes, proliferation, the expression levels of SDF-1, VEGF and 
TGFβ1 (Dmitrieva, Minullina et al. 2012; De Luca, Verardi et al. 2013). As stromal cells play 
an integral part in chemoresistance, this difference in tumour microenvironments should be 
considered in terms of assessing the in vivo efficacy of HXR9 to induce AML necrosis.  
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Despite the heterogeneity of the S.C. and BM tumour microenvironments, the in vivo 
chemoresistance to HXR9 could be a result of cell intrinsic or extrinsic factors. Therefore, the 
potential causes of chemoresistance should be studied in order to improve the in vivo efficacy 
of HXR9. Chemoresistance studies could be performed using a short-duration, ex vivo/co-
culture model, and could allow the role of stromal cells in HXR9 resistance to be determined. 
Possible mechanisms of resistance could include an interaction with AML cells, and or the 
expression of specific cytokines, growth factors and matrix proteins (Garrido, Appelbaum et al. 
2001; Konopleva, Konoplev et al. 2002; van Gosliga, Schepers et al. 2007; Schuringa and 
Schepers 2009; Civini, Jin et al. 2013; Lopez, Garcia et al. 2014). 
The specificity of HXR9 to target HOX-PBX interaction was previously studied 
(Morgan, Pirard et al. 2007; Plowright, Harrington et al. 2009). However, one of the main 
limitations of CPPs, which is the R9 sequence in HXR9 peptide, its non-specific uptake. In 
other words, CPPs are able to penetrate all tissues and organs, regardless of the administration 
route. This drawback can be overcome by binding targeting peptides with an R9 sequence that 
will produce a selective delivery system. For example, CXCR4 that is over-expressed in many 
cancers including AML can be targeted by a ligand that is bound to CPPs in order to inhibit the 
non-specific interaction of CPPs. This approach was done by attaching CXCR4 ligand to TAT, 
a CPP, and the anticancer peptide p53-activating peptide that led to increase the specificity of 
the delivery system and the efficacy of the anticancer peptide comparing to unguided CPP 
(Snyder, Saenz et al. 2005). Analogously, the specificity can be established by creating 
activatable CPP (ACPP) that constitute of a polycationic CPP linked to a neutralising polyanion 
motif via a cleavable linker. This structure blocks the electrostatic interaction of the ACPP with 
the negative charge cell surface by decreasing the charge of ACPP to approximately zero and 
ultimately blocks uptake into cells. Proteolysis of the cleavable linker by a specific protease 
releases the polycationic ACPP domain and enables it to enter cells. Many cancer associated 
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proteases are known, which are highly expressed in cancer tissues, but are absent or expressed 
at low concentrations in normal tissues such as metalloproteases (Vives, Schmidt et al. 2008; 
Regberg, Srimanee et al. 2012). For example, binding doxorubicin to ACPP that was sensitive 
to metalloproteases 2/9 effectively decreased the toxicity of doxorubicin and inhibited the 
proliferation of HT-1080 cells (Shi, Gao et al. 2012).   
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6.2 Conclusion 
In vitro results showed that HOX-PBX dimer might be a potential therapeutic target in 
a subset of AML that over-express HOX genes. This may potentially help development 
of personalised medicine for AML disease. The comprehensive analysis of the 
mechanism of HXR9 cytotoxicity may guide in the selection of the potential combination 
drugs. For example, agents that cause NOX, CaM, PKC activation should be avoided and 
vise versa. A proper in vivo systemic model should be used to assess the in vivo efficacy 
of HXR9 cytotoxicity, along with conducting more in vitro assays to investigate the 
mechanism of HXR9 in order to choose potential synergistic agents.   
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6.3 Future directions 
Combination therapy is becoming increasingly important in cancer treatment. The 
findings of this study reveal that HXR9 is able to trigger the necrosis of K562 and KU812F 
cells that express the BCR-ABL fusion protein; and HL-60 that expresses PML-RARA. It may 
therefore be valuable to assess combination therapy with HXR9 and first line treatment drugs 
such as imatinib and ATRA that target BCR-ABL and PML-RARA fusion proteins, 
respectively.  
Resistance to cell killing by HXR9 may involve anti-necrotic proteins, and thus agents 
that target such proteins are potential synergistic agents with HXR9. For example, tamoxifen 
and trifluoperazine, CaM antagonists, might be used in a combination with HXR9 (Ahn, Pan et 
al. 2003; Wang, Li et al. 2010). Likewise, enzastaurin that inhibits PKC activity and increased 
p21 levels in multiple myeloma cells could have potential synergistic effect with HXR9 (Raab, 
Breitkreutz et al. 2009). The HO-1 inhibitors, pegylated zinc-protoporphyrin and styrene-
maleic-acid-copolymer-micelle-encapsulated particles, which showed apoptotic effects in 
AML cell lines are also potential synergistic drugs with HXR9 (Herrmann, Kneidinger et al. 
2012). Arsenic trioxide exerts its cytotoxicity by inhibiting the JNK pathway thereby increasing 
the activity of c-FOS and p21 proteins; it will also be valuable to assess its combinatory effect 
with HXR9 (Huang, Liu et al. 2006; Liu and Huang 2008).   
Silencing c-FLIP in combination with HXR9 treatment seems an interesting 
combination to perform since c-FLIP is negatively regulated by c-FOS (Zhang, Zhang et al. 
2007). In addition, c-FLIP is a downstream effector for CaM and PKC (Hwang, Min et al. 2009; 
Kaunisto, Kochin et al. 2009). It is also able to inhibit apoptosis and necrosis by suppressing 
procaspase-8 and RIP1, respectively (Day, Huang et al. 2008; Wang, Du et al. 2008; He and 
He 2013).  
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The mechanism of cell killing by HXR9 requires further investigation. To understand 
how RIP1 activity can cause c-FOS over-expression after HXR9 treatment, at least in HL-60 
cells, the upstream regulators of c-FOS and downstream effectors of RIP1 such as apoptosis 
signal-regulating kinase 1 might be involved in this mechanism (Liu, Nishitoh et al. 2000; 
Vanlangenakker, Vanden Berghe et al. 2012). Such investigations may also include some c-
FOS upstream regulators, including  FOS related kinase and ribosomal S6 kinase 2 (Zhang, 
Zhang et al. 2007). In addition, p21 downstream effectors might be assessed. It is noteworthy 
to assess the role of RIP3 in HXR9 cytotoxicity since necroptosis was involved, at least in HL-
60 cells.  
A co-culture model to assess the efficacy of HXR9 in inducing AML necrosis needs to 
be conducted. Such a model can mimic the BM microenvironment in in vivo models. AML cells 
could be co-cultured either in direct or indirect contact with stromal cells such as human MS-5 
cells to evaluate the influence of stromal cells and the secretome in the efficacy of HXR9.  
A systemic in vivo model is needed to be established to assess the efficacy of HXR9 on 
AML disease. In this study, the nude mouse strain was used, but the growth rate was low which 
might due to the immune activity. In addition, C57BL/6 and SCID flank models do not 
represent AML disease. Therefore, it is noteworthy to establish a systemic in vivo model in 
other mouse mouse strains including NOG or NOD, the most common AML models, which are 
characterised by the lack of T and B lymphocytes, impaired NK cells and antigen-presenting 
cells (Shan and Ma 2013).   
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D) 
 
E) 
 
Appendix 1. R110 standard curves for the caspase-3 assay. R110 standard curves were used as additional controls 
for caspases-3 activity to show that free R110 reagent was fluorescent and its fluorescence correlated with its 
concentration. A range of concentrations (5μM -25μM) of R110 were prepared by diluting 5mM R110 into 1× 
reaction buffer. Then, R110 fluorescence was measured at 492nm. To validate individual experiments, R2 should 
be ≥ 0.95. Graphs show the mean of three independent experiments and error bars show the SEM.  
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A) 
 
B) 
 
 
Appendix 2. General inhibition of caspase activity in HXR9 treated AML cell lines by z-VAD-FMK. Cells were 
pre-treated either with or without 50 μM z-VAD-FMK for one hour. Then, cells were treated with the IC50 and 2× 
IC50 of HXR9 for two hours, or with 17.5 μM of DNR for 24 hours, which was used as a positive control. Next, 
cells were harvested and stained with annexin V and 7-AAD for 15 minutes in the dark and analysed by flow 
cytometry. There was no statistical difference in terms of sensitivity to HXR9 between pre-treated cells with or 
without 50μM z-VAD-FMK. Graphs show the mean of three independent experiments and error bars show the 
SEM. *p < 0.05, **** p < 0.0001 with respect to z-VAD-FMK untreated cells. A) Inhibition of caspase activity 
by z-VAD-FMK in K562 and B) HL-60 cells. 
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Appendix 3. Effect of EDTA on HXR9 cytotoxicity. Cells were pre-treated with or without 20mM EDTA for one 
hour. Then, cells were treated with 10μM, 20μM, 40μM HXR9 that prepared in media either with or without 
20mM EDTA or with an equivalent CXR9 concentration to the highest concentration of HXR9 for two hours. The 
cells were then harvested and stained with annexin V and 7-AAD for 15 minutes in the dark and analysed by flow 
cytometry. Pre- and co-treatment of cells with 20mM EDTA significantly inhibited the cytotoxicity of HXR9 
compared to EDTA untreated counterparts. Graphs show the mean of three independent experiments and error 
bars show the SEM.  *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 with respect to 20mM EDTA treated 
cells. A)  K562 cells and B) HL-60 cells. 
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Appendix 4. The Effect of CsA on HXR9 cytotoxicity. Cells were pre-treated with or without 5μM CsA for one 
hour. Then cells were treated with 1×, 2×, or 3× IC50 of HXR9, with an equivalent CXR9 concentration to the 
highest concentration of HXR9, with 20mM H2O2 as a positive control, or were untreated (negative control). Next, 
cells were harvested and stained with annexin V and 7-AAD for 15 minutes in the dark and analysed by flow 
cytometry. Results show 5μM CsA leads to a significant decrease in % viable cells and an increase in % early 
apoptotic and dead cells of HXR9 treated cells comparing to their counterparts. Graphs show the mean of three 
independent experiments and error bars show the SEM. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 
with respect to 5μM CsA untreated cells. A) K562 and B) HL-60 cells. 
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Appendix 5. The effect of blocking the MEK/ERK pathway in H2O2 cytotoxicity. Cells were pre-treated with or 
without 20μM of the MEK/ERK inhibitor U0126 for one hour. Next, cells were treated with 20mM H2O2 for two 
hours and the cytotoxicity was measured by LDH assay. U0126 significantly inhibited the cytotoxicity of H2O2. 
The graphs show the mean of three independent experiments and the error bars show the SEM. **p < 0.01 and 
****p < 0.0001 with respect to 20μM U0126 untreated cells. A) K562 and B) HL-60 cells. 
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Appendix 6. The effect of inhibiting the p38 pathway on H2O2 cytotoxicity. Cells were pre-treated with or without 
25 μM SB302580 for one hour, and were then treated with 20mM H2O2 for two hours. Cytotoxicity was measured 
using the LDH assay. Blocking the p38 pathway significantly reduced the cytotoxicity of H2O2. The graph shows 
the mean of three independent experiments and the error bars show the SEM. **p < 0.01 and ***p < 0.001 with 
respect to 25μM SB302580 untreated cells. A) K562 and B) HL-60 cells. 
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Appendix 7. The impact of JNK pathway inhibition in the cytotoxicity of H2O2 in HL-60 cells. Cells were pre-
incubated either with or without 60μM SP600125 for one hour, and then incubated with 20mM H2O2 in media 
supplemented with or no supplemented with 60μM SP600125 (red and blue bars, respectively). Next, the 
cytotoxicity was assessed using the LDH assay. 60μM SP600125 dramatically decreased the cytotoxicity of H2O2. 
The graph shows the mean of three independent experiments and the error bars show the SEM. ***p < 0.001 with 
respect to 60μM SP600125 untreated cells. 
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Appendix 8. The effect of blocking μ-calpain on the cytotoxicity of H2O2. Cells were pre-incubated with or 
without 60μM calpain inhibitor I for one hour, and then incubated with 20mM H2O2 prepared in media with or 
without calpain inhibitor I (red and blue bars, respectively). The cytotoxicity of H2O2 was then measured using the 
LDH assay. Blocking μ-calpain significantly inhibited the cytotoxicity of H2O2. Graphs show the mean of three 
independent experiments and error bars show the SEM. **p < 0.01 with respect to calpain inhibitor I untreated 
cells. A) K562 and B) HL-60 cells.  
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Appendix 9. Establishment of a systemic C1498-GFP model in C57BL/6 mice, only PB was harvested. 
Harvesting day Number of mice harvested Engraftment rate 
3 2 0 
7 2 0 
13 2 1 
17 2 1 
20 2 0 
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Appendix 10.  
A) Establishment a systemic C1498-GFP model in C57BL/6, PB, BM, kidney, liver and spleen were harvested. 
 
B) Establishment a systemic C1498-GFP model in C57BL/6, PB, BM, kidney, liver and spleen were harvested. 
 
  
 
 
 
 
Harvesting day Number of mice harvested Engraftment rate 
8 2 0 
15 2 1 
22 2 1 
25 2 0 
28 2 1 
Harvesting day Number of mice harvested Engraftment rate 
8 1 0 
15 1 0 
22 1 1 
28 1 0 
35 1 1 
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